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Abstract 
Adherence to guidelines for the management of community-acquired pneumonia (CAP) 
has been shown to improve patients’ clinical outcomes. However, several studies have 
indicated that the chosen antibiotic regimen is frequently not consistent with guideline 
recommendations. This might lead to suboptimal treatment, either by exposing patients to a 
greater risk of treatment failure or by unnecessary use of broad-spectrum antibiotics, which 
contributes to the emergence of antibiotic-resistant pathogens or consequent development of 
Clostridium difficile-associated diarrhoea. It has been demonstrated that active implementation 
of CAP guidelines can significantly improve adherence to recommendations, which 
consequently, might improve patients’ clinical outcomes.  
The present research developed, implemented and evaluated tailored intervention 
strategies to improve physicians’ concordance with CAP guidelines. A number of inter-related 
studies were conducted as a part of this research project.   
Firstly, baseline data was collected to measure the level of physicians’ adherence to 
national CAP guidelines in two Tasmanian hospitals, the Royal Hobart Hospital (RHH) and 
North Western Regional Hospital (NWRH). It was evident in that study that adherence to CAP 
management guidelines was poor at both study sites (16.1% and 7.5% for RHH and NWRH, 
respectively). 
This was followed by a study to identify and quantify potential barriers to the adherence 
to CAP guideline recommendations. A questionnaire was distributed to RHH doctors in non-
surgical areas of practice. Of the study population, 43.1% doctors responded to the survey; of 
those who responded, 46.4% thought the influence of senior doctors on their juniors could be a 
factor affecting adherence to the guidelines. Other barriers noted were a lack of guideline 
awareness (39.3%), the requirement to calculate the severity of CAP (35.7%), and the 
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existence of other guidelines that conflict with Therapeutic Guidelines: antibiotic, version 14 
(TG14; 28.6%). 
A qualitative study was then designed to determine factors that influence doctors 
working within the emergency department (ED) to prescribe ceftriaxone outside the TG14 
recommendations. Eight face-to-face interviews were performed with ED doctors. Five main 
themes emerged as influencing decisions regarding the selection of ceftriaxone for patients 
with CAP: (i) clinical intuition compared to a structured evaluation of severity, (ii) clinical 
uncertainty, (iii) prior clinical experience, (iv) source of guidance and (v) prescribing 
etiquette. 
A questionnaire survey was then sent to infectious disease pharmacists nationally in 
order to identify the strategies that have been used and perceived as successful for the 
management of CAP in their institutions. Of the study population, 41 pharmacists (27.3%) 
responded to the questionnaire. Of these, 90.2% pharmacists reported their hospitals having an 
antimicrobial stewardship (AMS) program. Multifaceted strategies to enhance antibiotic 
prescribing in ED for CAP, were mentioned as being in place in all responses. However, the 
largest number of the respondents (34.1%) considered use of CAP clinical pathways to be the 
most effective strategy.  
Intervention strategies were subsequently developed and implemented based on the 
findings from the above studies. Two interventions were implemented over two time periods: 
one with general strategies across medical units and a second focused on the ED.  During the 
general intervention period, local CAP guidelines (based on TG14) were released. The 
guidelines were developed and approved by the hospital’s medical and emergency 
departments. The release of the CAP guidelines was accompanied by a multifaceted 
educational package to increase awareness of the guidelines. Medical and ED teams were 
targeted in the educational package, which included group sessions, wall posters and 
vii 
laminated lanyard cards summarising the local guidelines. During the second time period, two 
further strategies were introduced (a CAP clinical management pathway and monthly auditing 
with feedback) and targeted specifically at ED staff. 
We evaluated the impact of the interventions on guideline adherence rates and clinical 
outcomes (mortality rates and hospital length of stay, LOS). To evaluate the impact of the 
intervention, two hospital sites were selected, one (RHH) acted as an intervention site and the 
other (NWRH) as a control site where no intervention was made. The study found the 
intervention had an overall impact on guideline adherence rates at the intervention site, and it 
reduced overall mortality rates and LOS for patients with non-severe CAP. Compared to the 
baseline data, the adherence rate increased significantly at the RHH during the intervention 
period (16.1% vs 50%; p < 0.05). However, no significant improvement was indicated in the 
control site (7.5% vs 19.1%; p > 0.05). The in-patient mortality was significantly lower in the 
intervention group when compared to the non-intervention groups (all baseline data plus the 
data from the NWRH during the intervention period) (3.4% vs 7.3%; p < 0.05). Sub-group 
analysis revealed patients with non-severe CAP in the intervention group had an average LOS 
0.8 days shorter than the non-intervention groups (p < 0.05).  
Results from the previous study indicated a positive impact of the intervention in the 
overall adherence to CAP recommendations. However, two main strategies were conducted in 
two consecutive times during the intervention periods, a general intervention and an ED-
focused intervention. Therefore, a time-series analysis was conducted to determine the impact 
of strategies over time at the intervention site. The rates of adherence to the CAP guidelines 
during the pre-intervention (5 months) and general intervention periods (5 months) were 
28.1% and 31.2%, respectively. The difference was not statistically significant. During the 
ED-focused intervention period (7 months), the level of adherence with guidelines was 
significantly higher at 61.5% (p < 0.05). 
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Finally, we evaluated the use of ceftriaxone in all indications in two time periods, before 
and after the initiation of the intervention. The aim of this study was to determine if our 
intervention in CAP management could affect the use of ceftriaxone in other indications. 
Concordance to the TG14 for all indications, with the exception of respiratory tract infection 
(RTI), was similar between the two study periods.  For the RTI, concordant use of ceftriaxone 
significantly increased from 50% during the first period to 64.5% during the second study 
period (p < 0.05). Among community-acquired lower respiratory tract infections, our findings 
indicated a significant decrease in the unnecessary use of ceftriaxone for patients with mild 
CAP and acute exacerbation of chronic obstructive pulmonary disease in the intervention 
group (both 19% vs 3.2%; p < 0.05). However, there were no significant changes in the 
appropriate prescribing of ceftriaxone for other indications.      
In conclusion, this research project identified, with in-depth analysis, potential factors 
that lead to the prescription of discordant antibiotic regimens for empirical management of 
CAP. It was subsequently demonstrated that a tailored multifaceted intervention significantly 
improved adherence to CAP guidelines, which consequently reduced the inappropriate 
prescribing of ceftriaxone for this indication. This was associated with a decrease in mortality 
rate and length of hospital stay among patients in the intervention group.  
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Chapter 1. Introduction 
1.1. Antibiotics  
The term “antibiotic” was firstly used in published papers in 1942 by Selman Waksman 
(1, 2). Since then, the term “antibiotic” has been used frequently in literature. In his article, 
Selman describe an antibiotic as “a chemical substance, produced by microorganism, which 
has the capacity to inhibit the growth of and even to destroy bacteria and other 
microorganisms” (2).  
Prior to the introduction of antibiotics and vaccination into medical practice, infectious 
diseases accounted for over 30% of the overall human deaths (3). However the antibiotic era 
has been associated with a marked reduction in mortality and morbidity associated with 
infections, for example, death rates due to pneumonia and influenza decreased by 0.5% per 
year during the antibiotic era (3).  
Historically, the modern antibiotic era started with the accidental discovery of penicillin 
by Sir Alexander Fleming in 1928 when he noticed that Penicllium notatum had destroyed 
staphylococcus bacteria in a culture plate (4), and since then, the course of medicine has been 
changed. This discovery was an avenue to other researchers to discover new antibiotics in the 
following years. It can be said that the period between 1950 and 1980 was the golden era of 
antibiotics, since most of the antibiotic classes in use today were discovered during that period 
(5).  
Coates et al. argued that there are five main reasons behind the limited development of 
new antibiotic classes (6). The first of these is that the cost and risk of developing analogues 
of the existing antibiotic classes is far less than developing wholly novel agents. Developing 
new classes with broad-spectrum antimicrobial coverage is now more difficult than it was in 
the 20th century. Large scale investments by the pharmaceutical industry in genomic 
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approaches to find a new antibiotic class have also failed. Furthermore, difficulties in securing 
product registration have been a disincentive to industry investment.  Finally, most 
pharmaceutical companies and universities have closed their departments working on 
antibiotic development, leading to deskilling in this specialised research area. According to a 
2009 report, only five pharmaceutical companies still have an active development program for 
antibiotic discovery, namely GlaxoSmithKline, Novartis, AstraZeneca, Merck and Pfizer (7). 
In recent years, concerns have increasing regarding the increasing rates of antibiotic 
resistance (ABR) (8).  In this era of increasing emergence of ABR, development of new 
antibiotic classes, that are effective against known resistant microorganisms is crucial (9). As a 
response to this public health concern, the Infectious Diseases Society of America (IDSA) 
raised the awareness about the problems in 2004 with a big campaign called Bad Bugs, No 
Drugs (10). This campaign was followed by calls for global commitment to develop 10 novel 
antibiotics by 2020 in order to respond to the challenge of resistance (11-13). Furthermore, it 
has been suggested that in order to tackle resistance at least 20 new classes of antibiotics are 
needed every 50 years to keep antibiotics effective (6). However, the future of antibiotic 
therapy is still in doubt, as the drug development pipeline suggests that there will be few new 
classes introduced in the next two decades (Figure 1.1) (14, 15).  Therefore, until this situation 
is rectified, preserving the utility of the antimicrobial agents already in existence is essential 
(16).  
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Figure 1.1: The number of newly approved antibiotic agents in the United States from 
1983 to 2012 (17). 
Data from several studies have identified a trend of increasing overall antibiotics use 
during the last two decades (18-22), with a significant shift toward prescribing of broader-
spectrum agents (23-26). In their analysis of pharmaceutical sale data from 71 countries, Van 
Boeckel et al. concluded that there was a 36%increase in antibiotic consumption between 
2000 and 2010 (27). Furthermore, it was estimated that global sales of antibiotics in 2009 
generated $42 billion dollars and that there was a 4% annual growth rate (28). The increasing 
trend of antibiotic usage has raised major public concerns since it has been believed that the 
rise of antibiotic usage, particularly broad-spectrum antibiotics, has led to the increasing 
problem of resistant microorganisms (29, 30). Further details regarding this will be discussed 
in the next section.  
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1.2. Impact of inappropriate use of antibiotics 
Inappropriate (non- adherence to recommended guidelines)  or unnecessary use of 
antibiotics has been shown to be associated with increase mortality and worsen clinical 
outcomes due to preventable side effects such as allergic reaction, under coverage of the 
suspected microorganisms such as in the case of empirical treatment of an infection, and 
subsequent infections with resistant microorganisms or subsequent infections with Clostridium 
difficile (C difficile (31-34).  
1.2.1. Adverse effects and antibiotics 
Antibiotics account for almost 20% of all drug-related adverse effects that result in a 
presentation to the emergency department (ED) (35, 36). In a study that looked at ED visits 
related to antibiotic administration, Shehab et al. found that allergic reactions were the most 
common cause of antibiotic-related morbidity, accounting for 4 out of 5 of these presentations, 
wherein penicillins and cephalosporins were responsible for 50% of these events (36). In such 
cases, the symptoms may range from mild itching and rash to more serious skin reactions and 
breathing problems (37). Gastrointestinal adverse effects attributable to antibiotics have also 
been commonly observed. A review article of  415 publications that looked at the efficacy and 
tolerability of amoxycillin/clavulanic acid found that gastrointestinal adverse effect was the 
most reported adverse effect related to the  use of this agent (38). A previous study has 
reported that 30% of the adverse effects related to third generation cephalosporins were 
gastrointestinal (39). The relationship between the use of some antibiotics, particularly 
aminoglycosides, and ototoxicity has been widely investigated (40, 41).  Lerner et al. 
investigated the impact of gentamicin on the rate of ototoxicity in 54 patients, and they found 
that ototoxicity occurred in 11% of the patients who were treated with this particular 
aminoglycoside (42). Aminoglycosides, alongside vancomycin, have been considered as 
nephrotoxic agents (43, 44).  In a study that looked at the prevalence of nephrotoxicity among 
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360 patients in intensive care units who were initiated with aminoglycosides, the authors 
found that 58% of the patients developed aminoglycoside-associated nephrotoxicity (43).  
Hence the suggestion that the best way to prevent these adverse effects is to avoid the 
unnecessary use of antibiotics (45).   
1.2.2. Clostridium difficile infection (CDI) and antibiotics 
C difficile is an opportunistic gram-positive anaerobic bacillus which is acquired through 
ingestion of material contaminated by faecal C difficile spores (46). C difficile can be 
transmitted by touching a contaminated area or via a person-to-person contact, such as other 
patients or even health care providers (47, 48). The spores resist stomach acidity and develop 
into vegetative bacteria in the small intestine (49). One of the most common reasons that 
would lead to the colonisation of C difficile and causing an infection is through disturbance of 
the normal intestinal gut flora (46). CDI may manifest in a range of forms, from 
asymptomatic, mild uncomplicated case to acute diarrhoea, which could be life threatening if 
not treated (49, 50).  
Over the past few years, there has been a significant increase in the incidence of CDI 
globally and in Australia (51-56). Within Australian hospitals, for instance, the rate of 
hospital-identified CDI increased from 3.25 to 4.03 cases per 10 000 patient days between 
2011 and 2012 (57, 58).  A recent surveillance report from Tasmanian Infection Prevention 
and Control Unit has indicated an almost three-fold rise in the incidence of hospital-identified 
CDI across all Tasmanian acute public hospitals from 2.3 per 10 000 patient days in the third 
quarter of 2009 to 6.3 per 10 000 patient days in the first quarter of 2014 (52).  The same 
report has indicated a similar increase in CDI at the Royal Hobart Hospital (RHH) from 2.1 to 
6.4 per 10 000 patient days between the first quarter of 2009 and the third quarter of 2014. 
According to Mitchell et al., the increase in the rates of the hospital-identified CDI among 
Tasmanian hospitals could be due to the increasing rates of the community-associated CDI as 
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observed in their study (59). One possible explanation of this increase, according to the 
authors, could be the possible increase of the use of antibiotic agents in the community.  
The association between CDI and increased mortality rate has been examined 
extensively in the literature (60, 61). Studies have found that the mortality rate due to CDI has 
increased over the last decade (62, 63). For example, in the United States, it was found that 
CDI-related mortality rates increased almost five fold, from 5.7 per million populations in 
1999 to 23.7 per million population in 2004 (62). In a systematic review article, Mitchell and 
Gardner have examined 24 case-controlled studies and found that infection with CDI was 
associated with in-hospital mortality rates ranging from 8% to 37.2% (64). The association 
between CDI and increased mortality rate has also been investigated in one Australian study 
(64). In their case-controlled study, Mitchell et al. showed that the mortality rate for patients 
with CDI was significantly higher than the control group at 60 days (12.6% vs. 6.3%), 90 days 
(14.6% vs. 7.3%) and 180 days (23.4% vs 9.2%). CDI has also been associated with prolonged 
LOS (57, 61, 65). Forster et al., retrospectively investigated the impact of CDI on LOS in a 
Canadian teaching hospital for 7 years from 2002 to 2009 (66). It was shown from the study 
that patients who were admitted with CDI were more likely to stay longer than those without 
CDI (34 days vs. 8 days). 
During the past decade, there has been an increasing amount of literature on the impact 
of CDI on healthcare costs as well (67-74). In one systematic review , the authors found that 
the estimated cost to treat patients with primary CDI ranged from $2,871 to $8,570 per case 
and, for recurrent CDI, the costs ranged from $13,655 to $18,067 per case (67). There are 
several factors that contribute to the high costs associated with CDI. These factors are 
associated with increased utilisation of healthcare resources, recurrent infection, treatment 
failure, and in particular an increased length of in-patient stay (68). Consistent with this, a 
retrospective observational study conducted by Al-Eidan et al. in 87 hospitalised patients with 
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CDI, found that 93.8% of the cost was related to the LOS, with the remaining 6.2% of the 
costs accounted for by laboratory tests and pharmacological therapy (75). 
Antibiotic therapy has been considered as the main cause of CDI due to their effect on 
disturbing normal gut flora (Figure 1.2). This has been supported by a large volume of 
published research that has examined the relationship between antibiotic usage and increased 
incidence of CDI (76, 77). In a systematic review of 48 studies regarding risk factors of CDI, 
Thomas et al. found that 41 studies indicated a positive correlation between antibiotic use and 
the incidence of CDI, with odds ratios ranging from 2.86 to 6.92 (76) .  
 
Figure 1.2: The risk of CDI after disturbing normal gut flora caused by an exposure to 
antibiotics. reproduced with permission (46).  
Whilst overall usage of antibiotics has been shown to be related to the increased 
incidence of CDI, particular classes of antibiotic have been shown to have more impact than 
others. In a study that was conducted by Pépin et al., the authors found that receiving 
fluoroquinolones, cephalosporins (first, second or third generations), macrolides, clindamycin 
or intravenous β-lactam/β-lactamase inhibitors were independent factors associated with CDI 
(78). However, among those antibiotics, they found that fluoroquinolones and third-generation 
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cephalosporins were the classes most prone to induce CDI (crude hazard ratio: 5.43 and 4.02, 
respectively). Results from a recently published systematic review found that the risk of CDI 
was highest within patients who received third-generation cephalosporins compared to other 
antibiotics (77).  
Due to the adverse impact on clinical outcomes and healthcare cost, strategies and 
guidelines have been proposed to reduce the incidence and spread of CDI (79-81). For 
example, the Society for Healthcare Epidemiology of America and the IDSA published 
clinical practice guidelines to treat and control CDI (82). Two major recommendations with 
regard to antibiotics were advocated to reduce the risk of CDI: 
1- To keep the consumption of antibiotics as low as possible by, for example, minimising 
the duration and the number of prescribed antibiotics.  
2- Implementation of an antimicrobial stewardship program to target the high-risk 
antibiotic classes, such as fluoroquinolones and third-generation cephalosporins. 
These recommendations are supported by studies examining the impact of minimising 
use of high risk antibiotics and the incidence of CDI (83, 84). In a prospective controlled 
interrupted time series (ITS) study which was conducted over three years, it was found that 
CDI incidence rates decreased significantly after an implementation of a policy that led to less 
use of broad-spectrum antibiotics such as cephalosporins and amoxycillin/clavulanate, and 
greater use of narrower-spectrum antibiotics, benzylpenicillin, trimethoprim and amoxycillin 
(85). Similarly, Talpaert et al. found that CDI incidence rates significantly decreased after 
revision of the hospital’s local antibiotic prescribing guidelines (86). The revised guidelines 
encouraged the use of low risk antibiotics and discouraged the use of high-risk antibiotics. 
This resulted in a significant reduction in fluoroquinolone and cephalosporin usage, which was 
associated with a consequential reduction in CDI (incidence rate ratio: 0.34; p < 0.0001). 
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1.2.3. Bacterial resistance and antibiotic therapy  
In the literature, the term antibiotic resistance (ABR) generally refers to bacterial 
pathogens that were once susceptible to an antibiotic, but which have since acquired resistance 
(8). The World Health Organisation (WHO) has raised concerns that if the increasing rates of 
the ABR are not controlled, we may reach a post-antibiotic era where common infections that 
have until now been easily treated, may become lethal (8). These concerns are supported by 
data from a recent WHO report which indicated a dramatic increase in the rates of ABR in 
common infectious diseases, such as urinary tract infection and pneumonia, both community 
and hospital-acquired infections (8). Of these resistant bacteria, the most commonly identified 
resistant pathogens that are associated with poor clinical outcomes are referred to as the 
“ESKAPE” pathogens (87): 
 Enterococcus faecium 
 Staphylococcus aureus 
 Klebsiella pneumoniae 
 Acinetobacter baumanii 
 Pseudomonas aeruginosa 
 Enterobacter species 
The rates of ABR for five bacterial pathogens (Staphylococcus aureus, Escherichia coli, 
Streptococcus pneumoniae, Enterococcus faecalis and Enterococcus faecium) have been 
investigated in Europe over four years from 2002 to 2006. The report estimated that the 
overall rate of resistance for these pathogens increased by 6.4% annually (88).  Another report 
from the United States (US) found that the rate of  hospitalisation with vancomycin‐resistant 
Enterococcus faecium (VRE) has almost tripled from 3.6 to 9.5 cases per 100 000 population 
over the period 2003 to 2006 (89). A report from the Centers for Diseases Control and 
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Prevention (CDC) indicated that carbapenem-resistant Enterobacteriaceae (CRE) has risen 
over the last decade, from 1.2% of strains in 2001 to 4.2% in 2011 (90).     
The rise in ABR has become a public health concern worldwide due to the impact this 
has on patients’ clinical outcomes and healthcare costs (91-95). With respect to mortality rates 
associated with ABR, data from the USA estimated almost 23,000 deaths per year due to 
infections were caused by resistant pathogens (45).  Studies indicate that mortality rates 
among patients who are infected with MRSA are higher than that among those who are 
infected with methicillin-susceptible Staphylococcus aureus (MSSA) (96-99). Other studies 
that investigated the mortality rates among patients in 1265 ICU from 75 countries, found that 
the mortality rate for patients with MRSA was almost 9% greater than those who were 
infected with the MSSA (29.1% vs 20.5%, respectively) (100).An observational study 
conducted on patients with blood infections caused by Enterococcus faecium found that 
patients who were infected with VRE had higher mortality rates than those who were infected 
with vancomycin-susceptible pathogens (101).Moreover, patients who are infected with ABR 
pathogens are more likely to stay longer in  hospital (8).  Mauldin et al. investigated the 
impact of infections caused antibiotic-resistant Gram negative pathogens on the LOS 
compared to antibiotic-susceptible Gram-negative pathogens. The authors showed that the 
LOS increased significantly, by 23.8% for patients with resistant pathogens (p < 0.001) (102). 
In another study, de Kraker et al. found that LOS was on average eight days longer among 
patients with bacteraemia caused by infection with Escherichia coli resistant to third-
generation cephalosporins, compared to patients with susceptible strains of the same pathogen 
(103).  
The costs of treating infections caused by resistant bacteria are believed to be 
consistently greater than for infections caused by susceptible pathogens. In their study of 662 
hospitalised patients with an infection caused by gram-negative bacteria, Mauldin et al. 
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reported that the estimated direct healthcare costs for patients with resistant pathogens were 
29.3% higher than the costs of susceptible pathogens (102).  Another study examining the 
healthcare costs of 725 hospitalised patients with infections caused by S aureus found that 
estimated total healthcare costs for patients with resistant pathogens were more than twice that 
for those patients with susceptible organisms ($34,657 vs $15,923 respectively; p < 0.001) 
(104). A study looking at 5,699 hospitalised patients found that the total cost was almost 
$10,000 more when a patient was infected with one of the ESKAPE pathogens (105).    
One of the major concerns regarding ABR is that use of antibiotics is now integral to 
many aspects modern medical practice and without access to reliable antibiotic therapy this 
may be jeopardised. For example, antibiotics play a major part in cancer treatments, general 
surgery and organ transplantations (45).  In their review article, Smith and Coast stated that 
losing antibiotic effectiveness to treat common infections would put the era of modern 
medicine in danger and this would lead us to return to the pre-antibiotic era (106).  
A large and growing body of literature has examined the association between antibiotic 
consumption and increased rate of ABR (29, 107-110). Prior exposure to antibiotics is 
considered as the major cause of the emergence and rise of ABR. In an investigation on the 
consumption of antibiotics in the outpatient settings of 26 European countries, it has been 
shown that ABR rates were higher in countries who consumed more antibiotics (Figure 1.3) 
(29).  
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Figure 1.3: Correlation between out-patient penicillin consumption and prevalence of 
penicillin S pneumoniae-resistant incidence among European countries. Reproduced with 
permission (29). 
DID: defined daily dose per 1000 inhabitants daily   
AT, Austria; BE, Belgium; HR, Croatia; CZ, Czech Republic; DK, Denmark; FI, Finland; FR, 
France; DE, Germany; HU, Hungary; IE, Ireland; IT, Italy; LU, Luxembourg; NL, The 
Netherlands; PL, Poland; PT, Portugal; SI, Slovenia; ES, Spain; UK, England only. 
 
 Whilst the use of any antibiotic may lead to the emergence of resistance, the use of 
certain antibiotics may be associated with a particularly significant increase in the rate of some 
resistant microorganism. For example, Bergman et al. conducted a study in which they tested 
S. pneumoniae isolates to indicate the rates of resistance to penicillin and macrolides (111). 
The data was then compared against the local consumption of macrolides and cephalosporins 
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in the 18 participating hospitals. The authors found that there was a significant association 
between increase macrolide usage, azithromycin in particular, and the increase of macrolide-
resistant S pneumonoae. Furthermore, a connection between increase use of cephalosporins 
and a rise of penicillin-resistant S pneumoniae was indicated. Therefore, the authors 
highlighted the importance of avoiding unnecessary use of these agents.    
Studies have been conducted to examine the effect of controlling broad-spectrum 
antibiotic use on ABR in some bacterial pathogens. For example, an Australian national 
restriction on the use of fluoroquinolones in human and animals was associated with reduction  
of the emergence of resistant E coli (112). Another example comes from Finland, where a 
decrease in the national consumption of macrolides in the outpatient setting was associated 
with a significant decrease in the detection of macrolide-resistant group A streptococci (113). 
It has also been shown that restriction of carbapenem antibiotics was associated with 
significant reduction of the rate of carbapenem-resistant Pseudomonas aeroginosa in 22 US 
teaching hospitals, where restriction was applied (114). Kaki et al. conducted a systematic 
review on the impact of quality improvement initiatives in critical care units to improve 
antibiotic prescribing (115). From the 24 analysed studies, 13 evaluated the impact on ABR; 
where the authors concluded that most of those interventions have been significantly 
associated with reduce resistance of key ICU pathogens.   
Based on the wealth of literature available regarding ABR, four core actions have been 
proposed in order to tackle the problem (45, 116): 
 Preventing the occurrence of infection and the spread of the ABR. 
 Tracking resistant microorganisms  
 Assisting pharmaceutical industries in developing new antibiotics and new diagnostic 
tests for resistant bacteria 
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 Implementing antimicrobial stewardship (AMS)   
Although the first three core actions are important strategies, it is beyond the scope of 
this thesis to discuss these topics in depth and the focus will hereafter be on AMS. 
1.3. Antimicrobial stewardship (AMS) 
AMS is a relatively new concept that is increasingly gaining popularity in hospital 
settings (117).  AMS is defined as “an ongoing effort by a health-care institution to optimise 
antimicrobial use in order to improve patient outcomes, ensure cost-effective therapy and 
reduce adverse sequelae of antimicrobial use (including antimicrobial resistance)” (117, 118).  
1.3.1. Evidence for AMS 
Evidence for the effectiveness of AMS in reducing broad-spectrum antibiotics usage, 
and improving clinical outcomes is growing (83, 115, 119-126).  An Australian study 
evaluating the impact of AMS at a tertiary care centre reported 10% and 17% reduction in the 
use of broad-spectrum antibiotic prescribing in the general medical and intensive care unit 
respectively (120). Additionally, Michael et al. conducted a prospective study of ABR and 
CDI rates three years before and after the implementation of AMS. The study found that the 
rate of CDI, VRE and MRSA decreased significantly after introduction of AMS to their 
institution. This was associated with a 9.8% reduction in antibiotic usage and an estimates 
saving of  more than $1.7 million at the end of the three years of the program(127).  
A systematic review of interventions aimed at improving antimicrobial prescribing 
practices  highlighted the unique role of AMS in improving clinical outcomes and decreasing 
the associated healthcare costs (128). In this Cochrane review article, the authors examined the 
effectiveness of AMS on reducing the incidence of ABR, CDI and clinical outcomes. It was 
found that AMS initiatives that aimed to minimise the unnecessary and inappropriate 
prescribing of antibiotics associated with a significant reduction in CDI and ABR incidences, 
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which was associated with a significant reduction in mortality rate. With regard to the effect of 
AMS in healthcare costs, the review study analysed ten studies where the healthcare costs 
were one of the measured outcomes. Eight of the analysed studies indicated a significant 
saving of money.   
1.3.2. AMS and clinical governance  
AMS has been proposed as an essential element of the clinical governance framework to 
improve antimicrobial prescribing within healthcare settings (117). There is an increasing 
interest from professional and governmental organisations in developing guidelines and 
recommendations to implement AMS in hospitals (117, 129-133).    
AMS is quite high on the agenda of the European Union with 16 European nations 
developing national strategies to combat ABR and encouraging prudent use of antibiotics 
(134). One such plan that stands out from others is the Scottish Management of Antimicrobial 
Resistance Action Plan (ScotMARAP) that was developed by the Scottish government in 2008 
(135). ScotMARAP recommends a national framework to implement AMS programs 
nationally in all acute-care hospitals. The Scottish clinical governance structure to influence 
the prescribing of antibiotics in a hospital setting is demonstrated in Figure 1.4. The 
application of the action plan was associated with a significant reduction in the incidence of 
CDI in Scotland and improved the management of common infections, such as CAP (136).   
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Figure 1.4: The proposed pathway to implement successful AMS, or antimicrobial 
management team, to influence antibiotic prescribing within acute hospital settings in 
Scotland. Reproduced with permission.  
 
The Australian Commission on Safety and Quality in Health Care (ACSQHC) 
established a program in 2007 with the aim of reducing the threat of resistant microorganisms 
(137). One of the program’s elements was the establishment of AMS in Australian hospitals in 
order to implement effective strategies to ensure appropriate and safe antibiotic usage. In order 
to facilitate implementation of AMS, ACSQHC published an electronic book, which is 
available online free, to provide guidance on establishing a successful AMS program among 
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Australian hospitals (117). The book provides specific examples of successful AMS initiatives 
in Australia. A 2008 national survey looking at antimicrobial stewardship programs among 
Australian hospitals found that only 25% of the 80 surveyed hospitals had AMS teams (138). 
In an investigation into barriers to establishment of AMS programs in Australian hospitals, 
Chen et al. found that lack of education, prescribing habits, inadequate resource and lacking of 
feedback on antimicrobial prescribing were the common identified obstacles to 
implementation of AMS program (139). Additionally, the study found that only 17.5% of the 
respondents who participated in the survey indicated the use of key performance indicators to 
determine the success of AMS programs; however, indicators were varied among institutions. 
Chen et al. argue that standard national standards to measure the success of AMS programs 
should be developed to be used as a model (139).   
ACSQHC has recently developed quality standards addressing the prudent use of 
antimicrobials in Australian hospitals. As a part of the accreditation standards, AMS is no 
longer an optional quality assurance activity in Australian hospitals.  Since January 2013, all 
hospitals in Australia have been required to establish AMS in their institutions in order to gain 
accreditation against the National Safety and Quality Health Service Standards (140).   
Recently, the US government has followed the steps of Australia and European 
countries in implementing a national action plan to combat the increasing rates of ABR (141). 
Besides proposed strategies to encourage the development of new antibiotics, the US 
government has ordered the implementation of a framework to evaluate the government 
regulations of AMS programs. In short, there has been an increasing governmental recognition 
of the problem of ABR and its correlations with the misuse of the existent antibiotics. To slow 
down the existence antibiotics turning ineffective due to ABR, many governments have 
established national strategies for optimal clinical practice with regard to antibiotic 
prescribing.    
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1.3.3. Elements for successful AMS 
Several elements of successful AMS have been reported in the literature (142). It has 
been suggested that an effective AMS program in a hospital setting requires a 
multidisciplinary team which could include general physicians, pharmacists, infection control 
professionals, microbiologists, administrators, and infectious disease physicians (117, 129, 
143). The main aim of the multidisciplinary team is to develop strategies that aim to enhance 
antibiotic prescribing among physicians. It is suggested that these strategies are developed by 
the AMS team and endorsed by an appropriate committee, along with support from hospital 
executives. ACSQHC considered the following as essential components of a successful AMS 
program in Australian hospitals (117): 
1- Development of local antibiotic prescribing guidelines based on the latest version of 
the TG, with incorporation of MINDME messages (144): 
o Microbiology guides therapy wherever possible 
o Indications should be evidence-based 
o Narrowest spectrum required 
o Dosage appropriate to the site and type of infection 
o Minimise duration of therapy 
o Ensure monotherapy in most cases  
2- Development of a restricted antibiotic list, including broad-spectrum antibacterial 
agents and a clear process of how to obtain the required approval.         
3- Reviewing antimicrobial prescribing at an individual level and make interventions with 
direct feedback to the prescriber. 
4- Monitoring the overall prescribing practice for antibiotics, such as the use of broad-
spectrum antibiotics, or the prescribing habits for a common infection. 
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5-  Ensure that the implemented antimicrobial guidelines reflect the findings from the 
hospital’s microbiology susceptibility reports. 
Other strategies have been found to effectively change antibiotic prescribing behaviour, 
such as education targeting healthcare professionals about the best use of antibiotics (145-
147), the use of a computerised decision support system (119, 122, 148, 149), routine AMS 
rounds (120), and the use of a web-based antimicrobial approval system (120). 
Among Australian hospitals, several strategies have been utilised by AMS teams to 
improve antibiotic prescribing and reported as successful in published studies. A snapshot of 
AMS activities across Australian hospitals found that multifaceted initiatives were used in 
order to optimise the use of antibiotics. The initiatives that were commonly reported as being 
used and perceived as moderately to extremely successful by most respondents include (138): 
 Obtaining approval from the Drug and Therapeutic committee or equivalent for the 
antibiotic list and their use 
 Having a restricted policy regarding antibiotic prescribing 
 Developing locally antibiotic policies 
 Involvement of a pharmacist and  an infectious disease physician in the AMS 
activities 
 De-escalation or streamlining antibiotic prescribing based on microbiology results 
 Utilisation of clinical guidelines and pathways   
 
1.4. Behavioural change in clinical practice  
A considerable amount of literature has been published showing that the research 
evidence frequently fails to be reliably incorporated into routine clinical practice in a timely 
way (150-152). In the case of antibiotic prescribing, for example, studies indicate that almost 
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half of all use is considered unnecessary or inappropriate (117). Accordingly, efforts have 
been made to implement evidence-based medicine in daily clinical practice relating to the 
treatment of infection.  
The impact of different strategies on modifying prescribing behaviour has been studied 
by several researchers (128, 153, 154).  One of the most commonly used strategies was the 
development and dissemination of evidenced-based guidelines.  However, to date there has 
been little agreement on the best approach to increase adoption of the recommendations in 
these guidelines (155). Therefore, it has been suggested that strategies to change clinical 
practice should be tailored to address the different barriers that may impede adoption of the 
desired recommendations (155). It has been shown that a multifaceted intervention based on 
these known barriers is more likely to lead to change (153). 
In general, a variety of barriers may hinder doctors from adhering to clinical practice 
guidelines. These barriers include three main themes: knowledge, attitude and behaviour as 
shown in Figure 1.5 (151). In terms of antibiotic prescribing, several qualitative and 
quantitative studies have investigated potential barriers that hinder doctors from adhering to 
recommended antibiotic guidelines (156-164). For example, in their recent survey of barriers 
to appropriate prescribing of antibiotics in three Australian tertiary teaching hospitals, Chaves 
et al. identified three barriers; a lack of antibiotic prescribing knowledge among junior 
doctors, lack of awareness about the restricted list of antibiotics, and a reliance on senior 
doctors to prescribe antibiotic (165). However, barriers to appropriate antibiotic prescribing 
might vary between countries, hospitals and even between different medical departments 
among the same hospital (166). Therefore, it is imperative to identify barriers that affect 
appropriate prescribing of antibiotics in an institution where an intervention would take place. 
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Knowledge   Attitude   Behaviour 
        
Lack of 
Familiarity  
 Volume of 
information 
 Time needed to 
stay informed 
 Guideline 
accessibility 
 
Lack of agreement with 
Specific guidelines 
 Interpretation of 
evidence 
 Applicability to 
patient 
 Not cost-beneficial 
 Lack of confidence 
in guideline 
developer 
  
Lack of agreement with 
guidelines in general 
 ‘Too cookbook’ 
 Too rigid to apply 
 Biased synthesis 
 Change to autonomy 
 Not practical 
 
 Lack of 
outcome 
Expectancy  
 Physician believe 
that performance 
of guideline 
recommendation 
will not lead to 
desired outcome  
 
 
External 
barriers 
 
Patient factors 
 Inability to 
reconcile 
 Patient preference 
with guideline 
recommendation 
 
Guideline factors 
 Guideline 
characteristics 
 Presence of 
contradictory 
guidelines 
 
Environmental 
factors 
 Lack of time 
 Lack of resources 
 Organisational 
constraint 
 Lack of 
reimbursement  
 Perceived increase 
in malpractice 
liability  
     
   Lack of safety-
efficacy  
 Physician believe 
that he/she cannot 
perform 
guidelines’ 
recommendations 
 
     
Lack of 
Awareness 
 Volume of 
information  
 Time needed to 
stay informed 
 Guideline 
accessibility 
  Lack of motivation/ 
Inertia of previous 
practice  
 Habit 
 Routine 
 
       
Figure 1.5: Barriers that could hinder doctors from adhering to clinical practice 
guidelines. Adapted and reproduced with permission (151). 
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1.5. AMS and disease-specific clinical practice guidelines      
Inappropriate use of antibiotics, particularly those with broad-spectrum antibacterial 
coverage, is frequent among common infections (167, 168). It was estimated that almost 4 out 
of 10 patients received antibiotic regimens that were deviated from recommended antibiotic 
guidelines among hospitals (172). Therefore, it seems reasonable to target those infections for 
quality improvement initiatives.  
It has been recommended that implementation of clinical guidelines for the management 
of common infections and surgical prophylaxis is a high priority when seeking to improve 
antibiotic use (133, 157). A number of studies have examined impacts of implementation of 
disease-specific clinical practice guidelines (169, 170).  Most of these interventions targeted 
antibiotic prescribing for surgical prophylaxis and empirical therapy for the management of 
skin and soft-tissue infections (SSTI), urinary tract infections (UTI), sepsis and lower 
respiratory tract infections (LRTI) (171-176). Table 1.1 provides some examples regarding the 
impacts of AMS initiatives for the management of these common infections on antibiotic 
prescribing performance and patients’ clinical outcomes. 
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Table 1.1: Examples of the impact of AMS initiatives to improve the management of 
common infections on the prescribing performance and patients’ clinical outcomes.   
Site of infection AMS initiative Outcomes 
Surgical 
prophylaxis 
(177) 
Implementation of an optimised 
and restrictive antibiotic 
prophylaxis policy based on 
national guidelines. 
The intervention resulted in Reduction 
in antibiotic use for surgical 
prophylaxis by 35%. 
Overall decrease of SSI from 5.4% to 4.5% 
(p = 0.22); significant. 
 SSTI (171) Implementation of clinical 
practise guidelines for the 
management of SSTI. The 
guideline was actively 
implemented by using three 
main strategies: educational 
campaign, electronic admission 
order set and auditing and 
feedback of the prescribing 
practice.  
The intervention resulted in less use of 
antibiotics with broad gram negative 
coverage (66% vs 36%; p < 0.001) and broad 
anaerobic coverage (76% vs 49%; p < 0.05). 
Additionally, the intervention resulted in a 
shorter median duration of antibiotic 
administration (13 days vs 10 days; p < 
0.01).  
UTI (178) Implementation of electronic 
UTI order set followed by audit 
and feedback to improve the 
empirical antibiotic 
management for patients with 
uncomplicated UTI who 
presented in the ED. 
The AMS intervention was associated with 
an increase of the compliance with the 
clinical guidelines by 38% (44% vs 82%; p < 
0.05) and a decrease use of broad-spectrum 
antibiotics, fluoroquinolones, by 31% (44% 
vs 13%; p < 0.001).  
Sepsis (179) Implementation of a first-dose 
stat antibiotic policy to deliver 
appropriate antibiotics within 15 
minutes to patients who were 
diagnosed with sepsis. 
The mean ICU LOS significantly decreased 
after the implementation of the policy (5.9 
days vs 4.2 days; p < 0.01). Moreover, the 
intervention was associated with a significant 
reduction in cost per case ($14,378 vs 
$12,311; p < 0.05). 
LRTI; hospital 
acquired pneumonia 
(HAP) (180) 
Implementation of local hospital 
guidelines for the management 
of HAP. 
The intervention led to significant increase in 
appropriate antibiotic prescribing (34% vs 
62%; p < 0.01). 
LRTI; community 
acquired pneumonia 
(CAP) (181) 
Implementation of CAP clinical 
practice guidelines in the 
emergency department.  
The intervention led to a 35.1% increase in 
the administration of appropriate antibiotic 
regimens (60.4% vs 95.5%, p < 0.001) and a 
17% reduction in hospital admission (36.5% 
vs 19.5%; p < 0.001).  In terms of clinical 
outcomes, mean LOS reduced by 1.1 day (p 
< 0.05), and re-admission within 30 days was 
less by 24.1% after the intervention (28.6% 
vs 4.5%; p < 0.05). 
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This thesis intends to examine and evaluate the impact of an intervention to improve the 
adherence to the CAP guidelines on antibiotic prescribing and patients’ clinical outcomes. 
Thus, this topic will be discussed in a greater length in the next section.      
1.6. Community-acquired pneumonia (CAP) 
1.6.1. Definitions 
Community Acquired Pneumonia (CAP) has been defined as an infection that occurs at the 
lung parenchyma, and for which the onset occurs outside of hospital or within 48 hours of hospital 
admission (144). However, different guidelines use different criteria to define CAP. For example, 
the guidelines of the Infectious Diseases Society of America/American Thoracic Society 
(IDSA/ATS) differentiate between patients who live in the community and those who are residents 
of  nursing homes (NH) or long care facilities, referring to the former as CAP and to the latter as 
nursing and health-care associated pneumonia (NHCAP) (182, 183). It has been found that elderly 
patients (65 years and older) with CAP are more likely to be infected with ABR pathogens as NH 
residents (10.2%) compared to patients who are admitted from a community-based setting (2.7%) 
(184).  With respect to clinical outcomes, one study suggested that the mortality rate is higher 
within NH residents (14.1%) then within non-NH residents (4.6%) (184). However, despite these 
possible differences, TG14 makes no differentiation between community-dwelling and NH patients 
when it comes to treatment recommendations (144).  
1.6.2. Diagnosis  
Clinical symptoms for patients with suspected lower respiratory tract infections include acute 
pulmonary symptoms (such as cough, sputum production, and chest pain), with or without fever. 
Other symptoms may be present such as headache and diarrhoea, and among the elderly, features 
present might not be specific (144). For example, it is less likely that patients aged 80 years or older 
would be present with chest pain, headache or fever (185). 
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Relying on physical examination to diagnose CAP can lead to misdiagnosis. Therefore, 
performing chest radiography is recommended in many guidelines for those patients who present 
themselves in the emergency department (ED) with a suspected diagnosis of CAP. The presence of 
any new or worsening chest radiological changes (such as an infiltrate) may help confirm the 
diagnosis of CAP and rule out other lower respiratory tract infections such as infective exacerbation 
of chronic obstructive pulmonary disease (IECOPD)  (144, 182, 186). 
1.6.3. Incidence  
The incidence of CAP varies between regions. In South America, the incidence of patients 
treated for CAP as out-patients ranges from 335.8 to 804.9 per 100,000 inhabitants per year (187). 
In the US, the estimated incidence of CAP within the age group 18-64 is 489 per 100,000 
inhabitants per year (188). In European countries, the annual incidence rate of CAP ranges from 
154 to 170 per 100,000 of the population (189). In Australia, the overall annual incidence of CAP 
data is lacking. However, the estimated number of pneumonia consultations at general practitioners 
is 343,000 per year (190). 
1.6.4. Hospitalisation 
CAP represents one of the most frequent conditions that require hospitalisation. It was 
estimated that around 100,000 patients with CAP were hospitalised in Australian hospitals in 
2003/2004 (191). In the US, more than four million visits to hospital clinics were due to pneumonia 
in 2006, and from those almost 600,000 patients were hospitalised (192, 193), while up to 680,000 
people in Germany are admitted to hospitals with CAP each year (194). 
1.6.5. Length of hospital stay (LOS) 
In Europe, the mean LOS for patients admitted to hospital due to CAP is estimated to be 6 
days (range: 2.2 – 9.8 days) (194-196). Several factors might contribute in delaying hospital 
discharge for patients admitted with CAP. These factors include advanced age, severe CAP, change 
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in mental status, co-existing cardiopulmonary diseases, diabetes mellitus, ICU admission and multi-
lobar pneumonia (195). Besides patient characteristics, inappropriate antibiotic prescribing has also 
been identified as an independent risk factor for long hospital stay (197).  
1.6.6. Mortality 
CAP is a major cause of mortality in Australia and worldwide. Pneumonia, alongside 
influenza, was responsible for 2% of all deaths in Australia in 2006, and the overall 30-day 
mortality rate for hospitalised patients with CAP was estimated to be 5.6% (198). Additionally, it is 
the 8th leading cause of death in the US (199). Inpatient mortality rates for patients with CAP 
ranged from 10% to 35% in South America (age ≥ 50) (187). In European countries, the mortality 
rates due to CAP varied widely from less than 1% to 48% of CAP patients (200).  
Several factors might contribute to the rise in mortality rates. First, mortality rate is 
dramatically increased with age (187, 200, 201). Patients aged less than 65 are more likely to 
present themselves with mild CAP, and their mortality rate is less than that among patients of an 
older age (1.7% vs 8.2%). The short- and long-term mortality rates were shown to be significantly 
lower among those of a young age (202). Moreover, mortality rate increases with severity, which 
ranges from less than 1% for mild CAP to 27% for patients with severe CAP (203). Pre-existing 
diseases could also play an important factor. For example, patients with COPD have a higher 
mortality rate than those without such a disease (204). However, another study has shown no 
significant differences between the two groups (205). 
1.6.7. Healthcare costs 
Globally, CAP has had a significant economic impact on the healthcare system. In European 
countries, around €10.1 billion are estimated to be spent annually on treating CAP, with a direct 
cost of €6.4 billion for inpatient care, outpatient care, and medications. The indirect costs of €3.6 
billion are due to lost work days as a result of the disease (200). In the US, the estimated direct and 
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indirect cost for population aged 18-64 is $10.6 billion per year. Of these, 80% are due to direct 
health care costs, and the rest (20%) comprise the costs of lost work days (188). Moreover, the 
estimated direct cost among the elderly (≥ 65 years old) is $7.3 billion per year (206), and the main 
factor that contributes to the increasing cost is LOS (207). In Australia, it is estimated that 20 
million Australian dollars are spent each year only on visits to the general practitioner due to CAP. 
The costs include consultations, chest X-ray, and medications (190). However, information 
regarding the healthcare cost of hospitalised patients in Australia is lacking. According to Lave et 
al.., it is estimated that hospitalisation due to CAP accounted for almost 92% of the overall cost, 
while outpatient treatment only accounted for 8% (208).  
1.6.8. Responsible pathogens  
Although many pathogens can cause CAP, only a limited number are responsible for most of 
the cases. Streptococcus pneumoniae is the most commonly identified pathogen in patients with 
CAP (209, 210).  In one Australian prospective study that was conducted in 885 patients, it was 
found that of 348 patients where the causative bacterial pathogens were identified, Streptococcus 
pneumoniae was responsible for almost one-third of the CAP cases (35.3%), followed by 
Mycoplasma pneumonia (22.4%) (Table 1.2) (210). Although bacteria remain the leading cause of 
CAP, viruses are frequently identified in patients with CAP (210, 211). However, several factors 
may alter the pathogen distribution. These factors include patients’ residence (NH vs community), 
severity of the disease, age, comorbidities, and prior antibiotic usage. 
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Table 1.2: Bacterial aetiology of CAP among Australian hospitals (210).  
Identified pathogen Percentage 
Streptococcus pneumoniae 35.3% 
Mycoplasma pneumoniae 22.4% 
Haemophilus influenzae 12.9% 
Legionella species 8.6% 
Chlamydophila species 4.3% 
Pseudomonas aeruginosa 4% 
Gram-negative enteric bacilli 3.7% 
Staphylococcus aureus 3.2% 
Moraxella catarrhalis 2% 
Others 3.6% 
 
The first factor to consider is patients’ area of residence. For example, while Streptococcus 
pneumoniae is the leading cause of pneumonia that develops outside hospital, one Japanese study 
suggested it remains as the second leading cause after  Staphylococcus aureus  for patients who live 
in NH (212). These resistant strains of the latter Staphylococcus aureus are seen more within NH 
populations, and are associated with a high severity of CAP (213). However, Australian data 
regarding the bacterial aetiology for patients residing in NH is lacking.  
Severity is another factor that should be considered since most guidelines based their 
empirical management on the severity of CAP (144, 182, 186). In Australia, Mycoplasma 
pneumoniae is the most frequently identified pathogen in mild cases, which is more common in 
people who are less than 50 years of age (210). Although Streptococcus pneumoniae is the most 
frequently identified pathogen in severe CAP, other organisms such as Legionella species and 
Pseudomonas species are seen commonly in such cases (210). 
Age plays an important role as well. Although Streptococcus pneumoniae and Mycoplasma 
pneumoniae are the most frequently identified pathogens in all age groups (202, 210, 214), the latter 
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is predominant in younger patients (aged < 65) (210, 214). Furthermore, gram negative bacilli have 
rarely been seen in those young populations (202). 
It has also been found that pre-existing respiratory diseases could increase the risk for specific 
microorganisms but the results are contradictory. For example, gram-negative bacteria such as 
Pseudomonas spp. are more likely to be identified in patients with IECOPD (210). However, other 
studies have shown no correlation between the presence or absence  of COPD in the case of 
microbiological profile (214).  
Prior antibiotics usage could also help predict the responsible pathogens. In one large cohort 
Spanish study, it was found that the rate of identified Legionella pneumophila was three times 
higher for patients with CAP who had received antibiotics before admission to the hospital than 
those who had not (215). The same study found, on the other hand, that Streptococcus pneumoniae 
was less likely to be identified in this group of patients.   
 Therefore, taking the patient’s medical history can provide a clue as to the possible 
microorganism responsible for CAP. Table 1.3 describes the specific risk factors, in an international 
context, associated with microbial aetiology of CAP according to IDSA/ATS. Some of these may 
be less relevant in Australia. 
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Table 1.3: Risk factors and most commonly identified bacterial pathogens (182) 
Condition  Commonly identified pathogens  
Alcoholism  
Streptococcus pneumoniae, oral 
anaerobes, Klebsiella pneumoniae, 
Acinetobacter species, Mycobacterium 
tuberculosis 
COPD and/or smoking 
Haemophilus influenzae, Pseudomonas 
aeruginosa, Legionella species, 
Streptococcus pneumonia, Moraxella 
catarrhalis, Chlamydophila pneumoniae  
Aspiration 
Gram-negative enteric pathogens, oral 
anaerobes 
Lung abscess 
community acquired methicillin resistant 
staphylococcus aureus, oral anaerobe, 
endemic fungal pneumonia, 
Mycobacterium tuberculosis, atypical 
mycobacteria  
Exposure to bat or bird droppings  Histoplasma capsulatum  
Exposure to birds Chlamydophila psittaci  
Exposure to rabbits  Francisella tularensis 
Exposure to farm animals or parturient 
cats 
Coxiella burnetti 
Human Immunodeficiency Virus 
(early) 
Streptococcus pneumoniae, Haemophilus 
influenza, Mycobacterium tuberculosis 
Human Immunodeficiency Virus (late) 
Streptococcus pneumoniae, Haemophilus 
influenza, Mycobacterium tuberculosis, 
Pneumocystis jirovecii, Cryptococcus,, 
Aspergillus, atypical mycobacteria, 
Pseudomonas aeruginosa, Haemophilus 
influenzae 
Hotel or cruise ship stay in the previous 
two weeks 
Legionella species 
Influenza active in community   
Streptococcus pneumonia, staphylococcus 
aureus, Haemophilus influenzae 
Cough more than two weeks with 
whoops or post-tussive vomiting 
Bordertella pertussis 
Structural lung diseases 
Pseudomonas aeruginosa, Burkholderia 
cepacia, staphylococcus aureus 
Injection drug use 
staphylococcus aureus, anaerobes, 
Mycobacterium tuberculosis, 
Streptococcus pneumoniae 
Endobronchial obstruction 
Anaerobes, Streptococcus pneumonia,  
Haemophilus influenza, staphylococcus 
aureus 
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1.6.9. Antibiotic-resistant Streptococcus pneumoniae 
The emergence of ABR has become a challenge and caused great problems for the 
management of CAP (216). One of the determining factors for the empirical management of CAP 
recommendations in various practice guidelines is antibiotic resistance to Streptococcus 
pneumoniae. The rate of antibiotic resistance to Streptococcus pneumoniae could vary from region 
to region, country to country, and even between states within the same country. This is why 
hospitals are encouraged to develop a local guideline for the management of CAP based on the 
national guidelines, taking into account the resistance rate of Streptococcus pneumoniae toward 
common antibiotic groups such as penicillins, macrolides, tetracyclines, and respiratory 
floroquinolones (117, 182, 186). 
The minimum inhibitory concentration (MIC) of penicillin toward Streptococcus pneumoniae 
has been changed since 2008 for non-meningeal infections (217) (Table 1.4). By this new 
definition, many isolated Streptococcus pneumoniae that were considered resistant bacteria would 
be defined as susceptible pathogens after 1st of January 2008, such that all publications before 2008 
should be interpreted with caution  For instance,  in one Australian prospective study that was 
conducted in the period 2004-2006, it found that around 7.3% of the isolated Streptococcus 
pneumoniae from CAP patients were considered to be intermediate resistance (MIC; 012-1 μg/ml) 
while only one isolate was considered a resistant pathogen (MIC; 2 μg/ml) (210). Under the new 
break point, all those isolates would be susceptible to penicillins. Therefore, penicillins, coupled 
with a good coverage of Streptococcus pneumoniae, is recommended as a first line therapy for 
patients with mild CAP as per TG14 (144). 
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Table 1.4: Break points to identify non-meningeal Streptococcus pneumoniae’s 
susceptibility toward penicillins. 
Period 
MIC (μg/ml) by susceptibility category 
Susceptible Intermediate Resistance 
Before 1st January 2008 ≤ 0.06 0.12 - 1 ≥ 2 
After 1st January 2008 ≤ 2 4 ≥ 8 
 
The incidence of macrolide-resistant Streptococcus pneumoniae varies among countries and 
can be as low as  1% and as high as 50% in different European countries (218).  In Australia, there 
is an increasing trend of macrolide-resistant Streptococcus pneumoniae. From 1994 to 2005, the 
macrolides’ resistance increased threefold in Australia (from 8% to 22%) (219). Therefore, a 
macrolide monotherapy regimen is only recommended by TG14 as an alternative therapy in the 
case of penicillin allergy or when an atypical pathogen is suspected to be the cause of diseases 
(144). Furthermore, the ATS/IDSA CAP guidelines only recommend the use of monotherapy 
macrolides as a first line therapy for mild CAP among patients who had been previously healthy 
and had not used any antibiotic within the last three months (182). 
Tetracycline (doxycycline in particular) is one of the most commonly prescribed antibiotics 
for the management of CAP (220). However, it is only recommended to be used alternatively as a 
monotherapy for patients with mild CAP (144). The resistance of tetracycline has been found to be 
as high as 18.4% in Australia according to 2005 data (219).  
1.6.10. CAP severity and scoring system 
To improve the care of patients with CAP, a number of different scoring systems have been 
developed to help assess its severity. These scoring system has been subsequently utilised to guide 
the appropriate antibiotic therapy in terms of drug selection, route and whether management should 
be in the out-patient or in-patient (including ICU) settings (144, 182, 186). Several severity scoring 
systems have been developed, with the most known being the Pneumonia severity index (PSI) and 
33 
 
CURB65. SMART-COP and CORB are advocated by TG14 (144). However, there is no agreement 
amongst physicians on the best scoring tool to use (221). Despite the recommendation to use a 
scoring system to assess the need for hospital admission, several factors should be taken into 
account. These factors include co-existing diseases, the presence of pleural effusion, complications 
from pneumonia, reduced compliance and social factors (222). 
Mortality predictors’ severity tools  
Both PSI and CURB65 severity tools are based on the 30-day mortality rate (Table 1.5) (223, 
224). The mortality rate increases with increased scoring (225). While the PSI is better at 
identifying patients with low mortality risk, the CURB65 could predict patients at high risk more 
accurately (226). However, several studies show that CURB65 is as effective as PSI in predicting 
mortality (227, 228). 
Table 1.5: Prediction of the mortality rates based on PSI and CURB65 values. 
PSI mortality rates by classes  Predicted mortality rate 
I - II 1.1% 
II (≤ 70) 0.7% 
III (71-90) 2.8% 
IV (91-130) 8.5% 
V (> 130) 31.1% 
CURB65 mortality rates by scores  Predicted mortality rate 
0 -1 1.5% 
2 9.2% 
3 or more 22% 
 
The British Thoracic Society (BTS) and IDSA/ATS CAP guidelines prefer to use the 
CURB65 tool to assess the severity of CAP. This is because it is easier to remember and calculate 
than PSI. The CURB65 index is simple and less complicated than that seen in the PSI index, which 
contains 20 variables that include several laboratory variables. On the other hand, CURB65 
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contains only 5 variables that need to be measured, and it is suitable for busy departments such as 
ED (182, 186). 
PSI scoring system was identified by Fine et al. in the US in 1997 (223). The main aim of PSI 
was to identify the patients with CAP at low risk of death based on the prediction of 30-day 
mortality rate. This was meant to allow the physician to make an appropriate decision on whether 
the patient should be treated in or out of hospital (182, 223). The PSI consists of five classes, 
starting with class I which represents the lowest risk of death (Table 1.6). The class I and II patient 
can be treated as an outpatient with oral antibiotics. Class V indicates the highset severity level 
wherein the patient needs to be hospitalised and ICU care should be considered. To determine the 
severity score, there are 20 variables such as demographic factors, co-existing disease, physical 
examination, laboratory and chest X-ray findings that need to be assessed. However, if the patient is 
under the age of 50, has no comorbidities, and has a normal physical examination, there will be no 
need to do laboratory tests and the patient will be classified as level I severity and should thus be 
treated as an outpatient with oral antibiotics. PSI has a low false negative rate which means that it is 
more sensitive for the identification of patients who have non-severe CAP (229). This can then give 
the physician more confidence in deciding if the patient needs to be hospitalised or not, especially 
for those patients who prefer not to be admitted (230).  However, due to the high value that the PSI 
places on age and comorbidities, patients could be categorised into a high risk class even when the 
risk is actually quite low (231).  
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Table 1.6: PSI scoring system to identify patients with mild, moderate and severe CAP. 
Patient’s characteristics  Points 
Demographic factors 
Age (male) Years 
Age (Female) Years – 10 
Nursing home resident 10 
Co- existing disease 
Neoplastic disease 30 
Liver disease 20 
Congestive heart failure   10 
Cerebrovascular disease 10 
Renal disease 10 
Physical examination findings 
Altered mental status  20 
Respiratory rate ≥ 30 breaths/minute 20 
Systolic blood pressure < 90 mm Hg 20 
Temperature < 35 ˚C or ≥ 40 ˚C  15 
Heart rate ≥ 125 beats/minute 10 
Laboratory and chest X-ray findings 
Arterial pH < 7.35  30 
Blood urea nitrogen ≥ 11 mmol/liter 20 
Glucose ≥ 14 mmol/liter 10 
Haematocrit < 30% 10 
Partial pressure  of arterial oxygen < 60 
mm Hg 
10 
Pleural effusion  10 
Mild CAP (≤ 70 points), moderate CAP ( 71 – 130 points), severe CAP (˃ 130 points) 
 
CURB65 scoring system was designed in the UK by Lim et al. in 2003 (224). The aim of 
CURB65 was mainly to identify people at high risk of death (Table 1.7).  It is based on 5 variables 
for detecting the severity of the disease: Confusion, Urea level (> 7 mmol/l), Respiratory rate (> 30 
breath per minute), Blood pressure (systolic blood pressure < 90 mm Hg or diastolic blood pressure 
< 60 mm Hg), and aged 65 years or older. CURB65 can divide patients into three groups according 
to the risk of 30-day mortality: low risk (score of 0-1) who might be treated as outpatients; 
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intermediate risk (score of 2) who should be hospitalised; and high risk (score of ≥ 3) of mortality 
who need to be hospitalised with consideration of ICU admission (182, 186, 224). 
Table 1.7: CURB65 scoring system to identify patients with mild, moderate and severe 
CAP. 
Patient’s  characteristics  Points 
Confusion  1 
Urea ˃ 7 mmol/liter 1 
Respiratory rate ≥ 30 breaths/minute 1 
Blood pressure (Systolic blood pressure < 
90 mm Hg or Diastolic blood pressure ≤ 60 
mm Hg 
1 
Age ≥ 65 1 
 Mild CAP (0 – 1 points), moderate CAP (2 points), severe CAP (≥3 points) 
 
Although both PSI and CURB65 have a good prediction rate for risk of mortality, they are not 
so good when it comes to identifying persons who are most likely to benefit from ICU admission 
(232). Because of their being heavily influenced by age, both scoring tools were found to be 
nonspecific and the patient’s severity could be overestimated (231, 233). 
Predictors of the need for Intensive Respiratory Support or Vasopressor Support 
(IRVS) 
SMART-COP and CORB are the scoring tools which are currently recommended to be used 
as per TG14 (Figure 1.6) (144) . Unlike PSI and CURB65, which are based on the prediction of 30-
day mortality rate to measure the severity, the SMART-COP/CORB scoring tools, which originated 
in Australia, aim to measure the severity of CAP according to the need for intensive respiratory 
support or vasopressor support (IRVS) and ICU admission (234, 235). This is supported by a meta-
analysis study which showed that SMART-COP provides better prediction as to the need of ICU 
than PSI and CURB65 (236). Unlike PSI and CURB65 tools, age has little effect on both SMART-
COP and CORB tools. Therefore, the probability of catching severe cases in younger patients is 
greater when the SMART-COP or CORB tool is used (234, 235).  
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CORB SMART-COP 
Variables Points  Variables Points 
Confusion 1 Systolic BP < 90 mm Hg 2 
O2 saturation ≤ 90% 1 Multilobar CXR involvement  1 
Respiratory rate ≥ 30 
br/min 
1 Albumin < 35 g/l 1 
Blood pressure 
Systolic BP < 90 mm Hg or 
Diastolic BP  ≤ 60 mm Hg 
1 Respiratory rate ≥ 30 br/min 1 
 
 
Tachycardia ≥ 125 bpm * 1 
  Confusion (acute) 1 
  
Oxygen low * 
PaO2 < 60 mm Hg, or O2 saturation 
≤ 90%, or PaO2/FiO2 < 250 
2 
PH < 7.35 2 
 
Moderate CAP 
(SMART-COP score < 5 and CORB score < 2 
Severe CAP 
(SMART-COP score ≥ 5 or CORB score ≥ 2) 
 
 
Br/min = breaths per minute, BP = blood pressure, O2= oxygen, PaO2 = partial pressure of oxygenation, CXR = 
chest X-ray, bpm = beats per minute, FiO2 = fraction of oxygen in inspired air. 
*For patients ≤ 50 years old, the value of tachycardia is ≥ 130; and the oxygenation values  are PaO2 < 70 mm 
Hg, O2 saturation ≤ 93 and PaO2/FiO2 < 333. 
Figure 1.6: Identifying the severity of CAP based on CORB and SMART-COP. 
The CORB severity tool is aimed at providing a simple tool that can help clinicians decide if 
the patient requires early aggressive management for CAP or not. CORB contains four easily 
assessed variables and no invasive testing is needed, which makes it a good tool for clinics and 
hospitals that may have few facilities. Patients are classified as having severe CAP when two or 
more of the CORB variables are detected (235).  
The SMART-COP severity tool is aimed at identifying the severity of CAP according to the 
need of IRVS as well as CORB.  SMART-COP, compared with PSI and CURB65, is better able to 
predict patients who need ICU admission and IRVS, and thus facilitates for the right decision to be 
made early in the ED. Charles  et al.. found that patients in classes VI and V with PSI or in group 
three with CURB65 were less likely to receive IRVS when compared to patients who scored three 
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or more using the SMART-COP scoring tool (234). Patients are classified as having severe CAP 
when they score 5 points or more (234). 
1.6.11. Empirical therapy and CAP guidelines  
Since there is no rapid diagnostic method to indicate which pathogens are responsible for the 
CAP, empirical therapy is commonly used. A patient’s clinical presentation is not enough for 
predicting specific causative pathogens responsible for CAP. The guidelines for empiric 
antimicrobial therapy are based on providing cover against pathogens most likely to be responsible 
for the disease (237). Based on the pathogens detected in one multi-centre study in Australia, the 
recommended antibiotic regimens (penicillin + doxycycline or macrolide) to cover both 
Streptococcus pneumoniae and atypical pathogens were considered adequate for 94.6% of patients 
with CAP (210). To improve the care of patients with CAP, many countries such as the US, UK and 
Australia have developed guidelines for the management of the disease (144, 182, 186). 
Those guidelines classify patients according to severity (mild, moderate or severe) and site of 
care (outpatient, inpatient or ICU), and the antibiotics regimen is accordingly recommended. 
Table 1.8 shows the recommended antibiotic regimens in IDSA/ATS, BTS and TG14 based on the 
severity and site of care.  
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Table 1.8: First-line therapy recommendations for CAP in adults as per IDSA/ATS, BTS 
and TG14 (144, 182, 186). 
Setting 
and 
severity 
IDSA/ATS (2007) BTS (2009) TG14 (2010) 
Mild CAP/ 
out-patient 
 Macrolide (azithromycin, 
clarithromycin, or 
erythromycin) a 
 Fluoroquinolone  
(moxifloxacin, 
levofloxacin, or 
gemifloxacin) 
 β-lactam (amoxycillin, 
amoxycillin/clavulanate, 
ceftriaxone, 
cefpodoxime, or 
cefuroxime) + macrolide 
(Azithromycin, 
clarithromycin, or 
erythromycin) 
 Amoxycillin  Amoxycillin 
 
Moderate 
CAP/ In-
patient (non-
ICU) 
 Fluoroquinolone 
(moxifloxacin, 
levofloxacin, or 
gemifloxacin) 
 Β-lactam (ampicillin, 
cefotaxime, or 
ceftriaxone or 
ertapenem) + macrolide 
(Azithromycin, 
clarithromycin, or 
erythromycin) 
 β-lactam 
(amoxycillin, or 
benzylpenicillin) + 
clarithromycin  
 Benzylpenicillin + 
doxycycline or 
clarithromycin 
Severe 
CAP/ICU 
 Β-lactam 
(ampicillin/sulbactam, 
cefotaxime, or 
ceftriaxone) + 
azithromycin or 
fluoroquinolone 
(moxifloxacin, 
levofloxacin, or 
gemifloxacin) 
 Amoxycillin/clavul
anate + 
clarithromycin  
 Ceftriaxone, 
cefotaxime, or 
(benzylpenicillin + 
gentamicin) + 
azithromycin 
a In the case of absence of co-existing diseases and no antibiotic used in the previous 3 months 
 
Although there is an agreement to empirically cover Streptococcus pneumoniae in all 
guidelines since it is the most likely cause of CAP, covering atypical pathogens (Mycoplasma 
pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila) for patients with mild CAP 
(or who are treated as outpatients) remains controversial (144, 182, 186). For example, the US 
guidelines recommend a regimen providing atypical cover, such as azithromycin as a first line 
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therapy or doxycycline as an alternative for the management of patients with mild CAP and without 
any risk factor of drug-resistant Streptococcus pneumoniae (182). Other guidelines, such as the BTS 
guidelines and Australian TG, recommend amoxycillin as a first line therapy, as the priority is to 
cover Streptococcus pneumoniae (144, 186). Doxycycline or clarithromycin is suggested only as an 
alternative to extending cover to atypical pathogens if they are suspected.  
Although macrolides cover Streptococcus pneumoniae and atypical pathogens, several 
reasons might lead to discouraging routinely prescribing for patients with mild CAP. Firstly, there 
are no differences with regard to clinical outcome between patients receiving antibiotics that only 
cover Streptococcus pneumoniae and those receiving extended spectrum antibiotics that cover 
atypical pneumonia  (238). Secondly, macrolide resistance to Streptococcus pneumoniae is high in 
some regions such as Europe (239). Therefore, the use of macrolides is not recommended in those 
regions. Another reason is the relationship between the high usage of macrolides and tetracycline in 
mild cases and the emergence of Streptococcus pneumoniae, which is the main causative organism 
in CAP (240). 
For moderate CAP, guidelines recommend covering Streptococcus pneumoniae and atypical 
pathogens (144, 182, 186). However, there is still controversy regarding a regimen that provides 
cover against atypical pathogens in moderate CAP. While there are studies that showed the benefit 
of using macrolides in CAP patients (241), other studies have shown that receiving antibiotics that 
cover atypical pathogens does not affect mortality rate or success of treatment (242). 
A broad-spectrum antibiotic for the treatment of severe CAP is warranted to cover 
Streptococcus pneumoniae, atypical pathogens, and Enterobacteriaceae spp. (144, 182, 186). As 
such, a combination therapy is often recommended to provide additional cover for the atypical 
pathogens that are commonly identified in severe CAP patients  (210), as it has been shown to 
reduce mortality (243). 
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1.6.12. Pattern of empirical antibiotic usage 
The main reason for choosing one antibiotic regimen over another is to cover the most likely 
pathogens that might be the cause of the infection being treated. In the real world, a range of 
antibiotic regimens have been used to treat patients with CAP. In an international cohort study, 
more than half of the patients with CAP received β-lactams plus macrolides as an empirical 
treatment, whereas quinolones and β-lactams alone were the second most likely regimen used (244, 
245). A β-lactam alone is less likely to be prescribed for CAP patients. This could be due to 
expected unfavourable clinical outcomes (244).  
The pattern of antibiotic prescribing could be different among regions and countries. In one 
study, it was found that doctors in Australian hospitals frequently prescribed a β-lactam plus either 
doxycycline or macrolides for patients who were diagnosed with CAP - as an empirical therapy. A 
penicillin-based regimen was commonly used (55.8%), and ceftriaxone-based regimens represented 
36.8% of cases (210). However, in Europe, doctors more frequently prescribe B-lactam 
monotherapy than a combination therapy (214).  
Antibiotic prescribing practice seems to be influenced by the patient’s age. For example,  
patients aged less than 65 years have been shown to be less likely to receive B-lactam antibiotics 
and more likely to receive quinolones than older patients (202, 246). 
1.6.13. Adherence rate to CAP guidelines’ recommendations  
The adherence rate to the guidelines for CAP varies greatly from country to country, and even 
between institutions within the same country. For instance, in one of the largest audit studies in the 
UK, which included 64 institutions, the overall adherence to the national guideline regarding CAP 
management was 56% (50% - 70%) (247). On the other hand, in one multi-centre study in Australia 
that included 26 institutions, the overall adherence to the national guideline regarding CAP was 
only 20% (220). Although the overall compliance with the national guideline was very low in 
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Australian hospitals, single institutions could reach very high levels of adherence. For example, in 
one teaching hospital in Australia, adherence to the CAP guideline was 72.3% while it was as low 
as 18% in another (220, 248). Compliance with the recommended CAP guideline was seen more in 
severe cases (220, 247). However, guidelines are less likely to be followed among patients admitted 
to ICU (249). 
Non-concordance to the guideline’s recommendations could lead to either under treatment or 
overtreatment. For instance, in one international study of an elderly population, it was found that 
around one-third of patients with severe CAP received non-concordant antibiotic regimens that 
were considered to be under treatment according to the guideline’s recommendation. On the other 
hand, around 60% of patients with moderate CAP received antibiotic treatment that was considered 
to be overtreatment according to the guidelines (244). 
Studies have used different criteria to measure adherence to the recommended guidelines. 
Several studies have measured adherence to the CAP guideline where the selection of antibacterial 
agent was based on the severity of CAP (221, 247), while others also considered the route of 
administration, dose, and presence of penicillin allergy when antibiotics were selected as the 
additional tools for measuring the rate of adherence (220, 248, 250). Some studies defined 
adherence to the guideline as any antibacterial regimen that was used according to the guideline 
regardless of the CAP severity (251, 252). This may explain the unusual variability in the 
concordance rates observed in the above-mentioned studies.  
1.6.14. Barriers towards adhering to the guideline’s recommendations 
 Few studies have assessed the barriers that could hinder the use of the recommended 
guidelines for the management of CAP. A lack of education and confidence seems to be the main 
barriers for junior doctors (253). However, the likelihood to council the recommended guideline 
becomes less as doctors get more experience. Other barriers include the high work load in busy 
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departments such as ED, and the lack of support from senior doctors.  Furthermore, the complexity 
of CAP guidelines could be one of the reasons for non- adherence (253). Awareness of the presence 
or change in the recommended guideline could be a major barrier. Almost half of the doctors (48%) 
in 7 Pittsburgh hospitals, who responded to a survey regarding the barriers towards adhering to the 
recommended local CAP guideline, were uncertain about the availability of the guideline (254). A 
lack of familiarity with the guidelines, lack of outcome expectancy, and the presence of other CAP 
guidelines that conflict with the recommended national CAP guideline were found to be the major 
barriers to physicians’ compliance with the CAP guidelines in a qualitative study (157). 
1.6.15. Impact of adherence on clinical outcomes, healthcare costs, and clinical 
practice 
Studies have shown that physicians are more likely to make inaccurate estimation of CAP 
severity if guidelines are not used, leading to an increase in mortality rates amongst this group of 
patients (255-258). Several studies have shown that adherence to the recommended guidelines for 
the management of CAP has clearly improved the process of care and patients’ clinical outcomes 
(257, 259).  
A number of studies showed that the survival rate for patients with CAP, who were managed 
according to the guidelines, was significantly higher than those who were not (169, 258-263). In 
one large retrospective study (115 institutions) for CAP patients who were not admitted to ICU, the 
mortality rate decreased significantly from 6.8% to 5.2% when the recommended CAP guideline 
was used (262). For ICU patients, with an overall mortality rate around 3 times higher than non-
ICU patients, compliance with the recommended CAP guideline can markedly reduce the mortality 
rate from 25% to 11% (264). Arnold et al. found that the in-patient and 30-day mortality rate for 
elderly patients was significantly less when patients with CAP received antibiotic regimens 
consistent with CAP guidelines’ recommendations (8% vs 17%; p < 0.01) (244). Concordance to 
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the guideline significantly increased the survival rate, which could reach 14% higher than those 
who have not been managed according to the guideline (264). 
Adherence to the recommended CAP guidelines has been associated with reduction in 
hospital LOS among patients with CAP (249, 259, 262, 265, 266). Dambrava et al. found that 
adherence to the national CAP guideline can significantly reduce LOS by two days from 10.4 days 
to 7.6 days (249) even though LOS for patients with CAP depends on the time needed for the 
patient to be clinically stable, which is correlated to the severity of the disease (266). The observed 
reduction in LOS for CAP patients who receive appropriate antibiotic regimens could be attributed 
to the shorter time needed for patients with CAP to be clinically stable.  In their study, Arnold et al. 
showed that the probability for patients with CAP to reach clinical stability within 7 days of 
admission was significantly higher for patients who received antibiotic regimens consistent with the 
guideline, which led consequently to a shorter LOS (244). Being recipient of concordant antibiotic 
regimen for the management of CAP is associated with lower treatment failure. Blasi et al. studied 
the effect of adherence to the national CAP guidelines on the rate of treatment failure; that is, 
worsening of symptoms or the need to change the antibiotic regimen. The analysis of the outcomes 
from 2,847 patients showed that  adherence to CAP guidelines led to statistically significant 
reduction in treatment failure (OR 0.74, 95% CI 0.06-0.9) (257). Therefore, overall, it seems that 
concordance to the recommended guideline can reduce LOS, time to clinical stability, treatment 
failure, and the rate of hospital admission, which in turn can reduce the healthcare costs of CAP. 
Concordance to the guideline can also reduce healthcare costs in several ways. In their 
analysis of healthcare costs of hospitalisation due to CAP, Menendez et al. found that around 70% 
of the cost of hospitalised patients with CAP were due to the room occupied and LOS (251). In 
terms of hospital admission, using the recommended scoring tool could help decide if patients need 
to be hospitalised or not (267). It has been shown that the rate of outpatient treatment for patients 
with CAP at risk groups I-III increased by 18% when the recommended PSI tool was used (268). 
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On that ground, it was estimated that more than one billion American dollars would be saved in the 
US if unnecessary hospital admissions were reduced (269). The estimated cost of treating 
outpatients with CAP in Australia is $20 million per annum (270). This cost could be doubled if the 
patients were admitted to hospital unnecessarily, such as in mild cases (271). 
Clinical practice  has been shown to improve after the implementation of guidelines (259). It 
was shown that the duration of antibiotic treatment and the time to switch from intravenous 
antibiotics to oral antibiotics could be reduced by more than two days in severely ill patients with 
guideline adherence. Alberto et al. found that patients who received antibiotic according to the 
recommended guideline reached clinical stability faster, leading to a rapid switch from intravenous 
to oral antibiotics. This led to a decrease in the overall duration of  antibiotic treatment, which was 
reduced by more than one day (259).  
1.6.16. Initiatives to improve compliance with CAP guidelines’ 
recommendations 
Many national and local initiatives have tried to improve the quality of CAP management 
(248, 250, 272). It has been agreed that there is a positive correlation between adherence to the 
recommended guideline and reduced LOS and mortality rate.  The main effort has been to actively 
implement the guideline. Studies showed that active implementation of the CAP guideline can 
significantly increase the rate of adherence. Reported rates of improvement in concordance with the 
guideline ranged from 6.2% to 28% (250, 257, 272, 273). 
It is not uncommon to perform more than one strategy in order to implement CAP guidelines. 
In one meta-analysis study, it was found that the intervention strategies most often used were 
educational meetings (63%) and dissemination of written materials (78%) (274). A combination of 
these two strategies was used in 52% of the studies. Most intervention studies resulted in a modest 
improvement in the adherence rate to the guideline, except in the case of audit and feedback 
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strategy, which when used alone resulted in either a lack of or only modest improvement (274). 
Increasing strategies to be multifaceted for implementing CAP guidelines in an institution has been 
associated with an increasing utilisation of the recommended guidelines. An American large 
randomised controlled study showed that the adherence rate in those hospitals, where high intense 
multifaceted strategies were performed, was significantly higher than those in hospitals where only 
low or moderate intense strategies were performed (65.6%, 29.3%, and 30.7%, respectively) (275, 
276). 
Some strategies might be more suited to a particular healthcare setting,  such as one-on-one 
academic detailing which might not be practical in busy areas such as ED, where it could take 12 
minutes on average (277). Similarly, ED might not be a good place to conduct one-on-one 
education due to the small area available. In contrast, group discussion might be more accepted in a 
busy department (277).Table 1.9 summarises the interventions that have been shown to improve 
implementation of recommended CAP guidelines:  
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Table 1.9: Summary of the interventions of recommended CAP guidelines that have been 
used to improve implementation (274). 
Intervention Intervention methods 
Educational 
 Dissemination of written materials (e.g. mailing)  
 Educational meetings (e.g. grand rounds) 
 Academic detailing (i.e. one-on-one meeting between prescriber 
and trained medical staff) 
Reminders 
 Patient chart reminder (i.e. standard treatment in the chart) 
 Electronic reminder (i.e. appearance of the recommended 
guideline when ordering) 
 Pre-printed forms 
 Undefined reminder (e.g. potters or tag card) 
Local opinion leader  
Audit and 
feedback 
 (i.e. feedback of the performance regarding adherence to the 
guideline throughout period of time) 
Multi-
participation 
 Multidisciplinary team (team from different specialities) 
 Local consensus process (i.e. including prescribers in the 
discussion regarding the guideline) 
 Patient mediated intervention  (i.e. third party intervention such 
as by a pharmacist)  
External guiding 
 Clinical pathway 
 Standing order (e.g. preauthorised order set)  
 Formulary adaption (e.g. limiting antibacterial choices)   
Structural 
 Computerised system (i.e. decision support) 
 Organisational (e.g. selected antibiotic stock at the ward) 
Other recorded 
factors 
 Quality improvement organisations (i.e. local or external 
organisations that focus on the improvement of CAP outcome) 
 
Interventions among Australian hospitals  
Several efforts and interventions have been made among Australian hospitals to improve the 
quality of antibiotics use for the management of CAP. One of the Australian programmes for 
improving the quality of antibiotics use was the Community-Acquired Pneumonia: Towards 
Improving Outcome Nationally (CAPTION) (250). The programme is aimed at improving the 
appropriate use of antibiotics in CAP through encouraging physicians to adhere to the national 
guideline. EDs around Australia (n=26) participated in the programme. The first step of CAPTION 
was to collect baseline data to measure the rate of adherence to the guideline before any 
intervention was made. These interventions were mainly educational, which included: 
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1- One-on-one academic detailing 
2- General slide presentation for the feedback of local data on guideline concordance, and an 
education session about the best practice management of CAP according to the guideline 
3- Supply letters to the prescribers 
4- Wall posters  
5- Tag cards that included PSI variables to be measured         
The overall improvement in the adherence to the guideline was moderate, with adherence 
rates rising from 20% to 30%. However, a limitation of the study was the low number of patients 
(20 patients in each hospital).  
Another intervention was made by one Australian teaching hospital to improve the use of the 
CAP guideline (248). In this intervention, the guidelines were made easily accessible in the ED and 
throughout the hospital computer system. Furthermore, physicians were encouraged to calculate and 
document the PSI on the medical record and to use that to guide patient admission and the use of 
recommended antibiotics. That study showed that even though it was difficult to apply the PSI in 
the ED, concordance to the recommended guideline was 20% more when PSI was documented. 
However, one limitation of the study was the lack of baseline data to measure the effect of the 
intervention. 
The type of intervention could significantly make a difference in the adherence rate. For 
example, the use of a computer support system could be more effective than academic detailing to 
implement a guideline. These two strategies were implemented in one Australian hospital in two 
different periods of time (148). During the first period, one-on-one academic detailing was utilised. 
In the second period, a computerised system for antibiotic prescribing, where the guideline’s 
recommendations came up on screen at the time of ordering was implemented. The transferable 
website included tools to calculate the PSI variables in order to guide the admission decision 
(outpatient vs inpatient), and CURB65 variables in order to decide whether the patient needed ICU 
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admission or not. The website also included recommendations about appropriate antibiotics, 
duration, time to switch therapy from IV to oral, and the relevant literature that supported the 
recommendations. This strategy increased awareness of the guideline and hence adherence. When 
compared to the academic detailing strategy, the rate of adherence was higher when a computer 
support system was utilised (68.7% and 89.7%, respectively). 
1.6.17. Management of CAP in ED settings 
Many guidelines encourage the use of the antibiotics as soon as a diagnosis of pneumonia is 
confirmed by the chest X-ray (144, 182, 186). Therefore, it is not surprising that antibiotics are 
more likely to be administrated in the ED before admission to the ward. In one study that was 
conducted in 1,370 admitted patients with a primary diagnosis of CAP, it was found that nine out of 
ten patients received their first dose of antibiotics in the ED (278). ED clinicians were likely to 
prescribe antibiotics to elderly patients more often than to younger patients (278). Furthermore, 
physicians at the ED were less likely to delay the administration of antibiotics for those patients 
with high temperature at the time of triage, high respiratory rate, history of cardiopulmonary disease 
or presence of abnormal chest X-ray. However, confused patients and those present with shortness 
of breath were less likely to receive antibiotics in the ED (278).  
ED would be an optimal place to start for any intervention aiming to enhance adherence to 
CAP guidelines for several reasons. In a hospital setting, most patients are initially diagnosed with 
CAP in ED (278). That makes ED the primary source of hospital admission for the vast majority of 
CAP patients. Furthermore, ED physicians are always encouraged to take timely decision when 
admitting or sending a patient home in order to avoid a back log of patients in ED and hospital 
inpatient beds (279). The first dose of antibiotics is more likely to be initiated while the patient is in 
the ED (278). Furthermore, ED physicians are more likely to overestimate the disease severity of 
CAP which leads to unnecessary hospitalisation and use of inappropriate antibiotics (275). For all 
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the above reasons, initiatives to optimise the management of CAP at EDs are likely to improve the 
appropriateness of CAP management in hospital settings (275). 
1.7. Study sites 
The Royal Hobart Hospital (RHH) is a principal referral hospital in Tasmania. It has 550 
beds serving around 240,000 people in the southern region of Tasmania. It represents a major 
clinical and research centre in the area, so it works closely with the University of Tasmania 
(280).  
An antimicrobial stewardship programme was officially launched in mid-2009 with the 
following responsibilities and routine activities (281): 
1- Development of antibiotic guidelines. 
2- Apply restriction polices for broad spectrum and expensive antibiotics. 
3- Perform regular rounds in intensive care and oncology units. 
4- Daily rounds to provide feedback on antibiotic prescribing to prescribers. 
The North Western Regional Hospital (NWRH), on the other hand, is a 160-bed 
secondary service hospital that provides services to north western Tasmania and King Island. 
The distance between the two hospitals is 330 Kilometres. Transfer to other tertiary hospitals 
might occur for some diseases (280).  
1.8. Background and rationale  
There have been an increasing number of studies that measure the adherence rates to 
CAP guidelines’ recommendations in hospital settings (257, 282-284). This focus is based on 
studies that showed a positive impact of adherence to CAP guidelines on clinical outcomes, 
particularly mortality rates and healthcare costs.  
A previous published study showed poor adherence rates to the national CAP 
guidelines’ recommendations for an empirical management of CAP among Australia’s 
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hospitals (220). However, despite the national initiative to increase adherence to the national 
CAP guidelines, improvement has been limited. A study conducted by Mclntosh et al. in 26 
Australian hospitals found that the active implementation of national guidelines for the 
management of CAP, by means of academic detailing and distribution of educational 
materials, had only a modest effect on raising the adherence rates to CAP guidelines in ED 
(30% vs 20%) (250). However, academic detailing was perceived as a time-consuming 
process, particularly in a busy clinical area such as ED. Since the adherence rate was low even 
after interventions, addressing factors that hinder the doctors’ adherence to CAP guidelines 
could provide some insights into the most appropriate strategies for actively implementing 
CAP guidelines. Overall, published studies on the management of CAP either evaluate these 
factors alone or evaluate the effects of selected interventions without addressing the factors 
that hinder doctors from adhering to the CAP guidelines. 
1.9. Thesis aims and outline  
The overall aim of this research project is to develop and evaluate the implementation of 
the CAP guidelines in an Australian hospital sitting, by tailoring an intervention through 
addressing potential factors that affect adherence to the same guidelines. The evaluation of the 
chosen tailored intervention strategies was aimed at measuring the extent to which the 
intervention would affect adherence rates and consequently clinical outcomes.   
Given the nature of studies being examined in this PhD thesis and the plurality of 
methods used in such studies, each chapter in this thesis will discuss separately the relevant 
studies’ methodology. Each chapter thus represents the results of a particular study that was 
designed to answer a specific research question(s). Throughout this thesis, the terms adherence 
and concordance will be used interchangeably to refer to prescribing or receiving medications 
as recommended by the guidelines. 
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Chapter 2 (baseline): This chapter will collect and analyse the baseline data retrospectively 
from both RHH and NWRH in order to measure the adherence rates and characterise antibiotic 
prescribing for the management of CAP before any intervention.  
Chapters 3 and 4 (barriers): In these two chapters, two studies were conducted (quantitative 
and qualitative) with the main aim of determining the potential barriers and factors that hinder 
doctors from adhering to the guideline’s recommendations towards the empirical management 
of CAP.  
Chapter 5 (enablers): A survey questionnaire was distributed to infectious disease 
pharmacists in Australian public hospitals. This study was aimed at determining strategies that 
have been used by institutions and perceived as successful towards improving the empirical 
antibacterial management of CAP. 
Chapter 6 (intervention): The findings from chapters 2, 3, 4 and 5 were utilised to design 
intervention strategies. In this chapter, we discussed how those findings influence our decision 
regarding selection of the interventions’ component. Furthermore, we discussed the rationales 
behind the chosen approaches to evaluate the impact of the intervention. 
Chapter 7 and 8 (outcomes’ evaluation): In these two chapters, we aimed at determining the 
impact of our intervention strategies on the rates of adherence to CAP guidelines and clinical 
outcomes (mortality and LOS).  
Chapter 9 (outcomes’ evaluation): This chapter aimed to show the effect of our intervention 
on the appropriateness of ceftriaxone prescribing of all indications, including CAP.        
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1.10. Significance of the research  
As a rule, the active implementation of clinical practice guidelines to improve 
management of CAP is found to be more effective than passive dissemination. However, there 
are a few published studies that addressed the rationale behind choosing an intervention 
component. Therefore, to maintain a sustainable effect, a clear understanding of factors and 
barriers that affect guideline adherence is warranted in order to ensure that clinical prescribing 
behaviour changes. In this research, we explored these factors in-depth and then designed an 
intervention component accordingly.  
1.11. Limitation of the research 
This research only focused on empirical antibiotic management. Therefore, this research 
project was not designed to evaluate other processes of care indicators such as time to 
antibiotic and diagnostic measurement. 
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Chapter 2. Adherence to TG14 recommendations for 
the empirical management of CAP: baseline study 
2.1. Introduction 
Two major changes affecting the empirical management of CAP were introduced with 
the 2010 edition of the Australian Antibiotic Therapeutic Guidelines (TG14) (144). The first 
related to the recommended severity assessment tool; in the previous CAP guidelines (TG13, 
2006), the pneumonia severity index (PSI) was recommended, whereas TG14 advocates the 
use of the alternative tools, SMART-COP or CORB(144). This change was due to the 
complexity of the PSI, which requires 20 variables to be considered; in contrast, no more than 
eight variables are required for use of the SMART-COP and CORB tools.  
The second set of changes related to the recommended antibiotic treatment regimens. 
For instance, roxithromycin was replaced by clarithromycin as a treatment option in TG14. 
Although there is no specific trial evidence to support this change, the recommendation was 
based on the consensus opinion of the expert group that roxithromycin is inferior to 
clarithromycin for the management of lower respiratory tract infections (144). Three IV 
antibiotics from the penicillin group (benzylpenicillin, amoxycillin and ampicillin) were 
recommended for moderate CAP in TG13 to cover S. pneumoniae, however, this was 
simplified in TG14, with just IV benzylpenicillin retained. This was on the basis of its 
narrower spectrum and the reduced potential for associated collateral damage; that is, 
disturbance of normal bacterial ecology that leads to the development of adverse effects and 
further increases the emergence of antibiotic-resistant bacteria or (31). TG14 also saw the 
removal of the previous recommendation to use a combination of antibiotics for the initial 
management for patients with mild CAP. This change was based on research showing no 
difference in mortality rate between patients treated with monotherapy and combination 
therapy (β-lactam/macrolide) (285).  
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Against the background of these changes to CAP management guidelines, the primary 
aims of the study were: 
 To characterise antibiotic prescribing for patients with CAP at the Royal Hobart 
Hospital (RHH) and North Regional Hospital (NWRH). 
 To assess the concordance between prescribing practice and the TG14 
recommendations for the empirical management of CAP.  
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2.2. Methods 
A retrospective study was conducted amongst adult patients (≥ 18 years) admitted to the 
RHH and NWRH, and diagnosed with pneumonia within 24 hours of admission. A list of 
patients who were classified as having pneumonia, CAP or lower respiratory tract infection 
(LRTI) during 1st July 2010 to 31st March 2011 was obtained from the clinical classification 
and information department of each hospital.  
2.2.1. Definition of variables 
A patient was considered to have CAP if a diagnosis of pneumonia was made by the 
physician and documented in the medical notes, or the radiologist or physician referred to the 
presence of consolidation, infiltration or pneumonia in a chest X-ray report. Empirical 
antibiotic therapy refers to the first regimen used within 24 hours of admission.  
2.2.2. Exclusion criteria   
Those excluded from the study were: (i) immunosuppressed patients (on chronic 
corticosteroids or immunosuppressive agents, chemotherapy within three months before 
admission, or a history of an immunosuppressive disease, such as HIV); (ii) patients who had 
been previously admitted to a hospital within 14 days of admission or had been admitted from 
an aged-care facility (ACF); (iii) patients who did not receive any antibiotic therapy or who 
had incomplete medical records; and (iv) patients who had a history of cystic fibrosis or 
bronchiectasis. 
2.2.3. Data collection 
The criteria for eligibility and guideline adherence were agreed by the research team, 
and the primary investigator undertook review of medical records to assess eligibility and 
guideline adherence. 
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Following exclusions,  the medical records of all eligible patients were reviewed to 
obtain data for clinical characteristics and demographics, enable calculation of Charlson’s 
comorbidity index, the antibiotic regimen used (agents, route of administration, dose and 
duration), the hospital department where antibiotics were first administered, and any 
antibiotics documented as being given within the seven days prior to admission. Clinical and 
diagnostic findings were extracted to calculate SMART-COP and CORB values, and used to 
stratify cases into mild, moderate and severe groups. Clinical outcome data, such as mortality 
and LOS, were extracted from the discharge summary. Antibiotics were considered to have 
been initiated in the ED when the documented time of administration was before the time of 
transfer to the ward. 
2.2.4. Outcome variables 
The primary measure was the empirical antibiotic regimen (first regimen administered 
within 24 hours of admission) for the management of CAP. The antibiotic regimen was 
considered to be consistent with TG14 recommendations when it was concordant with the 
following three variables: selection of antibiotic(s), dose, and route of administration, based on 
the level of CAP severity calculated by the researcher. Furthermore, the administration of a 
penicillin for a patient with a documented allergy to penicillin was considered to be discordant 
therapy (Figure 2.1). 
The second outcome measure was in-patient mortality rate and LOS. To analyse the 
LOS, only patients who were discharged to home according to the medical team advice and 
survived the admission were included for further analysis. 
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The presence of anyone of the followings: 
 Respiratory rate > 30 br/min 
 Systolic BP < 90 mm Hg 
 O2 saturation < 92% 
 Confusion (acute) 
 Arterial or venous pH < 7.35 
 PaO2 < 60 mm Hg 
 Multilobar CXR involvement 
  Mild CAP 
amoxycillin oral OR doxycycline 
oral OR clarithromycin oral 
 
 
 
 
 
 
CORB SMART-COP 
Variables Points  Variables Points 
Confusion 1 Systolic BP < 90 mm Hg 2 
O2 saturation ≤ 90% 1 Multilobar CXR involvement  1 
Respiratory rate ≥ 30 br/min 1 Albumin < 35 g/l 1 
Blood pressure 
Systolic BP < 90 mm Hg or 
Diastolic BP  ≤ 60 mm Hg 
1 Respiratory rate ≥ 30 br/min 1 
 
 
Tachycardia ≥ 125 bpm * 1 
  Confusion (acute) 1 
  
Oxygen low * 
PaO2 < 60 mm Hg, or O2 saturation ≤ 
90%, or PaO2/FiO2 < 250 
2 
PH < 7.35 2 
 
 
 
Moderate CAP 
(SMART-COP score < 5 and CORB score < 2 
Severe CAP 
(SMART-COP score ≥ 5 or CORB score ≥ 2) 
 
1- Benzylpenicillin IV PLUS EITHER 
doxycycline oral OR clarithromycin oral 
2- Ceftriaxone IV OR cefotaxime IV PLUS 
EITHER doxycycline oral OR clarithromycin 
oral** 
2- Moxifloxacin 400 mg oral** 
1- Ceftriaxone IV OR benzylpenicillin IV PLUS 
gentamicin OR cefotaxime IV PLUS (in all cases) 
azithromycin IV 
2- Moxifloxacin IV PLUS azithromycin IV** 
 
Br/min = breaths per minutes, BP = blood pressure, O2= oxygen, PaO2 = partial pressure of oxygenation, CXR = 
chest X-ray, bpm = beats per minutes, FiO2 = fraction of oxygen in inspired air 
Doses: Amoxycillin 1 g; doxycycline 200 mg (mild CAP) and 100 mg (moderate CAP); clarithromycin 250 (mild 
CAP) and 500 mg (moderate CAP); benzylpenicillin 1.2 g; ceftriaxone 1 g; cefotaxime 1 g; moxifloxacine 400 
mg; gentamicin 4 to 6 mg/kg 
*For patients ≤ 50 years old the value of tachycardia is ≥ 130; and the oxygenation values  are PaO2 < 70 mm Hg, 
O2 saturation ≤ 93 and PaO2/FiO2 < 333 
** Only recommended in case as an alternative regimen for patients with penicillin allergy 
Figure 2.1: Stratifying patients into different management groups based on severity 
as per TG14 (144). 
 
 
 
SMART-COP and CORB scores were calculated to 
assign patients into moderate or severe CAP  Yes 
NO 
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2.3. Results 
2.3.1. Patients’ characteristics 
A total of 276 patients from RHH and 68 patients from NWRH were assessed for 
eligibility. Of these, 83 patients from RHH and 15 patients from NWRH were excluded. 
Reasons for exclusion are summarised in Table 2.1. 
Table 2.1: Reasons for exclusions from the study. 
Exclusion criteria Number of patients 
 RHH (n=83) NWRH (n=15) 
Hospital admission in 
the previous 14 days 
21 5 
Immunosuppressed 
patients  
38 7 
Admitted from ACF 22 1 
No antibiotic prescribed 2 2 
 
Table 2.2 summarises the demographics, documentation of penicillin allergy and CAP 
severity assessment tool used, CAP severity classes and clinical outcomes for the eligible 
patients. 
With regard to the severity assessment tools, all CORB variables were recorded for all 
study patients; however, the laboratory and radiological tests required to use SMART-COP, 
were not always undertaken, in these cases the missing variables were considered as zero 
points. 
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Table 2.2: Patients’ demographics, characteristics and clinical outcomes. 
 RHH NWRH 
Number of 
patients 
193 53 
Gender (male) 105 (54.4) 30 (56.6) 
age  71 (18 – 96) 70 (20 – 95) 
Charlson’s 
comorbidity index 
score a 
5 (0 – 13) 4 (0 – 8) 
Change in chest X-
ray as defined by 
the radiology 
report 
117 (60.6) 27 (50.9) 
Mild CAP  64 (33.2) 31 (58.5) 
Moderate CAP 82 (42.5) 9 (17) 
Severe CAP 47 (24.4) 13 (24.3) 
CORB = 0 point 73 (37.8) 28 (52.8) 
CORB = 1 point 82 (42.5) 12 (22.6) 
CORB ≥ 2 points 38 (19.7) 13 (24.5) 
Prior antibiotic/s 
within 7 days of 
admission 
43 (22.3) 8 (15.1) 
Documented 
penicillin allergy 
30 (15.5) 8 (15.1) 
Admission via ED 191 (99) 52 (98.1) 
LOS in days   
 Overall 4 (1 – 36) 5 (1 – 25) 
Mild CAP a 3 (1 – 30) 4 (1 – 25) 
Moderate CAP 4 (1 – 26) 6 (2 – 9) 
Severe CAP 5 (1 – 36) 5 (1 – 15) 
In-hospital 
mortality rate 
  
 Overall 19 (9.8) 1 (1.8) 
Mild CAP - - 
Moderate CAP 5 (6.1) -  
Severe CAP 14 (29.8) 1 (7.7)  
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2.3.2. Documentation of severity score utilisation  
The use of any severity assessment tool was documented in only 9.4% of cases at RHH 
and in no cases at NWRH (Table 2.3). At the RHH, CURB65 and PSI were the tools most 
commonly documented (3.7% and 4.9%, respectively); use of either TG14 recommended tool 
(SMART-COP or CORB) was less than 1%. 
Table 2.3: Documented utilised severity tools in RHH and NWRH. 
Documented severity assessment tool 
RHH 
N (%) 
NWRH 
N (%) 
CURB65 9 (3.7) - 
PSI 12 (4.9) - 
SMARTCOP 2 (0.8) - 
 
2.3.3. Empirical antibiotic prescribing 
Three major classes of antibiotics were frequently utilised to treat patients with CAP: 
beta-lactams, macrolides and the tetracycline, doxycycline (Table 2.4). Overall, penicillin-
based therapy was most commonly utilised at the RHH (52.9 %). In contrast, patients at the 
NWRH most commonly received ceftriaxone-based therapy (64.2%). Of the macrolides, 
roxithromycin and azithromycin were the most commonly used at both study sites.  
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Table 2.4: Frequencies of prescribed antibiotics at the RHH and NWRH for the 
empirical management of CAP. 
Antibiotics 
RHH  
N (%*) 
NWRH  
N (%*) 
Beta-lactams 
Ceftriaxone - based 
therapy 
Ceftriaxone  
71 (36.8) 34 (64.2) 
Penicillin - based 
therapy 
Benzylpenicillin  53 (27.5) 3 (5.7) 
Amoxycillin 
Oral  16 (8.3) - 
IV 33 (17.1) 5 (9.4) 
Other beta - lactam 
based therapy 
Cefazolin 3 (1.6) - 
Cephalexin 1 (0.5) - 
Flucloxacillin 2 (1) 1 (1.9) 
Amoxycillin + 
Clavulanate 
5 (2.6) 2 (3.8) 
Ticarcillin + Clavulanate 1 (0.5) 2 (3.8) 
Piperacillin + Tazobactam  - 1 (1.9) 
Tetracycline Doxycycline  55 (28.5) 8 (15.1) 
Macrolides 
Roxithromycin 43 (22.3) 14 (26.4) 
Clarithromycin 4 (2.1) - 
Azithromycin 35 (18.1) 12 (22.6) 
Fluoroquinolones 
Moxifloxacin 5 (2.6) 2 (3.8) 
Ciprofloxacin - 2 (3.8) 
Aminoglycosides Gentamicin 4 (2.1) 2 (3.8) 
* As some patients received more than one antibiotic; the percentages do not add up to 
100% 
A wide variety of different antibiotic regimens were used for empiric treatment of 
patients with CAP, 29 at RHH and 19 at NWRH. Figure 2.2 shows the most commonly 
prescribed regimens at the two study sites. As can be seen, the combination of benzylpenicillin 
and doxycycline was the most commonly prescribed regimen for patients with CAP at the 
RHH (16.6%), while it was rarely prescribed at the NWRH (1.2%). Ceftriaxone monotherapy 
was the most commonly prescribed regimen at the NWRH (20.8%). 
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Figure 2.2: Prescribed regimens for empiric management of CAP at RHH and NWRH 
 
When stratifying patients into severity groups, the combination of benzylpenicillin and 
doxycycline was frequently prescribed to patients with non-severe CAP at the RHH (19.2%) 
and a combination of ceftriaxone and azithromycin was the most frequently prescribed 
regimen for patients with severe CAP (57.4%). In NWRH, ceftriaxone regimens were often 
prescribed, mostly as a mono-therapy for patients with non-severe CAP (20%) and as mono-
therapy or in combination with doxycycline for patients with severe CAP (23.8% and 23.8% 
respectively).  
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While there was no significance deference in ceftriaxone prescribing amongst severe 
cases between the two hospitals, the overall prescription rate of ceftriaxone was almost twice 
as high at NWRH compared to the RHH(p < 0.001). 
Within study sites, ceftriaxone-based therapy was more likely to be prescribed for those 
patients with severe CAP at the RHH (57.4%; p < 0.05). However, the use of ceftriaxone at 
NWRH did not appear to be significantly affected by severity of CAP, with rates in severe and 
non-severe CAP of 69.2% and 62.5%, respectively (Table 2.5).   
Table 2.5: Ceftriaxone-based therapy prescribing pattern by severity. 
ceftriaxone-based 
therapy by severity  
RHH 
N (%) 
NWRH 
N (%) 
Overall a 71/193 
(36.8) 
34/53 (64.2) 
Severe CAP 27/47 
(57.4) 
9/13 (69.2) 
Non – severe CAP a 44/146 
(30.1) 
25/40 (62.5) 
a P value < 0.05 
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2.3.4. Concordance with TG14 guidelines 
The overall rates of concordance with TG14 for the management of CAP were 16.1% 
and 7.5% for RHH and NWRH, respectively. At the RHH when patients were stratified by 
severity, the concordance to the guideline was found to be 3.1%, 20.7% and 25.4% for 
patients with mild, moderate and severe CAP, respectively (p < 0.01). At the NWRH, only 4 
patients received a concordant regimen Figure 2.3).  
 
Figure 2.3: Adherence to TG14 recommendations for the empirical management of CAP 
in RHH and NWRH collectively and by severity. 
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2.3.5. Alteration of antibiotic regimen within the first 24 hours of the initial 
administrated regimen 
Around half of all patients in both hospitals (56.5% at the RHH and 49.1% at the 
NWRH) had changes made to their antibiotic regimen within 24 hours of the first dose. 
(Table 2.6).   
Table 2.6: Change of antibiotic regimen within 24 hours of the first administrated 
regimen. 
 
RHH 
N (%) 
NWRH 
N (%) 
Overall  109/193 (56.5) 
30/64 (46.9) 
48/82 (58.5) 
31/47 (66) 
26/53 (49.1) 
15/31 (48.4) 
4/9 (44.4) 
7/13 (53.8) 
Mild CAP  
Moderate CAP  
Severe CAP  
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2.4. Discussion  
The most notable finding was the low level of concordance with the CAP management 
recommendations in TG14.  Poor adherence to national guidelines for CAP is not new in 
Australia and persists despite efforts to address this. A previous study conducted in 37 
Australian hospitals, including the two sites in this study, found that overall concordance with 
national CAP guidelines was only 18% (220). However, despite follow-up efforts to improve 
adherence to CAP national guidelines, only 10% rise in the adherence rate was seen from 20% 
to 30% (250).  
Adherence to CAP guideline recommendations varies from country to country and 
between institutions within the same country. For instance, a large UK study found 
concordance rates across 64 institutions ranged from 50% to 70% (247), which is higher than 
that seen in our study. Furthermore, while our study shows poor concordance with the national 
guidelines in both study sites, another Australian study that was conducted in a single tertiary 
hospital reported a relatively high concordance rate of 72.3% (248). This higher concordance 
could have been due to the efforts made by the hospital to improve the documentation of the 
severity tools and stratify patients into severity classes. As can be seen from our study, the 
adherence to the guidelines varied greatly between two sites within the same state. Whilst the 
RHH has had an established AMS program since 2009 and no such program existed at the 
NWRH at the time of the study, this may not provide an explanation for this variation. The 
reason for this is that the RHH AMS program has been focused on inpatients and consequently 
ED medical staff may have missed out on the opportunities to improve prescribing inherent in 
exposure to AMS initiatives. This may be particularly significant in terms of CAP 
management as the vast majority of patients with this condition received their first dose of 
antibiotics while in ED. This may result his might explain why adherence to the TG14 
recommendations for CAP management, remained poor at the RHH despite the presence of an 
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AMS program at that site.  Nonetheless, as a central aim of AMS programs is to reduce 
inappropriate use of broad-spectrum antibiotics, such as ceftriaxone, the absence of any such 
program at the NWRH may explain why ceftriaxone prescribing at the NWRH was 
significantly higher than at the RHH. However, it is important to bear in mind that limiting the 
use of ceftriaxone does not ensure adherence to the recommended guidelines.    
Published studies have used different criteria to measure the adherence to the 
recommended guidelines. Several studies measured the adherence to CAP guidelines solely in 
terms of the selection of antibacterial agent based on the severity of CAP (221, 247); while 
others, including our study, also considered the route of administration and presence of 
penicillin allergy when assessing the rate of adherence (220, 248, 250). For example, some 
studies defined adherence to the guideline without consideration of CAP severity (251, 252). 
This may explain why the adherence to guideline recommendations varied significantly 
between previous studies.   
Guidelines have been developed in an attempt to optimise CAP management and, when 
adhered to, these have been shown to be associated with better clinical outcomes (286). Key 
aspects of the guidelines include assessment of CAP severity and the rational use of 
antimicrobials (144, 182, 186). It has been found that if guidelines are not used, physicians are 
more likely to inaccurately estimate the severity of CAP, which is associated with an increased 
risk of mortality amongst those patients (287, 288). Physicians who do not adhere to 
guidelines may in some cases select an unnecessarily broad spectrum antimicrobial regimen or 
in other cases a regimen insufficient to treat the most likely CAP pathogens (244). It has been 
reported that S. pneumoniae is the main bacterial pathogen causing CAP in Australia.  
Furthermore, Charles et al. found that S. pneumoniae resistance to penicillin was infrequent in 
the study samples (210). These findings suggest that the vast majority of CAP patients in 
Australia could be treated successfully with penicillin-based therapy and this is reflected in the 
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TG14 recommendations for mild to moderate cases of CAP. This conflicts with current 
clinical practice where ceftriaxone-based therapy appears to be commonly prescribed as 
empirical therapy for CAP patients, irrespective of severity.  TG14 recommendations are that 
broader spectrum antibiotic therapy should be used as the severity of CAP increases (144), 
nonetheless cover should be provided against  S. pneumoniae in all severity groups. Coverage 
of atypical pathogens is optional in mild cases, but mandatory in moderate to severe cases. For 
patients with severe CAP, coverage should also be extended to include gram-negative bacilli. 
However, it was not uncommon that patients with severe CAP received ceftriaxone mono-
therapy, which does not provide coverage toward atypical pathogens. Our study also found 
that around four out of ten patients with severe CAP at the RHH received penicillin-based 
therapy, which does not provide coverage against gram-negative bacilli. On the other hand, 
ceftriaxone based-therapy was frequently utilised for patients with non-severe CAP, where 
narrower spectrum antibiotics, such as penicillin-based therapy, could provide the necessary 
coverage for the most likely bacterial pathogens in this group of patients (210). In short, our 
study found that non-adherence to CAP guideline recommendations included over treatment in 
some cases and under treatment in others.    
This study found the use of a severity scoring tool was rarely recorded in medical notes. 
A closer look at the data indicates that even when a severity score was documented, the TG14 
recommended tools (SMART-COP/CORB) were those least often utilised, whereas other 
severity tools such as CURB65 and PSI were used more frequently. A recent Australian study 
showed even poorer documentation of severity tools, where only one out of 69 patients had a 
severity score documented  (289). Several scoring systems have been developed in order to 
stratify patients according to severity of CAP (234, 235). In one Australian study, it was 
shown that patients who had a severity score documented in their files were more likely to 
receive concordant antibiotic regimens compared to those who did not (248).  Furthermore, 
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documentation of severity tool use may help inform other team care members of the rationale 
for treatment decisions. In our study, a wide variety of antibiotic regimens were utilised and 
these were often outside TG14 recommendation, irrespective of any consideration of severity 
level. Therefore adhering to guideline recommendations would limit the wide variety of 
prescribed antibiotic regimens.  
A variety of barriers may hinder clinicians from adhering to the clinical practice 
guidelines(151). One of the main barriers relates to knowledge, which may include a lack of 
awareness or lack of familiarity with the guidelines, including changes introduced in the most 
recent edition of guidelines, in this case specifically TG14. For example, nearly half of the 
doctors (48%) who responded to a US survey regarding the barriers to adherence with CAP 
guidelines, were uncertain about the availability of the guideline (254). This may also be true 
in our study since almost a quarter of the patients received roxithromycin as part of their 
treatment regimen despite removal of this macrolide from the TG14 recommendations for 
CAP management.  
Changing established prescribing practice is recognised as a significant challenge, and it 
could be argued that as our baseline study took place soon after the introduction of TG14, 
clinicians may not have had an opportunity to embrace the new guidelines. However, the 
TG14 recommendations regarding ceftriaxone use in CAP were unchanged from TG13, with 
this drug only recommend as a first-line therapy in severe CAP in both editions of the 
guidelines.  In our study 30.3% and 62.5% of cases of non-severe CAP in RHH and NWRH 
were treated with a regimen that included ceftriaxone. These findings suggested that even if 
the doctors were not aware of the new guidelines, there may also have been poor adherence to 
recommendations in the previous guidelines. 
Lack of awareness and familiarity with the updated guidelines may have been another 
barrier. In a qualitative study, it has been found the junior doctors were less familiar with 
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guideline recommendations compared to senior doctors (165).  This barrier to adherence might 
simply reflect the fact that familiarity with guidelines is acquired with accumulated experience 
or be due to junior staff having difficulty in accessing guidelines whilst working in busy 
hospital environments. This latter explanation is however unlikely to apply at either of our 
study sites where TG14 recommendations are readily available to staff via the hospital 
intranet. However, it is possible that despite the good availability of guidelines, doctors, 
especially juniors, may not have been aware of how to find them in their work place. 
Our study also indicated that almost half of the antibiotic regimens were altered within 
24 hours of the initial dose. These findings appear consistent with other Australian research 
which found that in most cases, only a single dose of a ceftriaxone-based regimen was given 
in the ED and this was not continued after the admission (168). Several reasons might lead to 
this change. Firstly, doctors subsequently involved in the patient’s care might differ in their 
assessment of CAP severity as discussed above. Since the severity assessment criteria were 
rarely documented, medical staff reviewing the patient after initial assessment might change 
the antibiotic regimen based on his or her clinical judgment since the rationale behind using an 
antibiotic regimen is not documented. In our study, we assessed the severity of CAP using the 
TG14 recommendation severity assessment criteria. However, doctors might use other ways to 
assess the severity. For example, a patient who is allocated into the severe CAP category 
based on the TG14 criteria might be stratified into another severity group when another 
method to assess the severity is used. Secondly, antibiotic prescribing could be initiated by 
junior doctors, who are most likely to be the first doctor to assess the patient in the ED. It has 
been found that junior doctors feel less confident when prescribing antibiotics and hence 
required higher levels of assistance in choosing an appropriate antibiotic regimen (165). Given 
the short time frame for junior doctors to make decisions in the ED, they might not have time 
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to consult with seniors regarding the antibiotic choices and this may lead to a change in the 
initial regimen when the patient is subsequently reviewed by more senior staff. 
Furthermore, almost half of the patients were diagnosed as having pneumonia with no 
supporting evidence from a chest X-ray. Published studies found that ED physicians are more 
likely to diagnose and treat patients with pneumonia even when the radiologist report indicates 
normal chest X-ray (290, 291). However, although this may be considered inconsistent with 
best practice according to published guidelines (144), it should be acknowledged that a chest 
X-ray may fail to identify changes in almost 30% of patients with clinical presentation of 
pneumonia (292). On that basis, and given that the main purpose of this study was to evaluate 
prescribing practice, we included those patients with a documented diagnosis of pneumonia 
even if this was not supported by radiological evidence.  
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2.5. Limitations 
There are several potential limitations applicable to our study. Firstly, this study 
collected data commencing just one month after TG14 was released; therefore, prescribers 
may not have been aware of the changes made regarding CAP management recommendations. 
However, the total duration of the study was 9 months and there was no evidence of a 
significant change in guideline concordance over that timeframe. Furthermore, the study was 
done to collect the baseline data for a longitudinal project aiming to improve the management 
of CAP and therefore, it was important to identify concordance with the most up to date 
guidelines to inform future interventions. In our study, patients who were admitted from an 
ACF were excluded. This is based on the literature which suggests the most common CAP 
pathogen amongst ACF residents is Methicillin Resistant Staphylococcus aureus, in contrast to 
S. pneumoniae for those who are community dwelling (293, 294). Furthermore, this study 
relied solely on a scoring system to identify patients with severe CAP and TG14 recommends 
the use of clinical judgment to supplement the use of severity tools. Therefore, patients with 
non-severe CAP based on use of SMART-COP/CORB severity tools might have been 
considered candidates for broader-spectrum therapy based on the clinicians’ judgment. 
Additionally, the absence of data required to calculate severity using SMART-COP was 
interpreted as indicating that parameter was normal. Although we acknowledge this approach 
might reduce the sensitivity of any scoring system, this approach is consistent with that used 
in the original study where the SMART-COP tool was developed (234). This approach was 
also used by Fine et al. who developed the alternative PSI severity tool (223). Furthermore, 
the use of severity tool was very limited in this study and any relative underestimation of 
severity had minimum effect on overall results. 
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2.6. Conclusion  
Our baseline data showed that concordance with national CAP guidelines (TG14) was 
poor in both study sites and that ceftriaxone is over-used in non-severe CAP. Based on these 
findings an investigation into the barriers to guideline adherence is warranted. Such an 
investigation would provide much needed insight into possible strategies to improve 
adherence to CAP management guidelines.   
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Chapter 3. Perceived barriers to Antibiotic 
therapeutic guidelines (TG14) for the empirical 
management of CAP 
 
3.1. Introduction 
Previous studies showed that adherence to CAP guidelines was historically very low in 
Australian hospitals (168, 220). However, even after national initiatives to enhance the 
management of CAP, the improvement in the adherence rate was only modest (250). 
Consistent with this, the data we have reported in Chapter 2 provides strong evidence that 
adherence to national guidelines (TG14) for the empirical management of CAP in two 
Tasmanian hospitals remains sub-optimal. In particular, ceftriaxone prescribing was frequently 
inconsistent with the guideline recommendations.  
A number of barriers have been reported to influence clinicians’ concordance with 
practice guidelines (151, 163, 295, 296). Barriers to guideline adherence differ from one 
institution to another (166). Therefore, it is important to assess and identify the specific 
barriers to adherence in any given hospital before designing an intervention to improve 
antibiotic prescribing in that institution (297). It has been shown that developing intervention 
strategies that are based on the identified barriers are more likely to improve adherence to 
guidelines (153).   
The purpose of this study was to collect information about barriers related to clinicians’ 
adherence to CAP guidelines at the Royal Hobart Hospital (RHH) in order to inform the 
development of specific interventions to improve CAP management at that site.  
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The specific aims of this study were: 
 To identify and quantify  potential barriers that may hinder doctors’ use of TG14 for 
CAP management at the Royal Hobart Hospital (RHH) 
 To ascertain RHH doctors’ perceptions regarding the reasons why ceftriaxone is not 
recommended routinely for CAP management.      
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3.2. Methods 
3.2.1. Study population 
Doctors within the general medical teams and ED at the RHH were surveyed for this 
study. This group of doctors was chosen because of their involvement in the management of 
patients admitted with CAP.  Paper surveys were distributed to a total of 130 doctors via each 
staff member’s hospital internal mail system. A reminder note and additional copy of the 
survey were sent to all the doctors one month after the initial distribution.   
3.2.2. Survey questionnaire 
A pool of 20 questions was initially constructed based on the framework of Cabana et 
al.., which classified the barriers to guideline adherence into three groups: knowledge, 
attitude, and external barriers (151). These were then reviewed by the RHH Antimicrobial 
Stewardship Team (Infectious disease physician, clinical microbiologist, and specialist clinical 
pharmacist), who made recommendations to modify and refine the question pool for local 
application.  
The final survey consisted of two main sections to identify potential barriers: the first 
consisted of three statements to assess doctors’ familiarity, agreement with, and access to 
TG14 (Appendix B). The second section consisted of ten statements to ascertain doctors’ 
views regarding factors that hinder their peers from adhering to TG14 when managing CAP. A 
5-point Likert-type scale was used for the 13 statements. Additionally, doctors were asked a 
number of specific questions regarding , their understanding of why ceftriaxone is not 
recommended for the majority of CAP cases based on six pre-defined statements; and the 
tool(s) that they routinely use to assess the severity of CAP in individual patients; . 
Respondents were also asked to provide details of their seniority (intern, resident, registrar or 
consultant) and their work location (emergency department or general medicine).  
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3.2.3. Statistical Analysis  
Statistical analysis was performed using IBM SPSS Statistics for Windows software 
(version 19.0. Armonk, NY: IBM Corb19). Chi-square and Fisher’s exact tests were used to 
assess the significance between categorical data. Fisher’s exact test was used if one of the 
expected values had less than five participants. The responses regarding knowledge, attitude 
and external barriers toward TG14 were grouped into three classes: strongly agree/agree 
responses were combined to indicate agreement with the statement, neutral, and strongly 
disagree/disagree responses were combined to indicate disagreement with the statement. A P-
value < 0.05 was considered statistically significant. 
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3.3. Results 
3.3.1. Demographic profile 
Of the 130 emergency department and medical team prescribers who were sent the 
survey, 56 responded (rate of 43.1%). Of these, 21 responses were from the emergency 
department (6 juniors and 15 seniors) and 35 responses from medical teams (15 juniors and 20 
seniors). The term junior was used to refer to interns and residents, while the term senior 
refers to registrars and consultants.    
3.3.2. Barriers to adherence to CAP guidelines  
Table 3.1summarises the level of agreement with statements regarding potential barriers 
that hinder medical staff from adhering to TG14 with regard to CAP management.  
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Table 3.1: Percentage of agreement with the statements regarding the barriers that could 
hinder adherence to TG14. 
 
Total 
N = 56 
Hospital 
department a 
 Medical staff 
seniority  
ED 
N = 21 
MT 
N = 35 
 
Junior  
N = 21 
Senior  
N = 35 
Thoughts regarding the possible barriers that hinder other doctors from adhering to 
the TG14 CAP guidelines 
 Influence of 
senior doctors 26 (46.4) 12 (57.1) 14 (40)  16 (76.2) 
b 10 (28.6) b 
 Lack of 
awareness  22 (39.3) 9 (42.9) 13 (37.1)  3 (14.3) 
b 19 (72.2) b 
 Calculation 
requirement to 
assess the severity  
20 (35.7) 9 (42.9) 11 (31.4)  4 (19) b 19 (54.3) b 
 Existence of other 
guidelines that 
conflict with 
TG14  
16 (28.6) 9 (42.9) 7 (20)  5 (23.8) 11 (31.4) 
 Not expected to 
follow the 
guidelines  
13 (23.2) 5 (23.8) 8 (22.9)  4 (19) 9 (25.7) 
 Lack of time  12 (21.4) 4 (19) 8 (22.9)  9 (42.9) 3 (8.6) 
 Interference with 
doctors’ 
autonomy  
6 (10.7) 3 (14.3) 3 (8.6)  2 (9.5) 4 (11.4) 
 Impractical to 
implement  3 (5.4) - 3 (8.6)  2 (9.5) 1 (2.9) 
 Not sufficiently 
evidence-based  2 (3.6) 1 (4.8) 1 (2.9)  1 (4.8) 1 (2.9) 
 Not clear  2 (3.6) 1 (4.8) 1 (2.9)  1 (4.8) 1 (2.9) 
Data are presented as number (%). 
a ED : emergency department; MT: medical teams  
b P value < 0.05 
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When the participants were asked about their familiarity, agreement and access to TG14 
in terms of CAP management, the majority reported self-familiarity and agreement with the 
guideline’ recommendations with no problems regarding accessibility to TG14 at workplace 
(Figure 3.1). 
 
Figure 3.1: Summary of responses regarding familiarity, agreement with, and access to 
TG14.  
 
The majority of participants reported that they were familiar with the TG14 (78.6%) and 
there were no differences observed in terms of seniority or the area of practice (Figure 3.1). 
Interestingly, nearly half of the respondents (39.3%) thought that the lack of awareness of the 
guidelines could be a reason for their fellow doctors’ non-adherence.   
While there was a high rate of self-reported agreement with the TG14 recommendations 
(91.1%), the main barriers relating to attitude were the view that the hospital did not expect its 
staff to use the guidelines (23.2% agreement).  
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In the case of external barriers, the vast majority of the respondents (94.6%) reported 
that they had access to TG14 in their workplace. The major reason cited for hindering 
adherence to the guidelines was the influence of senior physicians. Almost half of the 
respondents (46.4%) thought that prescribing was largely under the direction of senior doctors. 
The requirement to calculate CAP severity was acknowledged as a barrier by 35.7% of the 
respondents.  Just over quarter of the respondents (28.6%) reported that the presence of other 
CAP guidelines that conflict with TG14 as a potential barrier.           
Responses to these questions varied according to the level of medical staff seniority. For 
example, senior doctors were more likely than their junior colleagues to think that the lack of 
awareness of TG14 (72.2% vs14.3%; p < 0.05) and the need to calculate severity (54.3% 
vs19%; p < 0.05) were the main reasons for the non-adherence. On the other hand, junior 
doctors thought that the influence of the senior doctors was the main reason for non-adherence 
to the guidelines (76.2% vs28.6%; p < 0.05).  
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3.3.3. Perception about why ceftriaxone is not recommended for most 
patients with CAP   
Figure 3.2 shows that three reasons were commonly identified as why ceftriaxone is not 
a good choice for the majority of CAP cases: penicillins give the same results in most cases 
(86.4%), many cases are not severe (79.5%), and the risk of multi-drug resistance (77.3%).  
 
Figure 3.2: Respondents perceptions of why ceftriaxone is not recommended for the 
majority of CAP cases. 
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3.3.4. Self-reported use of CAP severity assessment tool(s)  
In response to the question ‘Which tool(s) do you use to assess the severity of CAP?’, 
different severity tools were utilised with only five participants  reported non-use of any tool 
as shown in Table 3.2.  
Table 3.2: Self-reported tool(s) use to assess the severity of CAP.  
Self-reported severity tool use  N (%) 
CURB65 31 (55.4) 
PSI 20 (35.7) 
SMART-COP 20 (35.7) 
CORB 6 (10.7) 
No tool used 5 (8.9) 
Table does not add up to 100% because some respondents reported the use of more than one 
tool.  
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3.4. Discussion  
This study Identified that a number of barriers affect doctor’s adherence to the 
recommendations in TG14 for management of CAP at the RHH. The influence of senior 
doctors, lack of awareness, the requirement to undertake a calculation to assess the severity of 
CAP, existence of other guidelines that conflict with TG14, and not being expected to follow 
the guidelines were the most commonly cited barriers. 
In general, the survey showed that doctors had a positive attitude toward the 
recommendations in the CAP guidelines, which is consistent with other studies (298). 
However, despite this, practice reflected poor adherence to the guidelines as shown in the 
baseline study. Moreover, despite most doctors reporting familiarity with, and ease of access 
to, the guidelines in practice; few doctors reported the use of the recommended severity 
assessment tools. This was also consistent with our baseline data, where the use of these tools 
was rarely documented in the medical notes, and where tools were used; they were often not 
the ones recommended in TG14 (section 0). Linder et al. found that doctors who reported 
being more familiar with the guidelines for the management of acute respiratory infections 
were more likely to prescribe discordant antibiotics (299). These findings, together with our 
study, suggest that the reported familiarity does not always translate into adoption of 
recommendations in clinical practice The most notable barriers found by our present study 
were the influence of senior doctors and a lack of awareness of a new version of the 
guidelines. However, according to our data, the perception of these two barriers was 
noticeably different between senior and junior staff. While the influence of senior doctors was 
the most frequently reported by junior physicians, senior physicians thought that the lack of 
awareness was the main explanation of poor adherence to the CAP guidelines. These two 
barriers have been the principal findings in quantitative and qualitative studies that looked at 
barriers to adherence with clinical guidelines (161, 163, 295, 296). As our study was 
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conducted in a teaching hospital, it is highly likely that the first doctor to see a patient will be 
a junior.  Junior doctors are more likely to be influenced by the prescribing habits of their 
seniors and supervisors (161, 163, 295, 296). Pieter-Jan et al. confirmed this finding in their 
qualitative study where junior doctors considered their supervisors as a role model with regard 
to antibiotic prescribing, which as a consequence  determined their prescribing behaviour 
(161).  Senior doctors, on the other hand, are more likely to rely on their clinical judgment to 
assess the individual case and guide the choice of antibiotics (163). In a qualitative study 
looking at factors influencing antibiotic prescribing in a 500-bed teaching hospital, it was 
found that personal experience become the major influence in antibiotic prescribing  with 
career progress (295).  Our data suggest that junior doctors strongly believe that the influence 
of senior doctors might be the major determinant of their antibiotic prescribing habits, unlike 
senior doctors who thought the lack of awareness of the guidelines might be the main reason 
behind prescribing discordant regimens. 
Despite the high level of self-reported familiarity with the new version of the guidelines, 
lack of awareness was the most commonly stated barrier that might contribute to low 
adherence with CAP guidelines according to the responding senior doctors. This is consistent 
with a recent Australian study that found a lack of knowledge and awareness of 
recommendations to be the major barriers to clinicians’ concordance with guidelines (300). 
Influence of the national guidelines for the management of CAP was low according to the 
study by Switzer et al.. (254). In their study, they found that more than half of the surveyed 
doctors reported that they had not seen the guidelines. Prescribing guidelines, including those 
for antibiotics, are revised regularly based on the latest evidence-based literature. However, 
the revised version may not always reach the clinicians who are meant to use them, due to 
ineffective methods of distributing guidelines. Van Kasteren et al. found that the main reason 
for non-adherence to local antibiotic guidelines for surgical prophylaxis was a lack of 
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awareness regarding the revised versions (301).  This might be more problematic with 
hospitals that have no local guidelines and rely solely on national guidelines. At the time of 
the survey, there were no local CAP guidelines at the study site, and the physicians were 
expected to follow the Australian national Therapeutic Guidelines. Nevertheless, lack of 
awareness might be one of the main reasons for non-adherence to the TG14 at the beginning. 
This was clear in our baseline study since the macrolide antibiotic, roxithromycin, was 
frequently prescribed for CAP management despite being absent from guideline 
recommendations. 
The third most frequently cited barrier to guideline adherence was the need to undertake 
a calculation to properly assess the severity CAP. This was reported to be a potential barrier 
by over half (54.3%) of senior doctors, but only around one in five responding junior doctors.  
Consistent with other international guidelines, TG comprises two sections regarding the 
management of patients with suspected CAP. The first part covers the assessment of CAP 
severity and this is a precursor to the second part, the selection of an empirical antibiotic 
regimen, based on the severity score. A number of severity scoring tools have been 
recommended by different CAP guidelines, (182, 186),  including the Pneumonia Severity 
Index (PSI), which was the recommended tool in the previous version of TG  (TG13) (302). 
Whilst all severity tools require some form of calculation to be undertaken, PSI is particularly 
complex, as it needs almost 20 variables to be considered. Recognising this, a number of less 
complicated tools have been developed, such as CURB65, CORB and SMART-COP (224, 
234, 235); the last two of these being those recommended by TG14. As discussed earlier, 
physicians may not be aware of the change of the guidelines with regard to severity tool, 
which might explain their perceptions regarding the barrier posed by the need for a more 
complex calculation.      
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An important consideration related to severity assessment criteria to inform appropriate 
use of antibiotics for CAP is the lack of uniformity across various clinical practice guidelines. 
For example, CAP guidelines developed by the Infectious Diseases Society of America 
(IDSA) and American Thoracic Society (ATS) were issued more than six years ago and do not 
make drug specific recommendations for hospital inpatients, instead they refer to classes of 
antibiotics such as Beta-lactams or macrolides, which leave interpretation open to using many 
possibilities (182). In contrast,  the British Thoracic Society (BTS) and the Australian 
Antibiotic Guidelines (TG) recommend specific antibiotic regimens instead of antibiotic 
groups (144, 186). Our survey indicated that almost one-quarter of respondents thought that 
existing of other guidelines that conflict with TG14 recommendations regarding CAP 
management might explain the poor concordance with TG14.  These findings are supported by 
the high self-reported use of the CURB65 severity tool (55.4%), which although 
recommended in the BTS and IDSA/ATS guidelines (182, 186), was not recommended in 
either TG14 or the previous TG13. 
The perception that staff were not expected to follow the guidelines is another barrier 
that was suggested as contributing to low rates of adherence to CAP guidelines. Although not 
directly related to antibiotic prescribing, research by Gurses et al. found that clinicians are 
highly likely to adhere to particular guidelines when they know this is the expectation and 
norm in their department (303). Since the initial prescribers of antibiotics would most likely be 
junior doctors, as discussed earlier, perceptions regarding any expectation to adhere to 
guidelines might be determined by the prescribing behaviour of senior doctors and supervisors 
(161). Accordingly, if the senior doctors and supervisors prescribe antibiotics according to 
guidelines, it may be more likely that junior doctors will follow their prescribing habits. 
Another possible explanation for this might be related to organisational factors. For example, 
in their study, Schouten et al. showed that organisational factors, such as unavailability of an 
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antibiotic, lack of time and delayed laboratory results were possible barriers to optimal 
treatment of CAP (157). Given that most of the severity assessment tools require one or more 
laboratory tests, delays in obtaining these results might lead to none or inappropriate 
utilisation of the recommended tools to assess the CAP severity, which could lead selection of 
an inappropriate antibiotic regimen.  
In this study, we also aimed to ascertain physicians’ knowledge regarding the reasons 
why routine use of ceftriaxone for CAP is discouraged. Approximately three-quarters of the 
respondents thought that most cases were not severe and penicillin would give the same 
results as ceftriaxone. These findings suggest that physicians are aware of the severity profile 
of patients presenting with CAP that we reported in the baseline study, where the majority of 
CAP cases were non-severe.  Additionally, most of the responders thought that one of the 
main reasons for not prescribing ceftriaxone for the majority of patients with CAP is due to 
the relationship of increased ceftriaxone usage and the emergence of multi-drug resistance 
microorganism.  In one Swedish qualitative study, which was conducted to ascertain 
physicians’ perceptions of antibiotic resistance in one hospital, it was shown that despite the 
high awareness of microorganism resistance, this awareness was less likely to influence 
prescribing decisions (304).  The findings from our study suggested that most responders were 
aware that most of the CAP cases are not severe and penicillin-based therapy would be as 
effective as ceftriaxone. However, this was not reflected in practice where patients with non-
severe CAP were frequently initiated on ceftriaxone-based therapy. These findings suggest 
that there might be other factors influencing the use of ceftriaxone for patients with non-severe 
CAP when it is not indicated. A qualitative study looking at barriers to CAP guideline 
adherence in three Dutch hospitals found that uncertainty about the suspected pathogen and 
lack of agreement with guidelines were common reasons for preferring broad-spectrum 
empirical antibiotic regimens. (157). Therefore, future research should concentrate on the 
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potential factors that could influence the use of ceftriaxone for patients with non-severe CAP 
at the RHH, taking into account that the vast majority of patients received their initial 
antibiotic regimens, including ceftriaxone, in the ED.   
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3.5. Limitations 
There are limitations to this study that should be acknowledged. Firstly, this study was 
conducted in a single hospital; therefore, the results may not be generalisable to other 
institutions. Nevertheless, the aim of this study was to identify the potential barriers at this 
specific hospital (the target of our intervention) in order to tailor an intervention to overcome 
these barriers. Secondly, the findings were based on the respondents’ thoughts about other 
doctors’ poor adherence to TG14 CAP guidelines, not the respondents’ assessment of the 
barriers affecting their own adherence.  However, it has been shown that self-reported 
behaviour might not reflect the actual practices of surveyed physicians (305). Therefore, this 
method was used to overcome the possible bias that might arise if the physicians were asked 
directly about their adherence to guidelines. The response rate was relatively low. This might 
be due to physicians who have limited recent experience with CAP being reluctant to 
participate in the study. It is acknowledged that investigation into barriers to clinicians’ 
concordance to guidelines using the quantitative approach is limited in its scope; this provided 
little room to explore barriers beyond those pre-determined as important by the researchers. 
Finally, demographics such as gender, age, and place of basic clinical training were not 
examined, and such factors may have influenced doctors’ perceptions about adherence to 
guidelines, both generally and in terms of the TG14 recommendations for CAP in particular.  
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3.6. Conclusion  
This study set out to determine potential barriers that might hinder doctors at the RHH 
from adhering to TG14 recommendations for CAP management. A variety of potential 
barriers to guidelines adherence was identified; the most frequently cited being the influence 
of senior doctors. On this basis, it is likely that the success of any intervention to improve 
CAP management at the RHH will be increased if this potential barrier is addressed. One way 
to do this would be to ensure involvement of senior medical staff in the development and 
implementation of guidelines at a local level.  
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Chapter 4. Factors influencing empirical ceftriaxone 
use in Community Acquired Pneumonia: emergency 
physicians’ perspectives    
 
4.1. Introduction 
The results from the survey study (Chapter 3) showed that despite a low level of 
concordance with the TG14 in treating CAP at the studied hospital (Chapter 2), the majority of 
doctors surveyed reported familiarity and agreement with the recommendations of TG14. 
Moreover, as observed in the baseline audit (Chapter 2) few doctors reported the use of 
severity assessment tools to stratify patients into mild, moderate and severe categories of CAP. 
As the severity assessment is the very first step in guideline concordant care of CAP, 
identifying the limitations surrounding the use of severity assessments tools at the studied 
hospital was recognised as important. 
A common observation from studies investigating physicians’ concordance with CAP 
guidelines is that ceftriaxone, a broad-spectrum cephalosporin, is often prescribed outside 
guideline recommended indications (168). The baseline audit study at the RHH and NWRH 
(Chapter 2) also found the use the use of ceftriaxone was excessive and non-concordant to 
TG14. It is becoming increasingly recognised that there are significant adverse consequences 
associated with the use of broad-spectrum antibiotics (306, 307).  Bloodstream infections 
caused by vancomycin resistant enterococci (VRE) are one of the life-threatening nosocomial 
infections that have been linked with the use of ceftriaxone (306).   Furthermore, high levels 
of ceftriaxone use have also been associated with an increased incidence of CDI (307).  
Given the fact that EDs are the first point of contact for most patients with CAP, an 
investigation to explore the factors limiting ED doctors’ use of severity assessment tools and 
over-use of ceftriaxone within this care setting can inform the development of interventions to 
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improve CAP management. However, given the limitations of quantitative studies in this field, 
it was recognised that a better understanding of the issues would be gained by undertaking 
qualitative research. A qualitative study was therefore designed, with the following aims: 
 To explore the emergency doctors views about the management of CAP in the ED 
setting. 
 To specifically explore what factors influence the prescribing of ceftriaxone for CAP 
by ED physicians. 
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4.2. Methods 
4.2.1. Participants and setting  
This study was conducted in the ED of the Royal Hobart Hospital (RHH). All 40 doctors 
employed in the RHH ED at the time of the study were invited to participate in the study, 
through a mailed invitation letter and an information sheet containing further details of the 
research. Those doctors who signed and returned the consent form were then contacted to 
arrange a place and time for the interview. A store voucher to the value of 50 dollars was 
given to participants at the end of the interview in recognition of their time.  
4.2.2. Data collection  
One to one semi-structured interviews were conducted with participants. This method 
was chosen to enable ED doctors, especially junior staff, to speak openly about their practice 
regarding the management of CAP without fear of being criticised, and to enable them to 
discuss the issues they felt were important. The following questions were used to initiate and 
sustain discussion surrounding empiric management of CAP and the reasons for using 
ceftriaxone in CAP. Additional questions were raised based on each participant’s answers to 
these initial questions (Appendix C).   
The four initiating questions were: 
 What are your thoughts on the empirical antibiotic management for patients 
presenting with CAP? 
 What source(s) of information do you often rely on when making decisions about 
CAP treatment? 
 What experiences do you feel have particularly influenced your prescribing practices 
in CAP? 
 What leads you to prescribe ceftriaxone for patients presenting with CAP? 
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4.2.3. Data analysis  
The interviews were conducted, recorded and transcribed verbatim by the student 
researcher (primary investigator; PI) and then analysed by using framework analysis (FA). FA 
is increasingly used in healthcare research due to its simplicity and the ability to provide direct 
link between conclusions and original qualitative data (308-311). FA was chosen for the 
present research as it also provides easy accessibility to the qualitative data for other 
researchers allowing them to review conclusions made by the original researcher. FA provides 
a systematic and rigorous process to manage qualitative data. It includes five distinct stages 
that result in the development of theme-based or case-based analysis, which can then lead to 
production of a chart which can be read by either cases or themes (311). FA includes five 
distinct stages: 
1. Familiarisation  
2. Identifying a thematic framework 
3. Indexing and charting   
4. Summarising and charting 
5. Synthesising data by mapping and interpreting   
4.2.4. Ethical consideration and approval 
Participants provided signed consent prior to the interviews and were assured that any 
information provided would be treated confidentially. The student researcher interviewed the 
participants and was previously unknown to the interviewees. Ethical approval for the study 
was provided by the Human Research Ethics Committee (Tasmania) Network [Ref no: 
H00124809]. 
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4.3. Results 
Eight doctors responded to the invitation to participate in this study. Table 4.1 
summarises the participants’ characteristics. In the quotes reproduced below, the numbers 
represent the participants’ order (i.e. P1 was the first participant interviewed and P8 was the 
last) and the subsequent letters represent seniority - consultant (C), registrar (G), or resident 
(R). This section will first describe the application of FA to the data obtained through 
interviews followed by the presentation of themes arising from the data. 
Table 4.1: Participants’ characteristics 
Participants’ 
number 
Professional 
seniority 
CAP 
cases/month 
Part/full time in ED 
P1 Consultant 6-12 Full time 
P2 Registrar 6-12 Full time 
P3 Resident 10 Full time 
P4 Consultant 4 Part time 
P5 Registrar 10 Full time 
P6 Resident 5 Full time 
P7 Registrar 10-15 Full time 
P8 Registrar 1-2 Part time 
 
4.3.1. Application of FA 
Familiarisation 
 The main purpose of this stage was to become familiar with all transcripts in detail 
before developing any themes. To ensure immersion into all details of the data, the PI 
undertook all the interviews, transcribed the data, and studied all the data independently. 
Becoming aware of the main recurring themes was the main advantage of this stage. This was 
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facilitated by the small sample size (8 participants) and each interview lasted only 10 to 15 
minutes.  
Furthermore, notes were taken after each interview to enable the PI to record their 
immediate thoughts and emerging issues. These notes were utilised to enhance questioning in 
the subsequent interviews as well as to assess in developing themes in the next stage. All the 
data were analysed by the PI, while three random transcript samples were analysed by expert 
qualitative research analysts to ensure consistency and rigour.  
Identifying a thematic framework  
At this stage, repeated themes were identified from the familiarisation stage, and a chart 
was developed using the qualitative data software program NVivo., After familiarisation, the 
PI recognised emerging themes. The PI used the field notes that were taken during the 
familiarisation stage for guidance. This stage ensured that the original research questions were 
fully addressed. The main two questions were “what is the participant’s strategy to manage 
patients with CAP in ED?” and “what might lead them to prescribe ceftriaxone in this case?”. 
These themes were discussed with a group of three, one of whom had qualitative research 
experience at the university. 
Indexing  
Based on the previous stage, the thematic framework was applied back to the original 
data and field notes. The data were indexed under themes that were developed in the previous 
stage, where the themes were annotated on the relevant text in the transcripts. This strategy 
enabled the PI to become even more familiar with the data, so that the themes could be refined 
to become clearer and more accurate. More immersion in this stage would ensure that key 
themes are not overlapped, and the data only fitted one theme and were not repeated in another 
theme. 
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Summarising and charting 
The main purpose of this stage is to briefly summarise what was said by participants and 
arranging these in a chart organised by themes. The same key word/s that the participants used 
was used in summarisation.   A line numbering function in Microsoft Word was utilised to 
make it easy to retrieve the original data and the number of the page and line were written at 
the end of each summary. This approach provided a clear audit for the PI and other 
investigators and charting in this way would provide clarity of where the data came from. 
Mapping and interpreting 
The final themes were reviewed against the original transcripts, notes and the digital 
records by a qualitative research expert. Refinement of the themes was made accordingly. The 
charts and summaries were checked and reviewed against the themes and original data for any 
changes that were also needed. The final theme framework was agreed with the research 
group. Constant refinement of themes and returning to the original data leads to the 
development of a conceptual framework (312). Furthermore, at this stage the transparency 
produced by returning to the original data enhances rigour (311). 
4.3.2. Emergent themes  
Five main themes emerged regarding the factors that influence decisions to prescribe 
ceftriaxone for patients with CAP:  
  Clinical intuition vs. structured evaluation of severity 
  Clinical uncertainty 
  Prior experience 
 Source of guidance 
 Prescribing etiquette.  
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Clinical intuition vs. structural evaluation of severity 
All participants mentioned that they would use ceftriaxone in cases of severe CAP. 
However, participants mentioned different methods to identify patients with severe CAP.  
Although most interviewees were aware that using a severity assessment tool is recommended, 
only some of the participants actually used such a tool, and fewer used one of the severity 
tools specifically recommended by TG14, i.e. SMART-COP or CORB.  
 “It is quite easy really, in the absence of guiding from microbiology, it’s a risk 
stratification based on the severity score. I would use the Therapeutic Guidelines, really. 
For empirical clinical management, [I would prescribe antibiotic regimen] based on the 
severity scores such as the CORB and SMARTCOP (P5 G)”. 
Some of the doctors who used a severity assessment tool, used an alternative such as PSI 
or CURB65, either due to familiarity and/or because that was what they had been taught to 
use. 
 “The one that springs to mind is CURB65 because it’s the one I know. Other ones I can’t 
remember. That [CURB65] is just the one I’ve learned (P2 G).”  
The other participants mentioned that they relied solely on their clinical judgment to 
assess the severity of CAP. 
 “Most of it is the clinical picture of the patient. You see patients have difficulty 
breathing, short of breath, can’t really speak, … are not stable, lower blood pressure, 
respiratory rate is elevated… .all of these things make you say OK this patient is not fine 
(P3 R).” 
Several reasons were stated regarding why CAP severity scores are not routinely used. 
The reasons included experience, education, and the changes in the recommended scoring 
system. 
“I am aware of a quite a number of scores and systems one could use... But I guess that 
as one goes through your career, sometimes just through your own judgment and knowing 
about few key things can kind of get a sense of that yourself (P4 C).” 
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“I know there are [severity tools], but they didn’t teach us at med [medical] school. Like 
there is this SMART-COP and things like that. But in ED I haven’t necessarily been 
encouraged to use that on the front line. I just go by your kind of gut feeling (P8 G).” 
“In the past, they use PSI score, but this now has disappeared. I can’t find it in TG 
anymore. So I just generally go by the clinical picture (P7 G).” 
Some participants mentioned that in those cases of CAP likely to be admitted as an in-
patient, the severity warrants ceftriaxone-based therapy. 
“for empirical, it is normally ceftriaxone or some other 3rd generation cephalosporin 1 
gram or 2 grams IV daily plus macrolide (azithromycin)… that’s normally for patients 
who are for admission (P3 R).” 
It was frequently mentioned that the perception of severity is often influenced by the 
presence of co-existing diseases, as one interviewee said: 
“A lot of patients have pneumonia which is only severe because of the comorbidity…the 
number of diabetic, ischemic heart disease, heart failure, …much more complicated 
patients than perhaps they were 20 years ago (P1 C).”  
Clinical Uncertainty  
Clinical uncertainty was a common theme that all participants believed could be a major 
factor explaining prescription of ceftriaxone outside of guideline recommendations. An 
example of this was where the prescriber was unable to identify the source of infection or a 
suspicion that there may be multiple sources of infection. 
“It is not clear in the first day what is really going on with this patient… it is not that 
clear it is the pneumonia causing the patient’s presentation. For the inpatient team, it is 
different story, but for ED you don’t really know what the patient has, you are the first 
line of the treatment (P7 G).” 
“If I was not entirely sure about the source, if there is concomitant UTI, I think 
ceftriaxone gives good broad spectrum coverage (P6 R).” 
Some participants mentioned that the time limitations in the ED could be one reason to 
prescribe ceftriaxone even if they are not sure about the diagnosis. 
 
102 
 
“I think in the emergency setting sometimes because people really in a hurry, they can’t 
really decide what to do, and they want to push the patients as soon as possible and let 
the patient go out from the ED and decide if the patient should go home or should be 
admitted. Actually, that’s the nature of the ED, to decide as quickly as you can. 
Sometimes, I feel that’s the reason why we prescribe ceftriaxone in ED (P3 R).” 
Prior experience 
It was frequently mentioned that the broad spectrum and generally good safety profile of 
ceftriaxone might make it attractive to be used in the ED as one interviewee put it:   
“I guess because ceftriaxone is a fire and forget weapon. Give it then the patient gets 
better. ..and there are very rare major side effects acutely. I guess people think that they 
cover their back by giving ceftriaxone (P7 G).” 
Some participants stated that ceftriaxone leads to less treatment failure than may be seen 
with other agents recommended for non-severe CAP. Talking about this issue, an interviewee 
said:  
“Just from my experience it [ceftriaxone] always works. I haven’t seen a lot of treatment 
failure with ceftriaxone. On the other hand, benzylpenicillin, I’ve seen several patients not 
getting better with that (P7 G).” 
Source of guidance 
Participants used different resources to guide their choice of antibiotic therapy, including 
ceftriaxone, for patients with CAP.  
All participants stated that they utilised Therapeutic Guidelines (TG) to inform empiric 
treatment of CAP patients in the ED. 
“I normally follow the TG [Therapeutic Guidelines: Antibiotics]. You need to make the 
decision whether to admit the patient or send the patient home. I found this quite helpful 
(P7 G).” 
However, when asked about their thoughts regarding empirical management of CAP, 
some participants reported occasional use of antibiotic regimens that were not in accordance 
with TG. 
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“I feel that I would rather give people [IV] amoxycillin rather than straightforward 
benzylpenicillin because I think it is slightly broader…I have never prescribed ceftriaxone 
for most people with pneumonia…sometimes I think I tend to give old smokers oral 
Augmentin [amoxycillin/clavulanic acid] when probably it is inappropriate, but they’ve 
been on it before and it’s got extended cover and it probably has less resistance (P1 C).” 
Some participants also utilised international references to seek guidance regarding 
treatment decisions.   
“In the hospital I usually use UPTODATE, which is an American site. We normally have 
it in the computers at the hospital. ..I know there are some other sites and applications 
would help you as well. I really feel comfortable with UPTODATE (P3 R).” 
Prescribing etiquette 
Discussion with colleagues regarding the use of ceftriaxone for CAP ranged from 
extremely rare with consultant participants, extremely rare to sometimes with registrars, to 
most of the time and always with residents.   
“No, not for ceftriaxone…the only time that I ask for sort of guidance are for people with 
sensitivities to antibiotics or when it is an unusual infection, significantly 
immunocompromised patient, then I might talk to ID about what would they like to 
give…invariably, it is not ceftriaxone (P1 C).” 
“I sometimes consult my colleagues, but I feel comfortable if I feel the patient is sick 
enough; I just give it. Sometimes I consult with my consultant whether they are happy 
with that plan. But in general if it is a sick patient, I don’t have too much doubt in giving 
them unless they are allergic and need to solve other problem (P7 G).” 
“Definitely I use the consultants because I’m a junior doctor... Because I was a junior I 
used to discuss it [ceftriaxone]; for example, before I give it to the patient (P3 R).” 
All consultants and most registrars thought that the inappropriate prescribing of 
ceftriaxone might originate with junior doctors. 
“It is difficult… particularly if people [juniors] have been working in these areas with 
septic patients in intensive care and oncology, and they have a rotation to ED, then they 
are going to feel that’s appropriate to use those antibiotics for the sicker patients, where 
the sickness is not necessarily related to the… you know the correlate between antibiotics 
and unwellness (P1 C).” 
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It was also mentioned that there is less restriction on prescribing ceftriaxone in the ED 
and most of the time senior doctors do not object when they have been asked. Participants also 
reported that the general principle of ‘do no harm’ applies to the use of ceftriaxone due to its 
safety. 
“I really sometimes think that we just give ceftriaxone to patients unnecessarily. And 
actually we did give those patients ceftriaxone unnecessarily many times.  I think you can 
see it with all doctors as a resident, as a consultant, as everyone. ..I always think that 
there is feeling in all of doctors that antibiotics won’t do anything [harmful] “one or two 
doses of ceftriaxone won’t kill anyone (P3 R).” 
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4.4. Discussion  
Following the work described in the previous chapter to identify barriers that hinder 
doctors from adhering to recommendations, this qualitative study was designed to determine 
factors that influence ED doctors to prescribe ceftriaxone outside the TG14 recommendations.  
Five broad themes emerged from the analysis that could describe and explain some of our 
findings from the baseline audit (Chapter 2) and survey study (Chapter 3).  
4.4.1. Assessment of CAP severity  
There was general agreement that ceftriaxone is required for patients with severe CAP. 
However, despite this, participants used different methods to assess CAP severity. For 
example, half of the participants reported not using any severity scoring tool despite an 
awareness of them. Those participants reported the use of non-objective measure of 
pneumonia severity such as need for admission, clinical judgment and co-exiting diseases. 
Subsequent to this self-perceived subjective assessment of pneumonia severity, ceftriaxone 
was being used for patients who would not have received it if treatment decisions were based 
on objective assessment of severity.  
Some of these findings were similar to previous published studies. For example, a 
qualitative study looking at reasons behind non-adherence to guideline recommendations 
among Dutch general practitioners found a perception that some guideline recommendations 
are not applicable to some groups of patients, such as those with a co-morbidity (159). A 
systematic review looking at factors influencing adherence to clinical guidelines among health 
care providers showed that patients’ characteristics, such as co-morbidity, increase the chance 
that recommendations are not followed (313). The need for admission was also reported as an 
indicator of CAP severity and consequently justification for using ceftriaxone. However, 
according to the TG14, some patients who are admitted may have moderate CAP and 
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ceftriaxone is not recommended unless the patient is allergic to penicillin. It should also be 
acknowledged that in some cases, the decision to admit for treatment may be related to social 
factors, rather than the severity of CAP as such (144). Reliance on clinical judgment to 
identify patients with severe CAP is another theme that was noted in this study. It has been 
reported that ED physicians are more likely to overestimate the severity of CAP, which leads 
to unnecessary hospitalisation and use of inappropriately broad-spectrum antibiotic therapy 
(275). It has also been reported that when ED prescribers deviate from guidelines, there would 
be a tendency to use broader spectrum antibiotics than those recommended by the guidelines 
(314).  Furthermore, in one Australian study, it was shown that most of the empiric 
ceftriaxone therapy initiated in the ED was subsequently altered after admission (168). It can 
perhaps be assumed that ceftriaxone usage was, in such cases, inappropriate in the first place.  
Even with those participants who reported use of a tool to assess CAP severity, there 
was inconsistency in their chosen tool. This is an important point as the use of different tools, 
such as PSI or CURB65, for an individual patient may result in a different severity score. 
Various severity tools have been proposed to assist doctors in making decisions regarding the 
empirical management of CAP, yet, there is no agreement about the best assessment severity 
tool (221). Therefore, national and international guidelines often recommend one or two of the 
validated assessment tools to assess the severity of CAP with justification based on experts 
opinion (144, 182, 186). The non-agreement about the best tool to assess the severity might 
lead doctors to gravitate towards the tool they are most familiar with and this was mentioned 
by some participants.  Uncertainty  
Uncertainty regarding the diagnosis appears to be an important influence on prescribing 
of ceftriaxone in the ED and this might be due to the nature of ED, where doctors have limited 
time to make a decision. Uncertainty over the source of infection or the effectiveness of 
narrower spectrum antibiotics in a specific case scenario could lead to the prescribing of a 
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broader-spectrum antibiotics “to be on the safe side” (304, 315). As an example, a doctor 
might prescribe ceftriaxone empirically if it is not clear whether a patient has UTI or CAP, and 
since ceftriaxone covers both E.coli, the pathogen most frequently identified as causing UTI, 
as well as S.pneumoniae, the most common pathogen in CAP; and this may be reasonable  
(144).  The high pressure ED environment might encourage use of ceftriaxone for patients 
with suspected CAP, as one of the participants reported.  In their studies, Fee et al. and Pines 
et al. found that there was an association between increasing volume of patients in the ED and 
delayed antibiotic administration for patients with CAP (316, 317). Efforts to reduce the 
overcrowding in EDs by introducing the 4-hour rule, that is, the decision to admit or discharge 
a patient from the ED should be taken within four hours of presentation to the ED (318), might 
have added to pressure on doctors at the study site to prescribe ceftriaxone. Uncertainty and 
difficulty in confirming a diagnosis of CAP upon admission, particularly for patients with a 
clear chest X-ray, was also reported as one of the issues that might lead to inappropriate 
management (253).   
4.4.2. Experience with ceftriaxone 
The interviewees frequently compared their experience with ceftriaxone and penicillins 
for the management of CAP, and it was always highlighting an advantage for ceftriaxone. 
Interviewees stated that a once daily dosing of ceftriaxone makes it attractive as a treatment 
option for patients with CAP. This advantage is not seen with other recommended antibiotics, 
particularly penicillins. For instance, benzylpenicillin is required to be administrated four 
times within 24 hours (144). With respect to clinical outcomes, there was a sense amongst 
interviewees that ceftriaxone, due to its broad-spectrum coverage, when compared to 
penicillin, has better clinical outcomes. As one of the participants mentioned, his own 
experience has led him to perceive patients are more likely to return to the ED a few days later 
with no improvement when penicillin-based therapy is prescribed. In their qualitative study of 
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barriers to CAP guideline adherence, Schouten et al. found that one of the reasons for not 
using penicillins for the management of CAP patients was doubts about the outcome with 
those narrow-spectrum antibiotics (157). This would suggest that the preference to prescribe 
ceftriaxone might be due to less confidence about penicillin-based therapy in some cases.  
4.4.3. Influence of senior doctors 
In common with other departments, the ED is staffed by doctors with varying levels of 
seniority and these may all be involved in the management of patients with CAP. The 
influence of senior doctors on prescribing practices of junior doctors has been demonstrated in 
several studies (163, 165, 315). According to Charani et al., the prescribing of antibiotics is 
influenced by “prescribing etiquette”; which does not reflect any written rules, but acceptance 
of culture norms (163). By way of illustration, Charani et al. found that senior physicians 
generally considered themselves to be experts and relied on their personal experience in 
prescribing (163). Junior doctors, on the other hand, are influenced by the prescribing habits of 
their seniors. Therefore, the authors suggested that despite most interventions promoting 
prudent use of antimicrobials being directed at junior doctors, the practice of the senior 
doctors is the main determinant of their junior colleagues’ prescribing (163). Hierarchies 
might play a role in influencing junior doctors’ decisions about prescribing antibiotics (163), 
our study showed that junior doctors are more likely to make decisions about prescribing 
ceftriaxone, yet,  they are likely to seek confirmation by consulting with their seniors. 
Interestingly, despite this finding from junior doctors, there was a sense amongst senior 
doctors that it was the junior doctors who were responsible for ceftriaxone prescribing outside 
guideline recommendations.  
Other possible explanations for unnecessary prescribing of broad-spectrum antibiotics 
are worth exploring.  Leake et al. identified several factors that might lead medical residents to 
prescribe broad-spectrum antibiotics unnecessarily. These factors included lack of awareness 
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of the possible serious adverse effects associated with prescribing such antibiotics and issues 
related to antimicrobial spectra (319). Another important finding in the present study is the 
influence of rotation on junior doctors’ prescribing practice as mentioned by one interviewee. 
This might provide juniors with conflicting opinions with regard to antibiotic prescribing. A 
qualitative study looking at factors influencing antimicrobial prescribing among junior doctors 
in two UK hospitals found that health care culture was the main factor that influences the 
antimicrobial prescribing (320). Among these cultural aspects, it was identified that there can 
be a major variation between wards in the same hospital in terms of antimicrobial prescribing 
expectation and support, particularly with rotations which need rapid adjustment to the new 
rules. 
4.4.4. Quantitative and qualitative studies: putting it all together   
The results from this qualitative study will now be compared to the findings of the 
earlier quantitative study reported in Chapter 3. Firstly, in the preceding chapter, we found that 
senior doctors were the most commonly reported influence on prescribing. The qualitative 
study explored how this influence was likely to occur. Secondly, the results from the 
questionnaire indicated that different severity scoring systems were used. This also concurs 
with the findings from the qualitative study which showed that different severity scoring 
systems were used among ED doctors to identify severe CAP. Apart from the established 
objective tools, other methodologies were also used as an indicator for severity, such as 
clinical judgment, co-existing disease and need for admission.  Thirdly, despite the high 
awareness of the relationship between use of ceftriaxone and emergence of multi-drug 
resistance, when doctors were asked about why this drug is not recommended for most CAP 
cases, none of them mentioned concerns about resistance as an influencing factor. This is 
consistent with other studies, which have reported that the desire to use a treatment with a high 
likelihood of curing the infection is the major driver at the time of prescribing (304, 315). 
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Finally, most of the survey respondents agreed with the statement that penicillin-based therapy 
would give the same results as ceftriaxone in most CAP cases. Nonetheless, some participants 
reported a lack of confidence in the effectiveness penicillin-based compared to ceftriaxone-
based therapy, according to their own experience with the both regimens.  
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4.5. Limitations 
A number of important limitations need to be considered. First, while prescribing of 
antibiotics in the RHH ED may be undertaken by any medical specialty, all participants in this 
qualitative study were ED-based prescribers. Therefore, the opinions of other staff who may 
have an indirect influence on ceftriaxone prescribing decisions in the ED were not recorded.  
However, the main aim of our study was to survey those first-line practitioners who initially 
assess patients in the ED. The sample size was also relatively small (8 physicians) which was 
a consequence of time pressures on ED staff; however, all the physicians who were 
interviewed were working in ED, and it has been shown that for a study with a high 
homogeneity level, as few as six interviews could be sufficient to reach saturation with 
meaningful themes and enable a meaningful interpretation (321). Finally, this study focused 
on the factors that influence use of ceftriaxone-based therapy for patients with CAP; the 
barriers hindering physicians from prescribing penicillin-based therapy received less attention. 
Nevertheless, one of the main purposes of antibiotic guideline development is to limit the 
emergence of resistance by limiting unnecessary use of broad-spectrum antibiotics, such as 
ceftriaxone; which is consistent with the targets of RHH antimicrobial stewardship team.           
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4.6. Conclusion  
Our study identified a number of modifiable and non-modifiable factors influencing the 
prescribing of ceftriaxone in ED. Factors such as clinical uncertainty are difficult to modify, as 
the limited time a patient spends in the ED can be challenging to make a definitive diagnosis 
of CAP and its degree of severity. In contrast, factors relating to the source of prescribing 
guidance and professional etiquette can be addressed by establishing local CAP management 
guidelines and treatment pathways, with engagement from senior clinicians.  The findings 
from the current study, together with the results from the preceding chapter provide an 
important insight into the barriers that hinder doctors from adhering to TG recommendations 
for the management of CAP.  Addressing each of these factors would be pivotal to the success 
of any intervention designed to increase adherence to CAP guidelines and specifically reduce 
inappropriate prescribing of ceftriaxone in the ED. 
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Chapter 5. Snapshot of intervention strategies used 
to improve CAP management in Australian public 
hospital ED departments 
 
5.1. Introduction  
The Emergency Department is the site of care where most patients with CAP, are 
initially seen and empirically treated with antibiotics (317). However, it has been shown that 
broad-spectrum antibiotics, such as ceftriaxone, have been commonly prescribed 
inappropriately for ED patients with CAP (168). Therefore, the ED is likely to be an ideal 
target for interventions to improve CAP management. 
Despite AMS activities being well-established in the in-patient setting, they have 
traditionally focused little attention on EDs in Australia. To help us identify appropriate 
strategies for our interventions, this study aimed to: 
 Explore the general role of AMS in ED 
 Explore the perception regarding effective strategies to improve the appropriate use of 
antibiotics for CAP patients in Australian EDs.  
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5.2. Methods 
5.2.1. Setting and participant characteristics 
An electronic link to a web-based questionnaire was circulated via email to the 
infectious diseases pharmacist group of the Society of Hospital Pharmacists of Australia 
(SHPA). The estimated number of pharmacists in this group was 150 at the time of the study 
in July 2013. Two e-mailed reminders were sent at one-week intervals.     
5.2.2. Questionnaire and measurement  
The questionnaire consisted of three main sections. The first included questions 
regarding hospital’s characteristics including state, number of beds, and information about the 
status of AMS within the institution. The second section included questions regarding 
initiatives that have been made by the participants’ hospital to improve antibiotic prescribing 
for CAP in the ED and the initiatives that were perceived as effective. In the final section, the 
participants were asked to briefly describe the overall role of the AMS program in their 
hospitals’ EDs.     
5.2.3. Data analysis  
Chi-square tests were used to identify statistically significant differences between 
variables and the value of p < 0.05 was considered statistically significant. All the statistical 
tests were performed by using IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: 
IBM Corp.   
Approval from the Human Research Ethics Committee (Tasmania) network was granted 
prior to the conduct of the survey [approval no.: H0013156]. 
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5.3. Results 
5.3.1. Response rate hospital characteristics  
Of the study population, 41 (27.3%) participants completed the questionnaire. Hospitals 
characteristics are described in Table 5.1. All respondents worked in public hospitals. 
Table 5.1: Hospital characteristics. 
State/ Territory  
Queensland (QLD) 10 
Victoria (VIC) 9 
New South Wales (NSW) 9 
South Australia (SA) 5 
Western Australia (WA) 5 
Tasmania (TAS) 2 
Australian Capital Territory 
(ACT) 
1 
   
Hospital’s capacity  
100 – 300 beds 9 (22%) 
301 – 500 beds 16 (39%) 
More than 500 beds 16 (39%) 
   
Year of establishment of 
AMS program 
Before 2011 (inclusive) 13 (31.7%) 
After 2011 24 (58.5%) 
No AMS program 4 (9.8%) 
   
Periodically monitor 
antibiotic usage in ED  
 
21 (51.2%) 
   
Utilisation of CAP 
guidelines  
TG14  18 (43.9%) 
Local guidelines 22 (53.6%) 
No guidelines recommended  1 (2.4%) 
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5.3.2. Process of care for the management of CAP in ED 
A number of different approaches were in place to improve the prescribing of antibiotics 
for patients with CAP (Figure 5.1). Academic detailing was the least common strategy that 
respondents reported as using to enhance CAP management (7.3%).  
 
 
Figure 5.1: Strategies that had been used to improve antibiotics use for CAP 
management in ED. 
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When the participants were asked about their perception of the effectiveness of the 
strategies that had been employed in their hospital, there was no clear preference for 
individual selected strategies (Figure 5.2).  
 
Figure 5.2: Strategies that had been perceived as effective to improve use of antibiotics 
for the management of CAP in ED. 
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Participants reported CAP clinical pathways (34.1%)  followed by academic detailing 
(24.4%) and auditing and feedback (17.1%) as the most effective strategies in improving the 
management of CAP at their hospitals. Surprisingly, only 1 participant reported that 
conducting group educational sessions was the most effective strategy (Figure 5.3).  
 
Figure 5.3: Strategies perceived as the most effective strategy for better use of antibiotics 
for patients with CAP in ED. 
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Those who reported the presence of AMS in their hospitals were invited to describe the 
extent of AMS activity in the ED. Of the 37 participants who reported their hospital had an 
AMS, 24 answered this optional question. The reported roles of AMS in ED are listed in 
Table 5.2. Nine respondents indicated no current AMS activity in the ED due to the program 
being new and the focus being on in-patient wards. 
Table 5.2: Roles of AMS in the ED setting (n= 15). 
Role of AMS program Frequency a 
Development of local guidelines 4 
Monitoring local antibiotic susceptibility  1 
Restriction policy  4 
ED pharmacist liaising with ID 2 
Regular education by ID 5 
Involvement of ED senior in AMS hospital program 4 
Audit and feedback 6 
Clinical decision support system (CDSS) 2 
ID physician rounds in ED 1 
a The cumulative frequency does not add up to 15 since more than one strategy might have 
been utilised. 
 
The presence of local CAP guidelines was significantly more likely in hospitals where 
AMS was in place in 2011 or earlier (84.2% vs 37.5%; p = 0.014). However, there was no 
difference in the periodic monitoring of antibiotic usage in ED between those hospitals who 
had implemented AMS in their hospitals before and after 2011 (69.2% vs 47.6%; p = 0.3). 
The vast majority of participants reported that ED staff required more education to 
increase adoption of CAP guidelines (63.4% strongly agree, and 29.3% agree).  
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5.4. Discussion  
The main objective of this study was to identify strategies that have been used and 
perceived as successful for the management of CAP among EDs in Australian hospitals. The 
results of this study showed the hospitals have used more than one strategy to enhance 
antibiotic prescribing in ED for CAP. However, most of the respondents considered the most 
single effective strategy to be the use of CAP clinical pathways. 
Our study indicates that multifaceted strategies are the most utilised and seemingly most 
effective methods to improve the empirical management of CAP within ED in Australian 
public hospitals. Similarly, another Australian study showed that the use of a variety of 
strategies to improve antibiotic usage was a common phenomenon (138). Several meta-
analyses related to the effect of single interventions in changing physicians’ decision-making 
process found limited improvement in changing prescribing behaviours (322-327). 
Multifaceted strategies have been demonstrated as an efficient approach that can effectively 
improve care, as well as clinical outcomes (117, 128, 146, 154, 170, 328-331). According to 
Grimshaw et al., multifaceted and active interventions are more likely to work in changing 
physicians’ prescribing behaviour than passive dissemination or single interventions (332).  
As a successful example of this type of approach, Wong-Beringer et al.. found a 30% decrease 
in empirical prescribing of broad-spectrum fluoroquinolone antibiotics, when multifaceted 
interventions were utilised (126).   
To ensure effective and sustained compliance with antibiotic guidelines both systematic 
and educational initiatives should be implemented. ACSQHC provides an example of an 
essential systematic change, endorsement of local guidelines that are based on the latest 
Australian national Therapeutic Guidelines, as one of the fundamental strategies for successful 
AMS (117). Development of ED-specific guidelines, or clinical pathways, accompanied by 
education could be a powerful strategy to encourage adoption of CAP guidelines in ED (333).  
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CAP clinical pathways were perceived as the most single effective strategy that could 
improve adherence with guidelines in ED. Using clinical pathways might be particularly 
effective for the ED where a quick decision is required to admit or discharge patients (333). A 
clinical pathway can help expedite the process with appropriate decisions regarding 
assessment, admission and antibiotic/s selection.  
The study also indicated that academic detailing was perceived as the second most 
effective strategy. In a Cochrane review relating to the effect of academic detailing on 
changing clinical practice including 69 studies, the authors concluded that using academic 
detailing approach have a positive but small effects on prescribing behaviour (327).  However, 
this strategy might be difficult to conduct in a busy clinical environment, such as ED. In a 
qualitative study to get participants’ thought about the academic detailing strategy that were 
used to  improve compliance with CAP guideline’s recommendations in Australian EDs, it 
was argued that this strategy was time-consuming for both the providers and for ED doctors 
(277). This may explain why academic detailing was the least reported approach by 
participants in our study.   
AMS plays a very important role in designing and implementing strategies to improve 
antibiotic prescribing in the in-patient and ED settings. This includes the development and 
promulgation of local guidelines. Respondents who reported the presence of AMS in their 
hospitals before 2011 were more likely to report the presence of local CAP guidelines.   
Almost 90% of participants in our study reported the presence AMS in their hospitals, but 
only one-third of them reported the AMS programs were officially implemented before 2012. 
This is consistent with a survey that was conducted in 80 Australian hospitals in 2008, where 
only 24% of  the respondents, pharmacy department directors or their nominees, reported the 
presence of AMS program in their institutions (138). Moreover, when AMS programs are first 
introduced, the first priority is invariably for admitted patients, and newer AMS programs 
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might not have perceived roles in the ED. This theory is supported by the responses from nine 
participants with a new AMS program.  
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5.5. Limitations  
The major limitation of this study is the relatively low response rate (27.3%). However, 
the aim of this study was to determine a snapshot of initiatives that have been performed in 
hospitals to improve the management of CAP in ED and is therefore unlikely to compromise 
the validity of the findings. 
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5.6. Conclusion  
These findings suggest that, in general, non-specific multifaceted strategies are 
frequently performed to improve use of antibiotics for CAP management in Australian EDs. 
However, CAP clinical pathways were perceived to be the single most effective strategy. The 
evidence from this study suggests that a CAP clinical pathway should ideally be part of any 
intervention designed to improve CAP management in the ED. The findings from this chapter 
alongside the findings from the chapters, 2, 3 and 4, would be used to develop targeted 
interventions aimed at improving adherence to CAP guideline recommendations, including 
attempts to reduce inappropriate ceftriaxone prescribing and improve clinical outcomes.     
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Chapter 6. Interventions  
 
6.1. Introduction 
The findings reported in Chapter 2 provided clear evidence of sub-optimal adherence to 
TG14 for the empirical therapy of CAP in adults in two Tasmanian hospitals, with the 
widespread use of ceftriaxone for patients with non-severe CAP, a significant contributor to 
this issue. Similar findings have been reported in the national and international medical 
literature (220, 334, 335).  Therefore, based on this evidence–practice gap, an intervention to 
change behaviour was designed, with the desired outcome being to improve adherence to 
guideline recommendations for empirical CAP management; which would consequently 
reduce the inappropriate use of ceftriaxone-based therapy for patients with non-severe CAP.  
The vast majority of patients with CAP were diagnosed and accordingly prescribed their 
first dose of antibiotics while in the Emergency Department (ED). In the vast majority of  
cases, these clinical decisions were made by medical staff based in the ED; but in some cases 
doctors from medical admission teams were consulted and prescribed antibiotics for CAP 
patients in the ED (250). Consequently, ED medical staff were the main professional group to 
be targeted by the intervention, however, recognising the involvement of other medical teams 
in some cases, they were also exposed to our intervention. 
To guide the choice and the design of the intervention, we identified the potential 
barriers that might hinder medical staff from adhering to national CAP guidelines for 
empirical therapy (Chapter 3). This was followed by a qualitative study involving prescribers 
in the ED at the RHH to gain an in-depth understanding of the factors that influence their 
prescribing of ceftriaxone for patients with suspected CAP (Chapter 4). In addition, the 
findings of Chapter 5 also highlighted some of the strategies that were considered by 
infectious disease pharmacists to be effective in improving the management of CAP.  
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Decisions regarding the most appropriate intervention strategies to improve adherence to 
CAP guidelines amongst RHH doctors was influenced by these collective findings, combined 
with the experience of the RHH Antimicrobial Stewardship (AMS) team.   
It has been shown that interventions to improve clinical practice are more effective if the 
interventions are based on addressing existing barriers to best practice (336, 337).  
Multifaceted interventions to improve clinical practice appeared to be more effective than 
single interventions (338). Therefore a multifaceted intervention combining several strategies 
was designed to improve the physicians’ concordance with CAP guidelines at the RHH.   
The following section of this chapter will describe the components of the multifaceted 
intervention followed by a plan to evaluate the effectiveness this intervention in improving the 
physicians’ concordance with CAP guidelines.  
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6.2. Components of the multifaceted intervention  
Feedback on the findings of the baseline (Chapter 2), qualitative (Chapter 4) and survey 
studies (Chapter 3 and 5) was provided to a meeting of the RHH AMS committee. This 
committee has representation from several departments in the hospital which include, but are 
not limited to, respiratory, infectious disease, microbiology, pharmacy, and emergency 
departments. The rationale for presenting the findings to the committee was to facilitate 
discussion, seek comments and feedback on the possible initiatives that could be implemented 
to improve CAP management at the RHH. A number of initiatives were agreed upon as a 
result of this process and subsequently implemented as a part of the multifaceted intervention 
as shown in Table 6.1.  
Table 6.1: Proposed initiatives based on the findings from the survey and interviews. 
Proposed intervention design Rationale 
 Development of local CAP guidelines    
(based closely on TG14) 
 Involvement of hospital stakeholders in the 
local guidelines’ development 
 To provide local 
ownership 
 To address perceptions 
that the organisation did 
not expect guideline 
adherence  
 To overcome the barrier 
regarding existence of 
other guidelines  
 To harness the support of  
senior doctors to be a 
positive influence   
 To overcome lack of 
awareness 
 To address inconsistency 
with regard to severity 
assessment 
 To unify the source of 
guidance  
General 
Intervention  
 Education package 
(posters, lanyard 
cards, presentations, 
and group discussions) 
ED focused 
interventions  
 Development of CAP 
clinical pathway in ED 
 Monthly auditing and 
feedback 
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6.2.1.  Local guidelines development  
The process of developing a local CAP guideline was initiated through an initial meeting 
with the key stakeholders including representatives from Respiratory, Infectious Diseases, 
General Medicine and Emergency Departments. Following this, further meetings and 
correspondence occurred to refine the document and this resulted in the production of a final 
draft version. This was circulated via email to gain final approval from stakeholders before 
proceeding to the relevant hospital committees for endorsement of the guideline, printing of 
hard copy resources and publication on the hospital intranet. 
The local CAP guidelines included recommendations regarding diagnostic strategies, 
admission decisions, severity assessments and antibiotic regimens.  With regards to the 
empirical management, minor changes to the TG14 recommendations, to take account of the 
opinion of the hospitals’ medical and emergency departments, were made (Table 6.2).  
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Table 6.2: Antibiotic recommendations for the management of adult patients with CAP 
at the RHH. 
 
With regard to the antibiotic regimen recommendations, the dose of doxycycline for 
patients with moderate CAP was recommended to be 200 mg initially instead of starting with 
100 mg as per TG14.  The rationale behind this decision was to make the dose consistent with 
what is recommended in mild CAP so reduce the risk of confusion. The same justification was 
applied to clarithromycin, where a dose of 500 mg was recommended for patients with mild 
CAP, rather than the 250mg as per TG14. Moreover, despite the fact that TG14 includes an 
option to use aminoglycoside-based therapy for patients with severe CAP, the AMS team 
preferred to only retain the ceftriaxone-based option. The rationale for this was that most 
patients in the baseline study were over 65 years, a group of patients in whom renal 
impairment is more prevalent, which increases the risk of harm with aminoglycoside therapy. 
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Furthermore, simplification of the guideline recommendations to provide doctors with fewer 
options at each level of CAP severity was deemed desirable.  
Another modification related to the recommended approach to CAP severity assessment. 
In TG14 two severity assessment tools are recommended, SMART-COP and CORB, with no 
preference given to either. A decision was made to specifically recommend CORB in the local 
guideline for a number of reasons. Firstly, CORB only requires consideration of four easy to 
remember variables. In addition, only vital signs needed by CORB, in contrast to SMART-
COP, where two laboratory tests, blood pH and serum albumin, are also required.  Finally, the 
CORB severity score less complicated to calculate, with each variable scoring one point; 
whereas SMART-COP is complex to calculate (some variables score one and some others 
score two, and the score for some variables is age dependent). For those reasons, it was felt 
that CORB was a more pragmatic tool, particularly in busy clinical areas, such as ED, where 
most patients with CAP are initially assessed.  
The CORB severity tool stratifies patients with CAP into one of the three severity 
groups; mild (score 0), moderate (score 1), and severe (score equal to or greater than 2). .  
In order to promote adoption of the local CAP guideline recommendations, two different 
types of interventions were conducted during two consecutive periods of times (Figure 6.1). 
Dec 
2012 
Jan 
2013 
Feb 
2013 
Mar 
2013 
Apr 
2013 
May 
2013 
Jun 
2013 
Jul 
 2013 
Aug 
2013 
Sep 
2013 
Oct 
2013 
Nov 
2013 
 
Figure 6.1: Intervention period timeline.  
 
 
 
General intervention ED-focused intervention General intervention 
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6.2.2. General intervention  
An email was sent to all RHH medical staff advising them of the release of the local 
CAP guideline. The release of the guideline was combined with educational sessions. Four 
presentations and six group discussions were held during December 2012, and two 
presentations and five group discussions were conducted during February 2013. The content 
of these was developed and reviewed by the RHH AMS team to provide background to the 
development of the CAP guideline and the content.  The key messages included: 
  The involvement of key opinion leaders from all related departments in the 
development of the guidelines 
  The recommended CAP severity assessment tool 
 Ceftriaxone only being recommended as a first-line therapy for patients with severe 
CAP 
 The adverse effects related to the use of ceftriaxone  
All educational sessions were led by the research team with full support from the RHH 
AMS team. 
Wall posters, with guideline recommendations and key messages, were displayed in all 
RHH medical departments (Figure 6.2). Furthermore, a lanyard card summarising the severity 
assessment tool and CAP guideline recommendations was distributed during the educational 
meetings (Figure 6.3). The pharmacy department subsequently assisted in further 
dissemination of lanyard cards to other medical staff who had not attended educational 
sessions.  
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Figure 6.2: Poster component of intervention, as placed in the RHH medical 
departments. 
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Figure 6.3: Lanyard card component of intervention, as distributed to RHH medical 
staff. 
 
 
 
 
Front side 
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6.2.3. ED-focused intervention  
During the next phase of the study, interventions were focussed on the ED (May 2013 to 
November 2013). A one-page CAP clinical pathway based on the local guidelines was 
developed and made available in the ED (Appendix I).  The CAP clinical pathway was 
designed to complement the CAP guideline and provide ED staff with clear information to 
support appropriate management of CAP. The pathway contained information on the CORB 
severity assessment tool and the recommended antibiotic regimens based on the severity score. 
Two educational sessions were performed with ED nursing staff in order to raise awareness 
and promote utilisation of the clinical pathway by medical staff who treat patients with 
suspected CAP. Furthermore, an email was sent to all medical and nursing staff in the ED to 
advise them of the presence of the CAP clinical pathway and its location in the ED. 
This was followed by monthly feedback on the management of 10 randomly selected 
patients with CAP. The feedback was sent from the stewardship team to the head of the ED 
department for onward distribution to ED medical staff (Appendix J). 
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6.3. Approaches to evaluate the impact of the multifaceted 
intervention  
The evaluation of intervention studies in clinical settings in real time is challenging. This 
is because changes in practice often taken place gradually over time and randomising cohorts 
of patients to standard practice vs. best practice has major ethical limitations (339). This is 
why quasi-experimental designs, such as controlled and uncontrolled before-after and 
interrupted time series analysis are more suited to interventions that are carried out in clinical 
settings (Figure 6.4) (339, 340) .  
 
Figure 6.4: Study design approaches to assess the effect of an intervention on the quality 
of care. 
 
 
  
  
  
Uncontrolled Before-after 
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The following sections briefly describe the advantages and disadvantages of the various 
experimental approaches that could be applied to assess the impact of the intervention and 
provides a justification for the methods chosen. 
Uncontrolled before–after approach 
 In this study design, data is collected in two time periods, before and after the 
introduction of an intervention, in order to try and demonstrate a significant change. However, 
this study design is relatively weak in terms of evaluating quality improvement interventions 
(339). It has been shown that the uncontrolled before and after approach overestimates the 
results of interventions when compared to a controlled approach (341). For example, other 
confounding factors might lead to changes in the measured outcomes which might be not 
related to the intervention itself. Therefore, it has been suggested that this approach should not 
be used to evaluate an intervention, and if it is used, the data must be interpreted with caution 
(339).  
Controlled before-after approach 
In this approach, a researcher attempts to evaluate the effect of an intervention in the 
presence of a control group, where the intervention is not applied. The data is collected before 
and after the introduction of a quality improvement intervention in both study groups (339). 
The outcome measurement during the post-intervention phase is then evaluated and a 
significant difference between the two groups would be assumed to be due to the intervention. 
Using this approach would overcome the problem of the sudden and secular changes that are 
found when using the uncontrolled before-after approach (150). However, it would be 
sometimes difficult to find a control group during the baseline period that has similar outcome 
measurement to the intervention group.  
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Interrupted-Time series approach 
This approach is designed to evaluate the effect of interventions at multiple equal time 
periods before and after interventions (342). When collecting data from a single study site to 
measure the effect of quality improvement interventions, interrupted-time series approach is 
always preferred over the simple uncontrolled before-after approach (150). A number of 
advantages might lead to a preference for using this approach over the before-after approach. 
Firstly, this is an alternative method to overcome the issues from the uncontrolled before-after 
design, and when it is difficult to find a comparable control group for the controlled before-
after approach (339). Secondly, more information would be obtained by using this approach 
by allowing researchers to evaluate direct and latent effects of the intervention visually and 
statistically (343). This could not be evaluated by using the before-after approach. However, 
the impact of other factors that would occur at the same time as the intervention could not be 
assessed by this approach. Finally, a significant change that might be found when using the 
uncontrolled before-after approach might not be due to the intervention itself, and it might be 
due to an already increasing trend during the pre-intervention period (Figure 6.5). For 
example, a UK study was conducted to assess the effect of mailing guidelines on the use of 
radiographic examination to 376 general practitioners. The simple before-after approach 
indicated that the intervention had a significant impact, and fewer referral requests were 
observed after the introduction of the intervention. However, the interrupted time-series 
analysis showed a non-significant difference (344).  
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Figure 6.5: Uncontrolled before-after vs interrupted time series approaches. 
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For a better understanding of the effect of our intervention on prescribing behaviour, two 
approaches were utilised to analyse the data:   
1- Controlled before-after approach: for this approach, the North West Regional 
Hospital (NWRH) was assigned as a control site and the RHH was assigned the 
intervention site. The RHH was selected as the site for intervention for several reasons. 
Firstly, the RHH has a well-established AMS program which would facilitate applying 
intervention strategies, whereas at the NWRH there was no AMS program at the time 
the study started. Secondly, the study to identify potential barriers to guideline 
adherence was conducted at the RHH and as discussed earlier, the whole project 
utilised an intervention designed to overcome the identified barriers. Finally, the RHH 
was conveniently located in close proximity to the investigators base. 
2- Interrupted time-series approach:  this approach was selected because two different 
intervention strategies were applied for two consecutive periods of time at the study 
site. Furthermore, the interventions were continuously applied during the whole 
intervention period. Therefore, the interrupted time-series approach would be useful to 
evaluate the effect of the different strategies over time, which could not be provided by 
using the previous approach. However, with the simple interrupted time-series analysis 
design, the main drawback is that other events might occur at the same time as the 
intervention and produce the same effect as the intervention. Therefore, using a 
combination of this method and the controlled before-after approach was deemed the 
most appropriate way to overcome this threat to internal validity.   
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6.4. Conclusions 
This chapter has briefly described the background and rationale for the chosen 
multifaceted intervention strategies to improve CAP management at the RHH. Evaluation 
approaches to assess real time interventions were also discussed followed by the rationale for 
the adopted approaches. The next two chapters will present the results of this multifaceted 
intervention at the study hospital. 
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Chapter 7. Evaluating the impact of a tailored 
multifaceted intervention to improve the 
management of community-acquired pneumonia: A 
controlled before and after study design  
7.1. Introduction 
Debate continues about the best strategies to improve adherence to clinical practice 
guidelines (155). In recent years, there has been increasing interest in investigating those 
interventions designed to overcome barriers to the adoption of recommendations in CAP 
guidelines (153, 154). Studies show that interventions to improve adherence to clinical 
practice guidelines are more likely to improve a process of care when they take into account 
the existing barriers to adherence (154, 345-348). Thus, identification of these barriers would 
help an authoritative hospital group, such as AMS team, to determine the best strategies to 
promote adoption of clinical practice guidelines.   
Our baseline study (Chapter 2) indicated poor adherence to TG14 for the empirical CAP 
management at both the RHH (intervention site), and the NWRH (control site). A major 
finding was that, the broad-spectrum third-generation cephalosporin, ceftriaxone, was 
frequently prescribed for patients with non-severe CAP. Accordingly, two studies (one 
quantitative and one qualitative), were conducted at the RHH to gain a better understanding of 
why physicians frequently failed to adhere to the TG14 recommendations for CAP 
management (Chapter 3 and 4). Since most patients with CAP in the baseline study were 
initially assessed and received their first dose of antibiotics in the ED, we conducted a survey 
of Australian infectious disease pharmacists to characterise the strategies they have used to 
improve antibiotic prescribing for CAP in the ED (Chapter 5). Based on our collective 
understanding from earlier studies (Chapter 3, 4 and 5), we designed an intervention to 
enhance the uptake of the recommendations in CAP guidelines (Chapter 6).   
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 Traditionally, studies investigating the impacts of interventions on CAP management 
have used an uncontrolled before and after study design at a single institution (181, 250, 349).  
However, there are certain drawbacks associated with use of this approach. This approach 
might overestimate the results of interventions (341). For example, this approach fails to 
control for secular trends and sudden changes to the quality improvement intervention (339). 
Until recently, there has been no published Australian research investigating the effect of an 
intervention to improve CAP guideline adherence with the presence of a control group. 
Therefore, by including the NWRH where no intervention was made, we were able to control 
for some variables that may have affected the reliability of our findings.  
The aims of this chapter were: 
1- To evaluate the impact of the intervention on adherence to the CAP guidelines 
2- To evaluate the impact of the intervention on ceftriaxone prescribing  
3- To assess the impact of the intervention on clinical outcomes, specifically patient 
mortality and length of stay (LOS)  
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7.2. Methods 
7.2.1. Study design and setting 
A retrospective, controlled, before-after, study was performed. Baseline data was 
collected in the period between July 2010 and March 2011 and the subsequent data collection 
period from December 2012 to November 2013 covered the periods during and after the 
release of the local CAP guidelines and implementation of interventions.  
7.2.2. Inclusion and exclusion criteria 
All patients (age ≥ 18 years) admitted with a suspected diagnosis of CAP within 24 
hours of the presentation at the ED in both hospitals during the study period were screened for 
eligibility. Patients were considered as having CAP if this diagnosis was documented in their 
medical notes or either the physician or radiologist indicated a change consistent with 
pneumonia on the chest X-ray. Patients with pneumonia were excluded if they were admitted 
from a nursing home (NH), previously admitted to a hospital within 14 days of the current 
presentation, immunosuppressed (chronic use of prednisolone, had received chemotherapy 
within 3 months, were taking any other immunosuppressive agents for the management of 
solid organ transplantation or were HIV positive), had co-existing cystic fibrosis or 
bronchiectasis, or where the patient files were incomplete. These are the same patient selection 
criteria applied to the baseline study. 
7.2.3. Data collection  
All patients’ files were reviewed retrospectively by a trained clinical research pharmacist 
in both hospitals and information was collected using a structured data collection form. The 
abstracted information included patients’ demographics, clinical history, and first prescribed 
antibiotic regimens. Severity of CAP was assessed using relevant clinical and laboratory 
parameters as described earlier in Chapter 2 and shown in Appendix A.     
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7.2.4. CAP guideline adherence and patients’ clinical outcome 
measurements 
Adherence to the CAP guidelines was assessed against the TG14 recommendations. 
Although physicians at the RHH were expected to follow the hospital’s local CAP guidelines, 
these were developed from and were largely consistent with the recommendations in TG14 as 
discussed in an earlier chapter (Chapter 6). Patients were considered to have received a 
guideline concordant regimen if they met the following criteria: 1) concordant selection of 
antibiotic/s, and 2) concordant route of administration. Clinical outcome assessment included 
hospital LOS and rates of in-patient mortality.    
7.2.5. Definitions  
Throughout this chapter, the term “intervention site” will be used to refer to the RHH, 
while the term “control site” refers to the NWRH. In addition, the term “intervention group” 
will refer to data from the RHH during the intervention period, while the term “non- 
intervention group” will refer to all baseline data plus the data from the NWRH during the 
intervention period 
7.2.6. Statistical analysis 
Descriptive statistics included frequencies, percentages, means, medians and standard 
deviations. Normality of the data distribution was examined using normality curve and 
Shapiro-Wilk tests. To compare categorical and continuous variables with non-normal 
distribution between the intervention and control groups Chi square, Wilcoxon rank sum and 
Fisher’s exact tests were used as per the analysis needs. To compare between normally 
distributed continues variables, Student’s t and nonparametric Wilcoxon rank sum tests were 
employed.  
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Logistic regression was performed with adherence to the guideline as the dependent 
variable. Patient demographics, Charlson’s comorbidity index, presence of chest x-ray change, 
severity and the four cohort groups (control and intervention sites, before and after the 
introduction of the intervention) were analysed against adherence to the guidelines. A cut-off p 
value of <0.25 was used to include variables in the regression analysis as recommended by 
experts in the field (350).  It has been shown that using the conventional P value cut-off point 
of < 0.05 could fail in identifying some variables known as influential (351).  
To assess the impact of the intervention on clinical outcomes, the data from the 
intervention site during the intervention period were compared to the collective data of the 
groups who had not been exposed to the intervention (control site and the intervention site 
before the introduction of the intervention). Patients’ characteristics were compared between 
the two groups to identify any other variables that may have influenced the results.  
All statistical analyses were performed using IBM SPSS statistics for windows, version 
20.0. Armonk, NY: IBM Corp. P values less than 0.05 were considered significant.  
7.2.7. Ethical approval  
Prior to commencing the study, ethical approval was sought from and granted by the 
Tasmanian Health and Medical Human Research Ethics committee (Approval numbers: 
H0011729; H0012810). 
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7.3. Results 
The pre-intervention group who were admitted to the RHH (intervention site) with a 
suspected diagnosis of CAP consisted of 276 patients. Of these, 83 (30.1%) patients were 
excluded. The intervention period ran from 1 December 2012 through to 30 November 2013. 
During this period, 425 patients at the intervention site were screened for inclusion, of whom 
157 (36.9%) were excluded. For the NWRH (control site), 68 patients were assessed for 
eligibility during the baseline period and 15 (22.1%) of these were excluded. During the 
intervention period, the control site consisted of 183 patients, where 73 (39.9%) patients were 
excluded. The reasons for these exclusions are summarised in Table 7.1. 
Table 7.1: Reasons for exclusion from the study. 
Exclusion criteria 
Intervention site 
 
Control site 
Baseline 
Intervention 
period 
Baseline 
Interventi
on period 
Hospital admission in the previous 
14 days 
21 44 
 
5 26 
Immunosuppressed patients 38 70 7 28 
NH 22 31 1 14 
No antibiotic prescribed within 24 
hours of admission 
1 3 2 3 
Bronchiectasis 1 6 - 2 
Fibrosis - 1 - - 
Incomplete file - 2 - - 
Total 83 157 15 73 
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7.3.1. Patients’ characteristics  
Patient characteristics from the intervention and control groups before and after the 
intervention are shown in Table 2. As evident from Table 7.2, most characteristics were 
similar between intervention and control groups apart from some differences in the severity of 
CAP and comorbidity index score.  Comparing the intervention and baseline populations, 
there were significantly more patients with a severe pneumonia at the intervention site (32.8% 
vs. 24.4% p < 0.05) and significantly less patients with mild pneumonia at the control site 
(33.6% vs. 58.5%; p < 0.05).  
A difference in the severity profile was also seen between both sites during the baseline 
period. Moreover, amongst patients in the control site, the comorbidity index score were 
greater during the intervention period (4.7 vs. 3.6; p < 0.01), and changes in the chest X-ray 
were more likely to be seen (71.8% vs. 50.9%; p < 0.05). A higher comorbidity index score 
was seen in patients at the intervention site during the baseline phase.  However, there were no 
significance differences in patients’ characteristics, apart from the mild CAP, between the 
non-intervention group and the intervention group (Table 7.3). 
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Table 7.2: Patients’ characteristics in the intervention and control sites before and 
during the intervention.  
Patients’ 
characteristics 
Intervention site (RHH)  Control site (NWRH) 
Baseline 
(N = 193) 
Intervention 
period  
(N = 268) 
 
Baseline 
(N = 53) 
Intervention 
period 
(N = 110) 
Gender (male)  105 (54.4) 154 (57.5)  30 (56.6) 66 (60) 
Age (years) 69.2 ± 16.1; 71 66.8 ± 18; 70  64 ± 18;  70 68.6 ± 16.6; 73 
Prior 
antibiotic/s 
within 7 days 
43 (22.3) 45 (16.8)  8 (15.1%) 25 (22.7) 
Charlson’s 
comorbidity 
index  
4.8 ± 2.3; 5 a 4.3 ± 2.5; 4  3.6 ± 2.1; 4 a 4.7 ± 2.5; 5 
Penicillin 
allergy  
30 (15.5) 37 (13.8)  8 (15.1) 17 (15.5) 
Change in chest 
X-ray  
117 (60.6) 175 (65.3)  27 (50.9) 79 (71.8) 
Severity  
   Mild CAP 64 (33.2)a 78 (29.1)  31 (58.5) a 37 (33.6) 
   Moderate CAP 82 (42.5)a 102 (38.1)  9 (17) a 40 (36.4) 
   Severe CAP  47 (24.4) 88 (32.8)  13 (24.5) 33 (30) 
Data are presented as number (%) for categorical variables and mean ± standard deviation; 
median for numerical variables 
Coloured cells indicate a significant difference (p < 0.05) at the same site before and after 
intervention.  
a P value < 0.05 between the intervention and control sites within the same period of time.  
 
 
 
 
 
 
 
149 
 
Table 7.3: Patients’ characteristics in the intervention group and non-intervention 
groups. 
Patients’ characteristics  Intervention group 
(N = 268) 
Non-intervention groups 
(N = 356) 
Gender (male) 154 (54.1) 201 (56.5) 
Age (years) 66.8 ± 18; 70 66 ± 16.3; 71 
Prior antibiotics/s within 
7 days 
45 (16.8) 76 (21.3) 
Charlson’s comorbidity index 4.4 ± 2.5; 4 4 ± 2.3; 5 
Penicillin allergy 37 (13.8) 55 (15.4) 
Change in chest X-ray 175 (65.3) 223 (62.6) 
Severity    
 Mild CAP a 78 (29.1) 132 (37.1) 
 Moderate CAP 102 (38.1) 131 (36.8) 
 Severe CAP 88 (32.8) 93 (26.1) 
Data are presented as number (%) for categorical variables and mean ± standard deviation; 
median for numerical variables 
a P value < 0.05 
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7.3.2. Adherence to guidelines for empirical CAP management  
Adherence rates to the TG14 recommendations regarding management of CAP during 
the baseline and intervention periods are illustrated in Table 7.4.  As can be seen, the 
adherence rate to recommendations at the control site during the intervention period was 
11.6% higher than that seen in the baseline period; however, the deference was not statistically 
significant.   . However, the rates of adherence significantly increased at the intervention site 
during and after the intervention period, and this improvement occurred across all CAP 
severity grades.    
Table 7.4: Adherence to the TG14 for the empirical management of CAP within and 
between groups. 
Adherence to 
TG14, by 
patient group 
Intervention site Control site 
Baseline 
Intervention 
period  
Baseline 
intervention 
period  
Mild CAP      
Total no. 64 78 31 37 
Appropriate 
regimen   
2 (3.1) 21 (26.9) a 1 (3.2) 2 (5.4) a 
Moderate CAP     
Total no. 82 102 9 40 
Appropriate 
regimen   
17 
(20.7) 
58 (56.9) a 1 (11.1) 6 (15) a 
Severe CAP     
Overall     
Total no. 47 88 13 33 
Appropriate 
regimen   
12 
(25.5) 
55 (62.5) a 2 (15.4) 13 (39.4) a 
Overall     
Total no. 193 268 53 110 
Appropriate 
regimen   
31 
(16.1) 
134 (50) a 4 (7.5) 21 (19.1) a 
Data are presented as number (%). 
Coloured cells indicate a significant difference (p < 0.05) at the same site before and after 
intervention.  
a P value < 0.05 between the intervention and control sites within the same period of time. 
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Logistic regression analysis was employed. Patient demographics, comorbid conditions, 
presence of chest X-ray change, severity and being in the intervention group were analysed 
against adherence to the guidelines, as shown in Table 7.5. 
Table 7.5: Patients’ characteristics depending on the guideline adherence. 
Variables Received concordant       
regimen 
(N = 190) 
Received discordant 
regimen 
(N = 434) 
Intervention group a 134 (70) 134 (30.9) 
Gender (male) 104 (54.7) 251 (57.8) 
Age; mean ± SD 68.3 ± 17.4 67.3 ± 17.2 
Penicillin allergy  27 (14.2) 65 (15) 
Comorbidity index;  mean ± SD 4.4 ± 2.3; 4 4.6 ± 2.5; 4 
Change in chest X-ray 63 (33.2) 163 (37.6) 
Severity a  Mild  26 (13.7) 184 (42.4) 
Moderate  82 (43.2) 151 (34.8) 
Severe 82 (43.2) 99 (22.8) 
Prior antibiotics/s within 7 days 32 (16.8) 89 (20.5) 
Data are presented as Number (%). 
a P value < 0.25 
Of all the independent factors included in the univariate analysis, only two variables 
showed a significant effect in influencing TG14 adherence (intervention and severity). A 
binary logistic regression was performed to identify the effects of these variables on the 
likelihood of receiving a concordant regimen according to TG14 recommendations for the 
management of CAP. The logistic regression model was significant (P < 0.05). This model 
explained 27.1% of the variance based on Nagelkerke R square. The model correctly classified 
73.1% of the cases. The model had 28.9% sensitivity, where the model predicted 28.9% of the 
guideline adherence. The specificity was 92.4%, where the model predicted 92.4% of the non- 
adherence to the guideline. Of all cases that were predicted to receive a concordance regimen 
62.5% were correctly predicted (positive predictive value). On the other hand, of all cases that 
were predicted as not having a concordant regimen, 74.8% were predicted correctly (negative 
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predictive value). The odd of being treated with a guideline-concordant regimen in the 
intervention group was 5.5 times that of the control group when severity was held (Table 7.6).  
Table 7.6: Logistic regression analysis of variables associated with adherence to CAP 
recommendations as per TG14.   
Factor OR 95% CI P 
Intervention  5.5 3.7 – 8.1 < 0.05 
Severity  2.3 1.8 - 3 < 0.05 
 
7.3.3. Ceftriaxone usage  
Changes in ceftriaxone prescribing were compared between intervention and non-
intervention groups. As shown in Figure 7.1, there was an overall 7% reduction in ceftriaxone 
prescribing in the intervention group compared to the non-intervention group; nevertheless, 
the Chi-square test did not show this difference to be significant. Importantly however, the 
data shows that ceftriaxone prescribing for patients with non-severe CAP in the intervention 
group was significantly 16.2% less than that seen in the non-intervention group (p < 0.05). On 
the other hand, for those patients with severe CAP, no significant difference was seen in 
prescribing ceftriaxone between the two groups.  
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Figure 7.1: Ceftriaxone-based therapy prescribing rates in the intervention and non-
intervention groups. 
  
7.3.4. Patients’ clinical outcome measurements 
Table 7.7 compares patients’ length of stay (LOS) and mortality rates between the 
intervention and non-intervention groups. As the table shows, LOS was not different between 
the two groups. Nevertheless, sub-group analysis revealed patients with non-severe CAP in 
the intervention group have an average LOS 0.8 days shorter than the control group (p < 0.05). 
The in-patient mortality was 3.9% significantly lower (p < 0.05) in the intervention group 
when compared to the non-intervention groups (Table 7.7). As shown in table 7.7, the sub-
group analysis revealed that in-patient mortality was lower in the intervention group compared 
to the non-intervention group, for both severe (8% vs. 18.3%, p < 0.05) and non-severe CAP 
cases (1.1% vs. 3.4%, p < 0.05).  
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Table 7.7: Patients’ clinical outcomes.    
Clinical outcome Non-intervention group Intervention group 
All Patients   
Patients’ number 356 268 
LOS (days)  5.8 ± 5.4; 4 5.9 ± 7.5; 4 
In-patient mortality a 26 (7.3) 9 (3.4) 
Patients with severe CAP   
Patients’ number 93 88 
LOS (days)  7.1 ± 6.2; 5 8.8 ± 8.5; 6.5 
In-patient mortality a 17 (18.3) 7 (8) 
Patients with non-severe 
CAP 
  
Patients’ number 263 180 
LOS (days) a 5.3 ± 5; 4 4.5 ± 6.7; 3 
In-patient mortality  9 (3.4) 2 (1.1)  
Data are presented as number (%) for categorical variables and mean ± standard deviation; 
median for numerical variables 
Deaths are excluded from the analysis of LOS outcomes 
a P value < 0.05 
 
Regarding the impact of adherence to CAP guideline recommendations on clinical 
outcomes, our data indicated a trend of decreased overall mortality rate among patients who 
received a concordant regimen (4.2% vs 6.2%; p = 0.32). Moreover, the mortality rates were 
even lower among patients with severe CAP who received concordant antibiotic regimens 
(8.5% vs 17.2%; p = 0.09). However, none of these differences were statistically significant 
(Table 7.8).  
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Table 7.8: Patients’ clinical outcomes and concordance with antibiotic regimens.  
Clinical outcome Received concordant 
regimen 
Received discordant 
regimen 
All Patients   
Patients’ number 190 434 
LOS days  6.4 ± 7.6; 4  5.6 ± 5.8; 4  
In-patient mortality  8 (4.2) 27 (6.2) 
Patients with severe CAP   
Patients’ number 82 99 
LOS days  7.9 ± 6.7; 5  7.9 ± 8; 6  
In-patient mortality  7 (8.5) 17 (17.2) 
Patients with non-severe CAP   
Patients’ number 108 335 
LOS days  5.3 ± 8; 3  4.9 ± 4.8; 4  
In-patient mortality  1 (0.9) 10 (3) 
Data are presented as number (%) for categorical variables and mean ± standard deviation; 
median for numerical variables 
Deaths are excluded from the analysis of LOS outcomes 
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7.4. Discussion 
The objective of this study was to evaluate the effectiveness of an intervention designed 
to overcome potential barriers to guideline adherence. This study showed that active 
implementation of CAP guidelines had a desirable impact on prescribing practice for 
empirical CAP management, with concomitant improved clinical outcomes. The current study 
found that adherence to the CAP guideline recommendation significantly improved during the 
intervention period from 16.1% to 50%. Furthermore, ceftriaxone prescribing was reduced by 
16.1% for patients with non-severe CAP in the intervention group. The study also found that 
the improved adherence to guidelines has been associated with reducing mortality rates and 
decrease in LOS. 
Intervention strategies thought to improve adherence to CAP management guidelines 
have been demonstrated in several studies (352). However, there is no agreement surrounding 
what is the best strategy (155). Therefore, it has been strongly suggested that a multifaceted 
intervention strategy be used to promote adherence to guidelines (117, 129). It has also been 
found that interventions could have a more positive impact when designed to overcome those 
factors that have been identified previously as barriers to the desired prescribing habits (154).  
This study strongly suggests that a tailored multifaceted intervention significantly 
improves adherence to guidelines for empirical management of CAP. These findings are 
consistent with the findings of Jeroen et al., which showed that tailoring multifaceted 
interventions to address identified barriers in a hospital setting could lead to a significant 
improvement in guideline adherence for the management of lower respiratory tract infections 
when compared to interventions which did not consider potential barriers (154). However, our 
study differs from this work, in that we made no intervention at all in the control site.  
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Besides the influence of the interventions on adherence to CAP recommendations, the 
logistic regressions analysis indicated that adherence was more likely to be influenced by the 
severity of the diseases. These results must be interpreted with caution because ceftriaxone-
based therapy prescribing was common in the non-intervention group. Therefore, high 
adherence to the therapeutic guidelines for patients with severe CAP might be due to co-
incident use of ceftriaxone-based therapy.  
 This finding corroborates the thinking of van der Velden et al. who suggested that non-
adherence to the recommended guidelines is significantly associated with more broad-
spectrum antibiotic prescription (314) . 
Our findings not only indicated an increase in adherence to CAP guidelines, but also 
demonstrated a significant decrease in prescribing of ceftriaxone for patients with non-severe 
CAP. According to national and international guidelines regarding the empirical management 
of CAP, patients are divided into groups either by severity or the site of care, and 
recommendations regarding antibiotic regimens are made accordingly (144, 182, 186). With 
this strategy, the broadest-spectrum antibiotic regimens are reserved for patients with severe 
CAP or those who are admitted to intensive care units. Therefore, our findings were consistent 
with one of the main aims of antimicrobial stewardship. This is to reduce unnecessary use of 
broad-spectrum antibiotics in order to reduce antibiotic resistance pressures and serious 
adverse effects, such as CDI (31). As a response to these issues, many initiatives have been 
conducted to reduce the consumption of these broad-spectrum antibiotics in order to decrease 
the emergence of difficult-to-treat microorganisms (86, 353, 354). For example, in a study 
conducted by Talbaert et el., the authors found that their antimicrobial stewardship activities 
have been associated with a reduction in the consumption of broad-spectrum antibiotics such 
as cephalosporins and fluoroquinolones, which was consequently associated with a significant 
decrease in the incidence of CDI (86).   
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Another notable finding from our study was the improved clinical outcomes (mortality 
and LOS) for patients in the intervention group. These key results seem to be consistent with 
other studies, which found that active implementation of CAP guidelines was associated with 
improved clinical outcomes (259). What is surprising is that the significant improvement in 
clinical outcomes in the intervention group was observed despite this group including a higher 
proportion of patients with severe CAP compared to population in the baseline study.  In our 
study, this was associated with a significant improvement in the adherence to the CAP 
recommendations regarding the empirical management of CAP. Previous studies have 
demonstrated that adherence to CAP guidelines is associated with a reduction in both LOS and 
mortality rates. For example, in their study looking at the impact of adherence to CAP 
guidelines on the clinical outcomes, Chen et al. were able to show that patients who received a 
concordant regimen were more likely to be discharged earlier than those who did not (355). In 
term of mortality, studies show that adherence to guidelines significantly improves the 
survival rate among patients with CAP (356, 357).  For instance, Nathan et al. argued that 
adherence CAP guidelines would save 20 lives every year in the US hospital setting (263).  
Furthermore, a study conducted in 1725 hospitalised elderly patients (age ≥ 65 years) with a 
principal diagnosis of pneumonia, found that besides a reduction in LOS and time to clinical 
stability, the patient group that received concordant-guidelines regimens had a 9% lower 
mortality rate than those who received discordant regimens (244).  In our study, the overall 
mortality rate was significantly lower in the intervention group when compared to the non-
intervention group. Moreover, the gap in the survival rate increased by 10% for patients with 
severe CAP. This finding is consistent with a study that was conducted on CAP patients were 
admitted to the ICU (284). This study found that the in-hospital mortality rate was 9% less for 
the group of patients who received antibiotic regimens based on guideline recommendations. 
However, it is important to bear in mind that despite the improvement in clinical outcomes 
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among patients in our intervention group, we could not find a direct association between 
improved clinical outcomes and adherence to guidelines 
The published association between the mortality rates and the prescription of the 
recommended antibiotic regimens has influenced recommendations for the management of 
CAP. For example, the British Thoracic Society and Infectious Diseases Society of 
America/the Society for Healthcare Epidemiology of America guidelines for the management 
of CAP advocate the use of CURB65 severity scoring system, which is based on predicting 
mortality from CAP, to stratify patients into severity groups (182, 186).  
One of the issues that emerged from these findings is that, despite the significant 
improvement in the clinical outcomes in the intervention group, a further analysis failed to 
find a significant direct association between the adherence to the guideline and the change in 
clinical outcomes when compared with the group who did not receive the intervention.   The 
failure to reject the null hypothesis might be explained by the small sample size in both our 
groups. As an example, our data showed that in-hospital mortality rate was 8.5% (n = 7/82) in 
patients with severe CAP who received concordant antibiotic regimen, compared with 17.2% 
(n = 17/99) in patients who received a discordant regimen. Although the difference is almost 
9% between the two groups, the Chi square test has failed to reach the level of statistical 
significance. To show such a difference between the two groups, approximately 254 patients 
would have been needed per group (at a power of 80% and p = 0.05). 
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7.5. Limitations  
Several limitations to this study need to be acknowledged. First, the CAP guideline 
introduced as part of the intervention has minor deviations from TG14 and doctors in the 
intervention group were expected to follow the local guidelines, and the non-intervention 
groups were expected to comply with the TG14 recommendations. Nonetheless, adherence to 
guideline recommendations for all groups in our study was assessed against TG14.  This was 
because the local guideline was based on TG14 and therefore considered to be a tool to 
promote adherence to the TG14 recommendations for CAP management.  Secondly, the 
components of the intervention were sequentially delivered over a period of the time, and 
there was no data collected after the end of our intervention to assess the sustained impact of 
the implemented strategies. Therefore, the results must be interpreted with a degree of caution. 
Third, almost one-third of the patients were diagnosed with pneumonia with no detected 
changes in the chest X-ray, and their inclusion in the study was therefore based mainly based 
on the doctor’s clinical judgment. However, although this might raise a question regarding the 
accuracy of the diagnosis, the main purpose of this study was to evaluate antibiotic prescribing 
practice when a doctor made a clinical decision to treat a patient as one with CAP. Fourth, 
different strategies were conducted in distinct consecutive times to improve adherence to the 
guideline recommendations. Nevertheless, this study could not identify the extent of the effect 
of individual strategies. Fifth, although we evaluated the impact of the intervention on two 
major clinical outcomes, mortality and LOS, other clinical outcomes, such as ICU admission, 
treatment failure, and time to clinical stability, which could be important, have not been 
investigated. Sixth, although there are a number of validated severity tools to assess the 
severity of CAP, we only used the CORB tool recommended by TG14 to determine severity 
and accordingly assess the prescribed antibiotic regimens. Finally, the study did not include 
patients with CAP who presented in the ED and were not admitted. Therefore, it is important 
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to bear in mind the possible bias in the study findings with regard to the antibiotic prescribing 
practice. 
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7.6. Conclusion  
The current findings add to a growing body of literature on the impact of the 
antimicrobial stewardship interventions on changing prescribing practice among physicians 
and improving clinical outcomes.  The results of the present study show that an intervention 
tailored to overcome identified barriers can successfully improve adherence to 
recommendations in CAP guidelines. The second major finding was an improvement in the 
clinical outcomes (LOS and mortality rates) among patients in the intervention group.  
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Chapter 8. Multifaceted intervention to improve 
adherence to management guidelines for CAP: 
Interrupted Time-series analysis  
8.1. Introduction 
One of the challenges in evaluating the impact of interventions in real time clinical 
settings is the absence of a control arm. As discussed earlier (Chapter 6), a number of types of 
study can be used to measure the effect of such interventions, including before and after, 
controlled before and after and interrupted time series designs (151, 274). Results from the 
previous chapter (Chapter 7), where the controlled before-after approach was utilised, 
indicated a positive impact of the intervention in the overall adherence to the CAP guidelines. 
However, the intervention included two phases, which were implemented in two consecutive 
time periods, one general and one focused on the ED (Chapter 6). Therefore, time series 
analysis was chosen as the most appropriate method to evaluate the impact of these distinct 
interventions strategies. The specific aim of this study was to: 
 Determine the impact of different strategies over time at the RHH, in order to highlight 
the most effective approaches to improving adherence to CAP guidelines. 
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8.2. Methods  
8.2.1. Study site, participants and data collection 
This study was conducted at the RHH; with patient inclusion and exclusion criteria, data 
collection, and assessment of adherence methods exactly alike to those used in the study 
described in the previous chapter (Chapter 7).   
8.2.2. Data analysis 
Data were collected on a monthly basis for the period between July 2012 and November 
2013, providing five data points for pre-intervention phase, five data points during the general 
intervention phase and seven data points during the ED-focused intervention phase. To 
perform interrupted time series analysis, the data was converted into percentages (monthly 
number of patients who received a guideline concordant CAP treatment regimen divided by 
the total monthly number of patients reviewed). These data were then plotted as a chart on a 
monthly basis to visualise the adherence rates over the study period. 
The mean, standard deviation (SD) and standard error of the mean (SEM) for adherence 
rates at baseline, and during the general and ED-focused interventions were calculated. All 
samples were tested for significance between interventions using a one-way analysis of 
variance between groups (ANOVA) test. If statistical significance was detected, a post hoc 
analysis was carried out to examine any significant differences across individual time periods. 
All data are expressed as the mean ± standard error of mean (SEM). Significance was agreed 
at one-tail values of p < 0.05.  
The statistical comparisons of patient characteristics and clinical outcomes were 
examined among the three time periods. The association between categorical data was 
examined using the Chi square test. Scaled date was examined using the Kruskal Wallis test. 
Statistical analyses were performed using SPSS version 19 (IBM, Armonk, NY, USA). 
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8.2.3. Ethical approval 
Ethical approval was granted by the Tasmania Health and Medical Human Research 
Ethics Committee [Approval number: H0012810]. 
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8.3. Results 
8.3.1. CAP cases 
A total of 593 patients were assessed for eligibility, with 195 (32.9%) patients being 
excluded. The reasons of exclusions were recent hospital admission (n = 54), 
immunosuppressed patients (n = 86), aged-care facility residents (n = 39), no antibiotic 
prescribed within 24 hours of admission (n = 7), bronchiectasis (n = 6), cystic fibrosis (n = 1), 
and incomplete patient’s file (n = 2).  The remaining 398 patients were considered as eligible 
for the study.   
Over the entire study period (July 2012 and November 2013), the average number of 
eligible patients per month was 23. This rate varied during the different phases of the study, 
with 26 per month pre-intervention (July to November 2012), 18 per month during the general 
intervention (December 2012 and April 2013) and 25 per month during ED-focused 
intervention (May to November 2013).  
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Patients’ demographics and characteristics among the three phases are summarised in 
Table 8.1, from which it can be seen that there were no significant differences among the three 
groups. 
Table 8.1: Patients’ demographics and characteristics.  
 Pre – 
intervention  
(N = 130) 
General 
intervention  
(N = 90) 
ED-focused 
intervention 
 (N = 178) 
Median age (years) 68 70.5 69.5 
Gender (male)  81  (62.3) 54 (60) 100 (56.2) 
LOS (days)  3 (1 - 20) 4 (1- 66) 3 (1 - 57) 
Charlson comorbidity 
Index score  
4 (0 – 12) 5 (0 – 11) 4 (0 - 12) 
Change in chest X-ray 
noted  
92 (70.7) 62 (68.9) 113 (63.5) 
Severity     
   Mild  40 (30.8) 29 (32.2) 49 (27.5) 
   Moderate  57 (43.8) 32 (35.6) 70 (39.3) 
   Severe  33 (25.4) 29 (32.2) 59 (33.1) 
Documented penicillin 
allergy  
20 (15.4) 13 (14.4) 24 (13.5) 
Antibiotic therapy in the     
7 days prior to admission  
22 (16.9) 13 (14.4) 32 (18) 
In-hospital mortality  7 (5.4) 4 (4.4) 5 (2.8) 
Data are presented in numbers (%) for categorical and median (range) for scale variables  
 
8.3.2. Exposure to the interventions 
During the general intervention period, 39 medical staff working in the ED attended the 
educational sessions and of these, 21 were of a junior grade (interns and residents). The 
number of doctors who attended from the other medical departments was estimated at 50. The 
lanyard card, with the guideline recommendations for empirical CAP management, was given 
to all general medical (n = 120) and ED doctors (n = 40).  
168 
 
8.3.3. Time series analysis results 
Figure 8.1 summarises the adherence rates to TG14 recommendations regarding 
empirical management of CAP for adults on a monthly basis, from July 2012 to November 
2013; spanning the pre-intervention, general intervention and ED-focused intervention phases. 
It can be clearly seen that the adherence rates increased during the ED-focused intervention. 
Before the general intervention, the adherence rate began at 22.2% in July 2012. During the 
ED-focused intervention, adherence rates fluctuated between 40.9% and 77.3%. However, all 
data points in the ED-focused intervention phase were above those in the baseline and general 
intervention periods. The mean adherence percentages for the pre-intervention, general 
intervention and ED-focused intervention phases were 28.1 (SEM ± 1.82; SD ± 4.1), 31.2 
(SEM ± 3.4; SD ± 6.8), and 61.5 (SEM ± 5.42; SD ± 14.3) respectively. One-way ANOVA 
test showed that there was a statistically significant difference among the three phases (p < 
0.001). A post hoc analysis showed that the adherence rate significantly increased after the 
ED-focused intervention when compared to the pre-intervention (P< 0.001) and general 
intervention (P<0.001). Meanwhile, the adherence rate during the general intervention phase 
was not statistically different to that during the pre-intervention phase.  
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Figure 8.1: Impact of general and ED-focused interventions on the monthly rates of 
adherence to TG14 for CAP management at the RHH.  
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8.4. Discussion  
A multifaceted intervention was delivered over a one-year period from December 2012 
to November 2013, aiming to improve adherence to the recommendations in TG14 for the 
empirical management of CAP. After development of the local consensus guidelines based on 
TG14, the multifaceted intervention was implemented in two phases over successive time 
periods. The first was a general educational intervention, when all medical doctors were 
targeted, including ED physicians. The second phase was focused in the ED where a CAP 
clinical pathway was introduced and followed-up with monthly feedback to ED doctors 
regarding adherence to the guideline recommendations. Overall, the results showed that the 
ED-focused intervention significantly increased the guideline adherence rate when compared 
to pre-intervention and the general intervention.  
It is recognised that there can be several barriers impairing medical staff adherence to 
guidelines (151). Therefore, to overcome these barriers, multifaceted intervention strategies 
were utilised in this study. To enhance adoption to the recommended guidelines, active 
implementation of guidelines has been strongly recommended (117, 129, 130). One of the 
active strategies, which has been considered essential to enhance guideline adherence, is the 
involvement of key local opinion leaders in the development and implementation of local 
guidelines that are broadly consistent with the latest version of national guidelines (117, 129). 
In our study, this involvement occurred from the earliest stages in the development of local 
CAP guidelines and continued through to their final approval and implementation.  
During the general intervention phase, a multifaceted educational approach was utilised. 
However, our data indicate this had no significant impact on adherence to the guidelines. This 
is consistent with previously published studies, which found educational interventions alone to 
have a limited impact (325, 327).   
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It has been reported that emergency departments receive minimal attention from 
antimicrobial stewardship teams compared to other hospital medical departments (333).  
However, the vast majority of CAP patients in Australian hospitals are initially seen and 
assessed by ED doctors and they invariably initiate empirical antibiotic therapy. So, it is 
logical to target this area for the initial management of CAP. During the ED-focused 
intervention, a clinical pathway was introduced in the ED and this was followed-up with 
monthly feedback about antibiotic prescribing practices for the management of suspected CAP 
in the ED.  
In a Cochrane review of 140 studies looking at the impact of audit and feedback on 
practice, a wide variation in impact was noted, ranging little or no effect through to a large 
effect (326). The authors concluded that the impact of audit and feedback is largely dependent 
on the format, source and frequency of the delivered feedback. For example, the author 
suggested that the maximum effect of this strategy might be achieved if the person responsible 
for the feedback has authority or is a senior colleague (compared to a researcher), and the 
feedback is delivered at least monthly in written and verbal forms. In our study, the selected 
patient profiles were reviewed and reported by the hospital antimicrobial stewardship team on 
a monthly basis and were sent to the head of the ED department for distribution to ED doctors.  
Moreover, a clear clinical pathway for CAP including diagnosis, severity assessment and 
recommended antibiotic therapy had been introduced to the ED, aiming to standardise each of 
these components to reduce the chance of non-adherence to guidelines. In their meta-analysis 
of 27 studies looking at the impact of clinical pathways on clinicians’ practice and patient 
clinical outcomes, Rotter et al. reported that the use of clinical pathways was significantly 
associated with reduced in-hospital complications and increased documentation in medical 
notes (358). A number of studies have found that implementation of clinical pathway for the 
management of CAP provide positive impacts in terms of clinical outcomes and process of 
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care (268, 359-361).  In a retrospective study of 22,196 patients admitted with CAP to 31 
tertiary hospitals, Hauck et al. reported that patients who were placed on the CAP clinical 
pathway were less likely to die than those who were not (OR = 0.37; 95% CI , 0.2- 0.7) (359). 
Conversely, a Canadian multicentre controlled study of 1743 patients with CAP in 19 teaching 
and community hospitals, could not indicate any significant difference in terms of patients’ 
clinical outcomes between a CAP clinical pathway and non-clinical pathway hospitals (268). 
However, the study showed an 18% reduction in the admission for mild CAP patients in those 
hospitals who were managed with the clinical pathway (31% vs 49%; p < 0.05). Furthermore, 
this study reported that hospitals using the clinical pathway were more likely to prescribe a 
single antibiotic when compared to the non-clinical pathway hospitals (64% vs 27%; p < 
0.001).    
Junior doctors appear to play an important role in the empirical management of CAP in 
the ED. As the study site is a teaching institution, it is more likely that the first-line medical 
staff involved in management of CAP will be less-experienced. This was supported by the 
large drop in guideline adherence rates during July and October 2013, when three-month 
junior doctor rotations began. Adjustment to the new department’s rules and expectations at 
the beginning of the rotation might be challenging for junior doctors (320).  During the first 
weeks of the rotation, junior doctors are more likely to be influenced by the prescribing habits 
of their seniors, and less influenced by guidelines (295).  It is therefore crucial to target both 
senior and junior doctors when wishing to implement a change in practice.  
The ED is one of the busiest hospital departments, with a requirement for rapid clinical 
decision making, which may impact on assessment and prescribing. Therefore, a CAP clinical 
pathway could serve to provide useful direction to junior medical staff, when it is difficult to 
consult senior colleagues within a short timeframe. Auditing and feedback provided a valuable 
opportunity to enlighten new and existing ED medical staff about the presence of the 
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guidelines and clinical pathway in their department, together with communicating the 
hospital’s expectation that these will be used.   
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8.5. Limitations 
A number of limitations regarding this study should be acknowledged. This was a 
retrospective study which measured adherence to guideline recommendations and it is 
acknowledged that clinical judgment might be required to apply the guidelines when assessing 
and prescribing for patients with CAP. However, the aim of this study was to assess the 
changes toward the desired prescribing behaviours for the management of CAP and this factor 
applies equally to both pre- and post-intervention phases. Moreover, our study was conducted 
in a single teaching hospital; therefore, other multi-site studies in hospitals with different 
systems are required to ensure generalisability of our findings.  
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8.6. Conclusion  
An ED-focused intervention including the introduction of a clinical pathway for CAP 
management and monthly feedback was a successful strategy to improve adherence to the 
CAP guideline recommendations. On the other hand, relying on a multifaceted educational 
intervention alone failed to improve adherence in the timescale that we studied. Our findings 
suggest that focusing an intervention to improve CAP management at the ED, with clear 
communication of the desired management practice via a CAP clinical pathway, coupled with 
regular feedback, is a preferable approach.  
 
 
 
 
 
 
 
 
 
 
 
 
176 
 
Chapter 9. Evaluation of empirical ceftriaxone 
prescribing at the RHH  
 
9.1. Introduction  
Several clinical practice guidelines have been developed in an attempt to improve 
antibiotic prescribing (144, 182, 183, 186, 362). The main aims of these are to promote timely 
commencement of treatment and minimise unnecessary use of broad-spectrum antibiotics, 
such as ceftriaxone, thereby assuring effective therapy whilst reducing unnecessary resistance 
and unintended side effects, such as CDI, which might be associated with poor clinical 
outcomes and increased healthcare costs (66, 69, 73, 363, 364).  
Several studies have reported an association between ceftriaxone consumption and the 
incidence of CDI in the hospital environment (31, 365, 366).  For instance, in one British 
study, it was found that changing the hospital policy by replacing cefotaxime with ceftriaxone 
for the empirical management of CAP led to an increase in ceftriaxone use by 35%, which was 
associated with a significant increase in CDI incidence (367). A possible explanation for  these 
findings may be that ceftriaxone is excreted in high concentration in bile, which would lead to 
extensive distortion of anaerobic bacteria that are associated with CDI (368). Conversely, it 
was found that restricting the use of ceftriaxone was associated with reduced incidence of CDI 
(369-371). As a result, the British Thoracic Society does not recommend ceftriaxone as a first-
line therapy, even for those patients with severe CAP (186). This recommendation was 
supported by other reports showing a decreased incidence of CDI when ceftriaxone use was 
restricted (367).  
Additionally, it has been shown that the consumption of ceftriaxone is linked with an 
increased incidence of resistant pathogens such as extended-spectrum beta-lactamases 
(ESBLs) producing bacteria, methicillin-resistant Staphylococcus aureus (MRSA), and 
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vancomycin-resistant Enterococcus (VRE) (306, 372, 373). Bloodstream infections caused by 
VRE are one of the specific life-threatening nosocomial infections that have been linked with 
the use of ceftriaxone. (306)  While the use of extended-spectrum cephalosporins generally is 
considered a risk factor for the emergence of resistant nosocomial pathogens, the high biliary 
concentration of ceftriaxone is thought to explain the particularly strong association between 
use of this drug and the emergence of VRE .(306) 
These reasons, coupled with the fact that it is one of the most commonly prescribed 
antibiotics in Australian hospitals, make it important to evaluate the appropriateness of 
ceftriaxone prescribing. For instance, third-generation cephalosporins, including ceftriaxone,  
represented almost half of the antibiotics prescribed in the ED for the management of lower 
respiratory tract infections (374). However, it has been shown that in almost half of cases 
ceftriaxone was prescribed inappropriately when assessed against the recommendations in 
TG14 (168).  Consequently, improved concordance with TG14 would be expected to lead to 
more appropriate ceftriaxone prescribing. 
To help inform initiatives to promote improvements in ceftriaxone prescribing, this 
study aimed to: 
1- Characterise the empirical prescribing of ceftriaxone at the RHH and to assess 
concordance with the recommendations of TG14 for each indication over two time 
periods (before and after the initiation of the intervention). 
2- Examine the association between the hospital’s ceftriaxone consumption and the 
incidence of hospital-identified CDI during the study periods. 
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9.2. Methods 
9.2.1. Ceftriaxone usage and concordance with TG14 
Inclusion and exclusion criteria 
All patients ≥ 18 years old who received ceftriaxone therapy in two time periods, 1 
January to 31 March 2012 (Period 1) and 1 April to 31 June 2013 (Period 2), were included in 
this study. When a patient received a course of ceftriaxone-based therapy more than once 
(whether due to readmission or due to other indications during one hospital stay), only the 
treatment associated with the first indication/admission was included in the study. Patients 
receiving ceftriaxone were identified in two ways. Firstly, the pharmacy department at the 
RHH provided a list of all inpatients for whom ceftriaxone had been dispensed. Secondly, 
because ceftriaxone is supplied by pharmacy as a stock item to the ED, the medical records of 
all patients who presented in the ED were screened to identify those who received ceftriaxone.  
Patients, who received ceftriaxone for prophylaxis (medical or surgical) or directed 
therapy, where the causative organism had been identified, were excluded. All other cases 
were considered to have received empirical therapy.  
Data collection  
Digital medical records were utilised to examine patients’ files. For ceftriaxone 
regimens, drug charts were screened to obtain information including dose, frequency, time of 
administration, course duration and penicillin allergy status. Doctors’ notes were screened to 
obtain principal indications, any prior antibiotic use, clinical examination, laboratory results, 
and patients’ characteristics.  
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Outcomes measurement  
Ceftriaxone use was considered to be appropriate for patients with a documented 
indication for which ceftriaxone is the first-line empirical therapy in TG14 (Table 9.1). In 
cases where ceftriaxone was recommended only in the presence of penicillin allergy, 
ceftriaxone was considered to be appropriate for those patients with a documented penicillin 
allergy, except where this was noted to be an immediate hypersensitivity reaction. In cases 
where gentamicin was the recommended first-line therapy, ceftriaxone was only considered to 
be appropriate for patients with pre-existing hearing and vestibular problems, which are 
accepted contraindications to aminoglycoside therapy. For patients with CAP, the 
appropriateness of ceftriaxone was assessed based on the severity, as per TG14.  
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Table 9.1: Indication for empirical use of ceftriaxone as per TG14. 
Site of infection Infectious disease 
Respiratory tract 
infections 
 Acute epiglottitis 
 Moderate to severe hospital acquired pneumonia  
 Severe community acquired pneumonia  
 Moderate community acquired pneumonia if non-immediate 
penicillin allergy 
Intra-abdominal 
infections 
 Ascending cholangitis or acute cholecystitis where 
gentamicin is contraindicated or non-immediate penicillin 
allergy 
 Severe diverticulitis if non-immediate penicillin allergy   
 Acute hepatic encephalopathy (unidentified precipitant) 
 Severe necrotising pancreatitis if non-immediate penicillin 
allergy 
 Peritonitis due to perforated viscus if non-immediate 
penicillin allergy 
 Spontaneous bacterial peritonitis 
Urinary tract 
infections 
 Acute pyelonephritis where gentamicin is contraindicated 
Central nervous 
system infections 
 Brain abscess or subdural empyema 
 Epidural abscess where gentamicin is contraindicated or non-
immediate penicillin allergy 
 Meningitis 
Genital and 
sexually 
transmitted 
infections 
 Sexually acquired infection  
 Epididymo-orchitis where gentamicin is contraindicated 
Skin and soft 
tissue infections 
 Bites and clenched fist injuries (established infection) 
Cardiovascular 
system infection 
 Infected aneurysms and intravascular prostheses 
Eye infections  Orbital cellulitis 
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9.2.2. Association between ceftriaxone consumption and hospital identified 
CDI 
 Data collection 
To identify whether there was an association between ceftriaxone consumption and the 
incidence of hospital identified CDI, data for these variables were examined for the period 
January 2012 to June 2013. Ceftriaxone consumption data, in terms of grams per quarter, were 
obtained from the RHH’s pharmacy department. Data about the number of hospital-identified 
CDI cases per quarter was obtained from the Tasmanian Infection Prevention and Control Unit 
(375).   
9.2.3. Statistical analysis  
Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 
19.0. Armonk, NY: IBM Corp. Chi-square and Fisher’s exact tests were used to test the 
significance between categorical data. Fisher’s exact test was used if one of the expected 
values had less than five patients or events. To compare categorical and scale data, the Mann-
Whitney U test was used. To compare continuous data a student t-test were utilised. P-value of 
< 0.05 was considered statistically significant. 
9.2.4. Ethical approval  
Ethics approval was granted by the Tasmania Health and Medical Human Research 
Ethics Committee [Ref no. H0012489]. 
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9.3. Results 
9.3.1. Ceftriaxone usage and concordance with TG14 
Ceftriaxone was administered to a total of 299 and 355 patients at the RHH during study 
periods 1 and 2 respectively. Of these, 54 patients (18.1%) and 72 patients (20.3%) were 
excluded during periods 1 and 2 respectively, the reasons for this are summarised in Table 9.2. 
Table 9.2: Reason for exclusion from the study. 
Exclusion criteria  Period 1 Period 2 
Directed therapy 32 41 
Prophylaxis 22 31 
Patients’ characteristics  
Patient characteristics in the two study periods were similar and are summarised in 
Table 9.3. The only parameter where there was a significant difference between the study 
periods was the length of stay (LOS) which was longer in period 2.  
Table 9.3: Patients’ characteristics. 
Patients’ characteristic 
Period 1 
N = 245 
Period 2 
N = 283 
Gender; male 121 (49.3) 158 (56) 
Age (years); median (range; 
percentile quarter 25th – 75th) 
66 (18 - 95; 50 - 77) 66 (18 – 98; 47 – 78) 
Allergic to penicillin 38 (15.5) 47 (16.7) 
Estimated glomerular filtration 
rate (mL/min/1.73m2) 
68.8 ± 24.5 68.5 ± 24 
Prior antibiotics within 7 days 17 (6.9) 14 (5) 
Death during admission 22 (9) 20 (7.1) 
LOS (days); median (range; 
percentile quarter 25th – 75th) a 
5 (0-139; 3-9) 6 (0 – 137; (3 – 12) 
Data presented as number (%) for categorical variables and mean ± standard deviation for numerical 
variables unless otherwise stated. 
a The result is significant at the p = 0.05 level. 
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Ceftriaxone prescribing profile 
Respiratory tract infections (RTIs), intra-abdominal infections and sepsis were the most 
common reasons for the empirical prescribing of ceftriaxone in both time periods (Figure 9.1). 
There was no significant difference between the two groups in terms of infection site profiles.   
 
Figure 9.1: Ceftriaxone prescribing rates by site of infections during period 1 (n = 245) 
and period 2 (n = 283). 
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As can be seen from Table 9.4, CAP represented the majority of RTI cases where 
ceftriaxone was prescribed, accounting for 54.3% and 56.1% in the first and second periods, 
respectively. Within those infections classified as intra-abdominal, cholangitis, appendicitis 
and diverticulitis represented the main reasons for prescribing ceftriaxone in each time period. 
For septic patients, the source of sepsis was unknown for the majority of cases where 
ceftriaxone was prescribed; 54.3% and 60.5% for the first and second period, respectively.  
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Table 9.4: Empirical prescription of ceftriaxone within sites of infections. 
Site of infection Infectious disease  Period 1 
N (%) 
Period 2 
N (%) 
Respiratory- 
tract infections 
 
CAP a 51 (54.3%) 60 (56.1%) 
HAP a 14 (14.9% 26 (24.3%) 
AECOPD a 12 (12.8%) 2 (1.9%) 
sinusitis 2 (2.1%) 2 (1.9%) 
Aspiration pneumonia  5 (5.3%) 2 (1.9%) 
Lung abscess 1 (1.1%) - 
Pneumonia 
(immunocompromised) b  
6 (6.4%) 12 (11.2%) 
Tonsillitis  1 (1.1%) 1 (0.9%) 
Pneumonia (fibrosis) 1 (1.1%) - 
Pulmonary oedema 1 (1.1%) - 
Ear infections - 2 (1.9%) 
 Total  94 107 
Intra-
abdominal 
infections 
Cholangitis  14 (23.7%) 16 (20.8%) 
Appendicitis  9 (15.3%) 19 (24.7%) 
Diverticulitis   9 (15.3%) 16 (20.8%) 
Cholecystitis 8 (13.6%) 12 (15%) 
Hepatic encephalopathy 
(unknown source) 
6 (10.2%) - 
Pancreatitis  3 (5.1%) - 
Peritonitis  3 (5.1%) 3 (3.9%) 
Hepatic encephalopathy 
(SBP) a 
2 (3.4%) 2 (2.6%) 
Gastroenteritis  2 (3.4%) 1 (1.3%) 
Ulcerative colitis  2 (3.4%) 6 (7.8%) 
Duodenitis  1 (1.7%) - 
Liver abscess  - 1 (1.3%) 
Small bowel obstruction  - 1 (1.3%) 
Total 59 77 
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Sepsis  Unknown source  19 (54.3%)  26 (60.5) 
Urinary 11 (31.4%) 10 (23.3%) 
Abdominal  2 (5.7%) 5 (11.6%) 
Respiratory 2 (5.7%) - 
Skin 1 (2.9%) 2 (4.6%) 
 Total 35 43 
Urinary tract infections 18 10   
No clear indication  20 24 
Central nervous 
system infections 
Meningitis  5 (71.4%) 10 (90.9%) 
Encephalitis  2 (28.6%) 1 (9.1%) 
 Total 7 11 
Skin and soft 
tissue infections 
Cellulitis  4 (66.7%) 3 (42.9%) 
Wound infections 2 (33.3%) 3 (42.9%) 
Scrotal abscess - 1 (14.3%) 
 Total 6 7 
Genital and 
sexually 
transmitted 
infections 
Epididymo-orchitis 2 (66.7%) 1 (25%) 
Pelvic inflammatory 
diseases 
1 (33.3%) 2 (50%) 
Scabies - 1 (25%) 
 Total 3 4 
Others Iliopsoas collection  1 (33.3%) - 
Tooth abscess 1 (33.3%) - 
Postpartum infection 1 (33.3%) - 
 Total 3 0 
a Abbreviations are as follow: CAP “Community-Acquired Pneumonia”; HAP “Hospital-Acquired 
pneumonia”; AECOPD “ Acute Exacerbation of Chronic Obstructive Pulmonary Disease”; SBP “ 
Spontaneous Bacterial Peritonitis”.  
b Immunosuppressed patients are those patients who met at least one of the following criteria: (i) 
chronic use of prednisolone, (ii) had received chemotherapy within 3 month, (iii) on any other 
immunosuppressive agents for the management of solid organ transplantation or, and (iv) HIV 
positive. 
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Ceftriaxone dosing and site of administration  
Within 24 hours of commencing ceftriaxone, 41 (16.3%) and 45 (15.9%) patients received 
more than one gram of ceftriaxone in periods 1 and 2, respectively (Table 9.5). Doses greater 
than one gram were more likely to be initiated in ED rather than non-ED units during the first 
study period (p < 0.05). However, no significant differences were found during period 2. In 
both study periods younger patients (< 65 years old) were more likely to receive a ceftriaxone 
dose exceeding 1g/day (p < 0.05).  
Table 9.5: Patients who received more than 1 gram of ceftriaxone within the first 24 
hours, by site of infection. 
Site of infection Period 1 (n = 245) Period 2 (n = 283) 
Respiratory tract infections a  
 
13 (5.3%) 11 (3.9%) 
Intra-abdominal infections 
 
3 (1.2%) 6 (2.1%) 
Sepsis 11 (4.5%) 11 (3.9%) 
 
No clear indications 
 
3 (1.2%) 5 (1.8%) 
Urinary tract infections 
 
- 1 (0.4%) 
Central nervous system infections 
 
6 (2.4%) 9 (3.2%) 
Skin and soft tissue infections 
 
2 (0.8%) 2 (0.7%) 
Others  
 
2 (0.8%) - 
Genital and sexually transmitted 
infections 
 
- - 
a The result is significant at the p = 0.05 level. 
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Treatment duration with ceftriaxone  
The median duration of ceftriaxone courses was two days (range = 1 – 11; IQR = 2 – 4) 
during period 1 and three days (range = 1 – 17; IQR = 2 – 4) in period 2. This difference is 
significant at the p = 0.05 level. As shown in Figure 9.2: Treatment duration of ceftriaxone 
during period 1 and 2., the majority of patients received ceftriaxone for three days or less 
during both the first (69.3%) and second periods (63.6%). Ceftriaxone-based therapy was 
altered in 94 (38.4%) and 70 (24.7%) patients after the first 24 hours of the initial 
administration during periods 1 and 2, respectively (p < 0.05). Ceftriaxone therapy was more 
likely to be ceased within the first 24 hours if it was initiated in the ED compared to non-ED 
units (p < 0.05); this was true for both time periods. 
 
 
Figure 9.2: Treatment duration of ceftriaxone during period 1 and 2. 
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Concordance with TG14 
The ceftriaxone prescribing based on the indication, as per TG14, in the two groups are 
shown in Table 9.6. Ceftriaxone was considered appropriate in just 68 (27.8%) cases during 
study period 1 and 91 (32.2%) cases in period 2. The chi-square test did not show any 
significant differences between the two groups at p = 0.05 level.  
Table 9.6: First-line and alternative indications of ceftriaxone as per TG14. 
Indication Period 1 Period 2 
First-line therapy n (%) 56 (22.9%) 73 (25.8%) 
Alternative therapy n (%) 88 (35.9%) 99 (35%) 
 Eligible n (%) 12 (13.6% out of 88) 18 (18.2% out of 99) 
Not indicated n (%) 81 (33.1%) 87 (30.7%) 
No clear indication 20 (8.2%) 24 (8.5%) 
 
The comparative rate of TG14 concordant ceftriaxone use according to the infection site 
between the two study periods is shown in Table 9.7. Concordance to the TG14 for all 
indications, with the exception of RTI, was similar between the two study periods.  For the 
RTI, concordant use of ceftriaxone significantly increased from 50% during the first period to 
64.5% during the second study period (p < 0.05).  
Table 9.7: Concordant indications of ceftriaxone with TG14, by site of infection. 
Site of infection Period 1 (n = 245) Period 2 (n = 283) 
Respiratory tract infections a  47/94 (50%) 69/107 (64.5%) 
Intra-abdominal infections 14/60 (23.3%) 10/82 (12.2%) 
Sepsis 2/32 (6.3%)  0/42 (0%) 
No clear indication 0/20 (0%) 0/22 (0%) 
Urinary tract infections 0/21 (0%) 1/22 (9.1%) 
Central nervous system infections 5/7 (71.4%) 11/11(100%) 
Skin and soft tissue infections 0/6 (0%) 0/6 (0%) 
Others  0/3 (0%) - 
Genital and sexually transmitted 
infections 
0/2 (0%) 0/2 (0%) 
a The result is significant at the p = 0.05 level. 
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Ceftriaxone prescribing for community-acquired lower respiratory tract 
infections (CAP and AECOPD): subgroup analysis 
During the first study period, 94 courses of ceftriaxone were prescribed for RTI. Of 
these, 63 (67%) courses were prescribed for either CAP or AECOPD. For those patients, 
ceftriaxone was only consistent with TG14 in 28 cases. During period 2, 107 courses of 
ceftriaxone were prescribed for RTI. Of these, 62 (57.9%) were prescribed for CAP or 
AECOPD and of these, prescribing was concordant with TG14 in 42 (67.8%) cases. The 
differences in ceftriaxone prescribing for these infections between period 1 and period 2 are 
highlighted in Table 9.8. 
As the table shows, there was an increase in ceftriaxone prescribing for patients with 
moderate and severe CAP during the second study period. However, none of these differences 
were statistically significant. Interestingly, ceftriaxone prescribing was observed to be less 
likely to be given to patients with mild CAP and AECOPD during the second period. The 
results are significant at the p = 0.05 level. 
Table 9.8: Empirical management with ceftriaxone and concordance with TG14 for the 
management of patients with community-acquired lower respiratory tract infection.   
Concordance Infectious 
disease 
Period 1 (n = 63) Period 2 (n = 62) 
Concordant 
Indications 
Severe CAP 21 (33.3%) 31 (50%) 
Moderate CAP: 
documented 
penicillin allergy  
7 (11.1%) 11 (17.7%) 
Discordant 
indications 
Moderate CAP: 
no 
documentation of 
penicillin allergy 
11 (17.5%) 16 (25.8%) 
Mild CAP a  12 (19%) 2 (3.2%) 
AECOPD a 12 (19 %) 2 (3.2%) 
a The result is significant at the p = 0.05 level. 
The patients were assigned to a severity group based on the TG14 severity scoring system as 
shown in Figure 2.1.    
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9.3.2. Association between ceftriaxone consumption and hospital-identified 
CDI 
Figure 9.3 illustrates the identified rates of CDI and the volume of ceftriaxone consumed 
at the RHH between January 1st 2012 and June 30th 2013. The mean consumption of 
ceftriaxone 1 gram vials was 2003.2 per quarter. The mean rate of hospital-identified CDI was 
8 cases per 10 000 patient days. Overall, there was no obvious association between the 
hospital consumption of ceftriaxone and the rates of hospital-identified CDI (p > 0.05). 
 
Figure 9.3: Number of ceftriaxone vials (1 gram) and rate of RHH identified CDI per 10 
000 patient days by quarter. 
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9.4. Discussion  
The current study has two main findings. First, it was clear that ceftriaxone was often 
prescribed outside TG14 recommendations. Second, this study has demonstrated that 
ceftriaxone prescribing for the management of patients with RTI was improved significantly 
in the second study period during the multifaceted intervention to improve the management of 
adult patients with CAP.  
Our finding demonstrated that ceftriaxone prescribing is frequently inconsistent with 
guidelines is in line with a previous Australian study. Conducted in the late 1990s in 51 
Victorian hospitals, compliance with national guidelines regarding use of third-generation 
cephalosporin drugs was almost identical to that found in this study (167). However, after 
more than a decade, and despite the implementation of antibiotic stewardship programs in 
many Australian hospitals (117), empirical prescribing of ceftriaxone frequently remains 
inappropriate. 
Most patients who received ceftriaxone presented with RTI, with the majority of these 
being diagnosed with CAP. It was shown in one Australian study that more than 30% of 
patients with non-severe CAP received ceftriaxone as an empirical therapy in the ED (374), 
when ceftriaxone is only indicated to be used as a first-line treatment in severe cases. This 
problem has led to national initiatives to improve the adherence to the CAP guidelines in 
hospitals around Australia. However, only modest improvement has been seen; despite the 
educational programs, ED doctors continue to prescribe ceftriaxone for patients with mild 
CAP, and for patients with moderate CAP where there is no documented allergy to penicillin 
(250).  
In one of the largest Australian studies looking at causative pathogens in CAP, 
Streptococcus pneumoniae was responsible for the vast majority of cases (210).  
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Consequently, the empirical use of narrower spectrum antibiotics could be as effective as the 
broader spectrum antibiotics for many cases of CAP, but carry a lower risk of both CDI and 
promoting the emergence of drug-resistant organisms.  
With respect to ceftriaxone dosing, around 16% of the study population received more 
than one gram of ceftriaxone within the first 24 hours of therapy. Most of these cases were 
RTIs and sepsis. In these cases, when ceftriaxone is indicated, the TG14 recommended dose of 
ceftriaxone is one gram daily. It has been shown that two grams of ceftriaxone has no 
superiority over the one gram regimen for the management of moderate to severe CAP (376). 
For patients with sepsis, increased volume of distribution of antibiotic is a common 
phenomenon, requiring higher than usually recommended dose.  However, the likelihood of a 
one gram ceftriaxone regimen producing serum concentrations below the minimum inhibitory 
concentration after twenty-four hours is low for common bacterial pathogens, even in severely 
ill septic patients (377). It is also worth noting that patients in the second period were 
significantly less likely to receive more than one gram of ceftriaxone initially. It seems 
possible that this result is due to the intervention to improve CAP management where the 
recommended dose is one gram/day.    
In terms of ceftriaxone duration, it has been shown that the median duration of 
ceftriaxone administration was significantly longer than that seen in the first period (2 days vs 
3 days, p < 0.05)). Since most of the patients who received ceftriaxone did so for CAP, it is 
likely that more patients in the second period were correctly classified as having severe CAP 
and ceftriaxone might be assumed to be the appropriate antibiotic for those patients during the 
second and third days. This assumption was supported by a significant decrease in rate of 
ceftriaxone cessation during the first day in the second study period compared to the first, 
which might suggest that more cases in the first period were inappropriately initiated with 
ceftriaxone. 
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Another important finding from the study was a significant improvement in the 
adherence to the recommended guidelines with regard to the ceftriaxone usage for the 
management of RTI during the second period since the second study period coincided with the 
multifaceted intervention to improve CAP management, we could not ignore the influence of 
the intervention on the overall improvement of ceftriaxone usage for patients with RTI.  
Among patients with mild community-acquired lower respiratory tract infections (CAP and 
AECOPD), ceftriaxone prescribing was significantly reduced consistent with TG14. While the 
lower prescribing of ceftriaxone in period 2 could be explained by the hospital’s intervention 
to improve CAP management, it was interesting that the prescribing of ceftriaxone was also 
reduced in AECOPD. This may however be related to the intervention for CAP. The emphasis 
on the accurate diagnosis of pneumonia might lead to less ceftriaxone prescribing when the 
change in chest X-ray was not evident, as the TG14 does not recommend the use of 
ceftriaxone for patients with AECOPD unless a diagnosis of CAP is confirmed. There was a 
16.7% increase in ceftriaxone prescribing for severe CAP during the second study period, 
which would be consistent with greater concordance with TG14, however this did not reach 
statistical significance.  
During the intervention for CAP management, one of the key messages was to highlight 
the relationship between the misuse of ceftriaxone and the emergence of pathogens resistant, 
to antimicrobials.  However, our intervention showed no effect on ceftriaxone prescribing 
other than for RTI.  The results from this study might suggest that to improve ceftriaxone 
prescribing more widely, an intervention across all hospital departments is required. 
Studies found that despite doctors’ awareness of the direct relationship between 
excessive use of broad-spectrum antibiotics and the rise in antibiotic resistance (378, 379), 
there may be factors that lead them to prefer using ceftriaxone empirically. The first could be a 
suspicion of multiple infection sites as reported in chapter 3 when ED doctors were 
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interviewed about factors affecting their ceftriaxone prescribing. For this reason, doctors 
might choose ceftriaxone with its broad spectrum in order to cover the most likely pathogens 
in multiple body sites. TG14 only provides recommendations for the management of 
infectious diseases in single body systems and not for those with clinical presentations that 
may reflect multiple sites.  However, it is also possible that insufficient education about 
infectious diseases in medical school might also lead to misuse of antibiotics, especially by 
inexperienced junior doctors (380, 381). Other possible factors include lack of awareness of or 
disagreement with some of the antibiotic guidelines’ recommendations (300).  
Contrary to expectations, this study has been unable to demonstrate the relationship 
between ceftriaxone consumption and CDI incidence at the RHH. However, it is important to 
bear in mind that the risk of CDI is multifactorial. Those risk factors might relate to 
medications or patients’ characteristics. Medications that have been shown to be associated 
with an increased incidence of CDI include proton pump inhibitors (382, 383), histamine 
receptor blocker (383, 384),  and other broad-spectrum antibiotics, such as fluoroquinolones 
(385, 386).  Risk factors for CDI related to patients characteristics include leucocytosis (white 
blood cell count > 13,000 cells per millilitre) and hypoalbuminaemia (serum albumin < 2.7 
milligrams per decilitre) (383). Furthermore, previous admission within 60 days, obesity, 
severe disease and increasing age also considered as independent factors that have been shown 
to increase the risk of being infected with CDI (387-390). On the other hand, studies show that 
some factors might protect against CDI. For example, it has been shown that patients who 
used statin prior to hospital admission are less likely to be infected with CDI than those who 
did not (391). Moreover, it has been shown that CDI incidences are less likely when patients 
receive doxycycline as part of ceftriaxone-based therapy when compared to those who 
received different ceftriaxone-based regimens (392).   
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9.5. Limitations  
There are several limitations to this study that should be acknowledged. This was a 
retrospective study with a reliance on documentation in medical records. Also, post-surgical 
indications were excluded, since it was not clear whether the indication was for prophylaxis. 
Therefore, some post-surgical ceftriaxone usage for empirical purposes might have been 
missed.  
With respect to ceftriaxone consumption and the incidence of CDI, the current study has 
only examined the effect of ceftriaxone on the CDI incidence rates; however, the study did not 
control other risk factors that might contribute in CDI, nor take into account cases of CDI that 
presented in the community following hospitalisation and receipt of ceftriaxone.  
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9.6. Conclusion  
Ceftriaxone was often prescribed outside the recommendations in Therapeutic 
Guidelines. Most patients who received ceftriaxone presented with RTI, with the majority of 
these being diagnosed with CAP and receiving their first dose in ED. Furthermore, this study 
has shown that the multifaceted intervention to improve the management of CAP has impacted 
favourably on the overall use of ceftriaxone for patients with RTI, with reductions in use of 
ceftriaxone for mild AECOPD as well as CAP. Accordingly, interventions to improve the 
management of other infections might lead to overall reduction of ceftriaxone.   Since most 
ceftriaxone courses were initiated in ED, efforts to improve the empirical use of ceftriaxone 
should include a focus on the ED. With respect to ceftriaxone consumption and the rates of 
CDI, our data failed to find any significant relationship. Future research should, therefore, take 
into account other risk factors associated with CDI.     
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Chapter 10. Conclusions and future 
recommendations  
Non-adherence to guideline recommendations for empirical management of adults with 
CAP continues to negatively impact on attempts to improve the quality use of antibiotics in 
hospitals.  The main goal of the current project was to implement and evaluate the impact of 
the selected interventions on the guideline adherence rates and patients’ clinical outcomes.  
One of the most significant findings to emerge from this research project was the positive 
impact of the ED-focused intervention strategies, introduction of a CAP clinical pathway and 
monthly feedback to the prescribers on the adherence to CAP guidelines. The second major 
finding was a reduction of inappropriate ceftriaxone use for patients with non-severe CAP in 
the intervention group. The third major finding was the improvement in mortality rates and 
LOS, among patients in the intervention group compared to the non-intervention group.  
Before selecting and implementing the interventions’ strategies, we conducted quantitative 
and qualitative studies to identify barriers that might hinder doctors from adhering to the 
guidelines.  Furthermore, we conducted a survey among Australian hospitals in order to 
identify strategies that have been used to improve the empirical management of CAP and 
perceived as successful.  The findings from these studies influenced our decision regarding 
intervention strategies.  Taken together, these results suggest that tailoring interventions to 
identified barriers and enablers can significantly improve the adherence to CAP guidelines and 
patients’ clinical outcomes as well as reducing the unnecessary use of ceftriaxone.    
The findings from this project make several contributions to the current literature. It is 
the first Australian study that explores barriers to CAP guideline adherence and then uses 
these findings to influence the choice of intervention strategies. The investigation has also 
gone some way toward enhancing our understanding of factors that influence doctors to 
prescribe ceftriaxone empirically for the management of CAP in ED sitting. Furthermore, this 
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is the first Australian study reporting that improve adherence to CAP guidelines favourably 
impacts on clinical outcomes. Finally, the methods used to enhance adherence to CAP 
guidelines may be applied to other community-acquired infections where the initial hospital 
treatment is given in the ED, such as urinary tract and intra-abdominal infections. 
Additionally, these strategies might be generalised to other hospitals who share the same 
healthcare system. 
Although this research project has successfully demonstrated that the intervention 
increased adherence to CAP guidelines and improved clinical outcomes, it has certain 
limitations in terms of that this intervention was only applied at one hospital. 
This project indicates the need for further research to: 
1- Confirm the association between guidelines adherence and clinical outcomes  
2- Investigate the efficacy of tailored intervention compared with standard intervention, 
such as education sessions. 
3- Further identify and characterise barriers to guideline adherence conducted.    
4- Investigate the impact of the intervention on other outcomes, such as readmission 
rates, treatment failures, time to clinical stability and ICU admission. 
5- Determine if the impact of the Clinical CAP pathway with monthly feedback can be 
reproduced in other hospitals in order to help to confirm that these strategies are 
effective tools for AMS teams to use    
6- Assess the long-term effect of the intervention 
7- Investigate the effect of the same intervention strategies on other common infections  
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Appendices  
Appendix A. CAP Auditing tool. 
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Appendix B. Survey on the management of community-acquired 
pneumonia for medical staff at the RHH 
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Appendix C. Information sheet and consent form for the 
interviewees  
USE OF CEFTRIAXONE FOR COMMUNITY ACQUIRED PNEUMONIA  
 
Dear Dr ……………………, 
The Unit for Medication Outcomes Research and Education (UMORE) at the School of Pharmacy, University 
of Tasmania would like to invite you to take part in a study examining the views of health professionals on the 
use of ceftriaxone for patients with Community-Acquired Pneumonia. This research is being undertaken as a 
component of Maher Almatar’s PhD studies. 
 
What will it involve? 
Participation will involve an audio-recorded interview with Maher, either during normal business hours or 
after hours, whichever is convenient for you. For logistical reasons some of these interviews may need to take 
place over the phone. It is expected that these interviews will take approximately 30 minutes. To thank you for 
your time we would like to provide you with a $50 gift voucher at the end of the interview. 
 
If you would like to take part, simply fill out the consent form attached and return it either by mail (an 
enclosed free envelope for you to return the survey is provided), email (malmatar@utas.edu.au) or fax (03 
6226 7627). All of the information that you provide will be carefully managed to protect your confidentiality. 
The audio-recorded interview will be labelled using a code number and in any reports or publications arising 
from this study only the combined results will be published. Although some verbatim quotes might be 
reported to illustrate the findings, they will be labelled using a pseudonym and edited to remove identifying 
information. 
 
If you have any questions about your participation in the study, please contact Maher Almatar via phone: (03) 
6226 1083 or email: malmatar@utas.edu.au. If you have any concerns of an ethical nature, or complaints 
about the manner in which the project is conducted, please contact Human Research Ethics Committee 
(Tasmania) Network (Ph: 03 6226 1956, Email: Adele.Kay@utas.edu.au).  
Thank you for your assistance. 
Yours sincerely, 
 
Prof Gregory Peterson 
Professor of Pharmacy and 
Head of School 
Mr Maher Almatar 
PhD Candidate 
Phone: 03 62261083 
Mobile: 0424993368 
Email: malmatar@utas.edu.au 
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CONSENT FORM 
 
 
 
MANAGEMENT OF PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA 
 
1 I have read and understood the introductory letter for this study. 
2 The nature of the study has been explained to me, and any questions that I have 
asked have been answered to my satisfaction. 
4 I understand that the study involves an audio-recorded interview with a researcher 
about my experiences and opinions prescribing ceftriaxone for patients presenting with 
community acquired pneumonia. 
5 I understand any information provided in this study will be kept strictly 
confidential.  
6 I understand all the data collected in this study will be stored in a locked cabinet or 
password protected computer in the School of Pharmacy and will be securely destroyed five 
years after publication of the data. 
7 I have been informed that the results of the study may not be of any direct benefit 
to me.  
8 I agree that research data gathered for the study may be published provided that 
pseudonyms will be used to ensure no individual data is identified. 
9 I agree to participate in this study and understand that I am free to withdraw at any 
time without explanation or prejudice and to withdraw any unprocessed data previously supplied.  
 
Name: _______________________________________  Date: _____/______/2012 
 
Phone number: ________________________________ (to arrange a time and place for the interview) 
 
 Signature: _____________________________________ 
 If you would like to be informed of the overall results of the study please mark this 
box    □ 
 and a copy of the results will be forwarded to your workplace. 
 Statement by the researcher 
I have explained this study and the implications of participation in it to this volunteer and I 
believe that the consent is informed and that he/she understands the implications of 
participation. 
 Name of researcher:  Maher Almatar Signature: 
 Date:       
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Appendix D. Interview Outlines 
(N.B The schedule that follows is for a semi-structured interview, thus, the ordering of the questions will vary 
according to the way the interview evolves. Other questions not listed in this schedule may be asked to expand a 
topic if/as it emerges in the interview) 
 
Before we start the interview, do you have any questions about the study? 
 
I’d like to discuss the empirical use of ceftriaxone for patients presenting with community 
acquired pneumonia (CAP). I am interviewing emergency department medical staff in 
order to get a broad picture of what influences the decision to use ceftriaxone in this 
patient group. 
 
In these interviews I am hoping to hear your experiences and opinions. All of the interviews 
will be treated confidentially and your name will not be used in any transcripts, reports or 
publications arising from this study.  
 
Demographic/General Questions 
1. What is your professional position (i.e. intern, registrar or consultant)  
2. How many years have you been practising within emergency medicine? 
3. Approximately how many cases of CAP are you involved with in an average month? 
 
Interview Outline 
4. What are your thoughts on empirical antibiotic management for patients presenting 
with CAP? 
5. What source(s) of information do you often rely on when making decisions about CAP 
treatment? 
6. What are your thoughts on the TG14 guidelines on CAP management? Any 
comments?  
7. What leads you to prescribe ceftriaxone for patients presenting with CAP? i.e. What 
are the things you might consider when deciding to prescribe ceftriaxone for CAP 
patients? 
8. Do you normally consult with any other doctors before making a decision to prescribe 
ceftriaxone for CAP? 
9. What experiences do you feel have particularly influenced your prescribing practices 
in CAP? 
 
 
Well those were all the questions I wanted to ask you. Is there anything you would like to 
add? Or anything you feel is important that we have left out? 
Would you like to clarify any comments you have made?   
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Appendix E. Survey tool for antimicrobial pharmacists among 
Australian hospitals 
Cover letter 
Initiatives to optimise the empirical usage of antibiotics for patients with  
Community-Acquired Pneumonia (CAP)  
Dear Sir/Madam, 
You are invited to take a part in a research study that aims to learn more about initiatives that 
have been performed to optimise CAP management in Australian hospital emergency 
departments. This study is being conducted by Maher Almatar (Pharmacy PhD student) under 
the supervision of Prof. Gregory Peterson (Professor of Pharmacy) and Mr Angus Thompson 
at the University of Tasmania. 
Participation in this study involves the completion of an on-line questionnaire, which will take 
approximately 5 to 10 minutes. Once you have completed the questionnaire, you will be 
entered into a prize draw for the chance to win an iPad mini.  
Your responses to the questionnaire will be totally confidential and anonymous, and all 
reported data will be aggregated. Details collected for entry into the prize draw are separate 
from the survey data. Should information collected through this study be published or 
presented at a conference, no participant or their institution will be identifiable.  
It is important that you understand that your involvement is this study is entirely voluntary. 
While we would be pleased to have you participate, we respect your right to decline.  
Should you have any questions about completing or participating in this study, please feel free 
to contact Maher Almatar on (03) 6226 1069 extension 8535 or via e-mail at 
malmatar@utas.edu.au.  
This study has been approved by the Tasmanian Health and Medical Human Research 
Ethics Committee.  If you have concerns or complaints about the conduct of this study 
you should contact the Executive Officer of the HREC (Tasmania) Network on (03) 6226 
7479 or email human.ethics@utas.edu.au.  The Executive Officer is the person 
nominated to receive complaints from research participants. You will need to quote 
[H0013156]. 
Thank you for taking the time to consider this study. If you are willing to participate, please 
click the button below to proceed to the questionnaire.  
Your completion and submission of the questionnaire will be taken as indicating your consent 
to participate in this study. 
Thank you for your assistance. 
 Sincerely yours, 
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The questionnaire 
This questionnaire aims to learn more about any initiatives that your 
institution/department has made to optimise the empirical usage of antibiotics for the 
management of community acquired pneumonia (CAP) in ED.  
1- Which state/territory is your institution in? 
a. NSW 
b. VIC 
c. QLD 
d. SA 
e. WA 
f. TAS 
g. ACT 
h. NT 
2- Total number of hospital beds 
a. Less than 100 beds 
b. 100-300 beds 
c. 301-500 beds 
d. More than 500 beds 
3- Do you have an antimicrobial stewardship program in your institution? 
 No 
 Yes  
 No answer 
a. If yes, in which year it was officially implemented? 
i. 2011-2013 
ii. 2008-2010 
iii. before 2008 
4- Does your institution/department periodically monitor antibiotic use for the 
management of CAP in the emergency department? 
 No 
 Yes  
 
5- Does your institution/department utilise guidelines for the management of CAP? 
 No 
 Yes – Therapeutic Guidelines (Antibiotic) 
 Yes – local guideline 
If yes, 
a. What initiative/s does your institution/department use to promote uptake of 
the guidelines in the emergency department? 
i. Group educational sessions 
ii. Academic detailing  (one-on-one) 
iii. Drug restriction policy 
iv. Auditing and feedback 
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v. CAP management pathway 
vi. Computer prompts or alerts/decision support 
vii. None 
viii. Others (please specify …………………….) 
 
b. Which of the following do you think is/are effective to promote the uptake 
of the CAP guidelines? (Please indicate all that apply) 
i. Group educational sessions 
ii. Academic detailing  (one-on-one) 
iii. Drug restriction policy 
iv. Auditing and feedback 
v. CAP management pathway 
vi. Computer prompts or alerts/decision support 
vii. None 
viii. Others (please specify …………………….) 
c. Which ONE of the following do you think is the most effective to promote 
the uptake of the CAP guidelines? 
i. Group educational sessions 
ii. Academic detailing  (one-on-one) 
iii. Drug restriction policy 
iv. Auditing and feedback 
v. CAP management pathway 
vi. Computer prompts or alerts/decision support 
vii. None 
viii. Others (please specify …………………….) 
 
If no, 
 
d. What initiative/s does your institution/department use to optimise the use of 
antibiotics for patients with CAP in the emergency department? 
i. Group educational session 
ii. Academic detailing  (one-on-one) 
iii. Drug restriction policy 
iv. Auditing and feedback 
v. CAP management pathway 
vi. Computer prompts or alerts/decision support 
vii. None 
viii. Others (please specify …………………….) 
 
e. Which of the following do you think is/are effective to optimise the use of 
antibiotics for patients with CAP? 
i. Group educational session 
ii. Academic detailing  (one-on-one) 
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iii. Drug restriction policy 
iv. Auditing and feedback 
v. CAP management pathway 
vi. Computer prompts or alerts/decision support 
vii. None 
viii. Others (please specify …………………….) 
 
f. Which of the following do you think is the most effective to optimise the use 
of antibiotics for patients with CAP? 
i. Group educational session 
ii. Academic detailing  (one-on-one) 
iii. Drug restriction policy 
iv. Auditing and feedback 
v. CAP management pathway 
vi. Computer prompts or alerts/decision support 
vii. None 
viii. Others (please specify …………………….) 
 
6- Please rate your level of agreement with the following statement: “There is a need 
for additional education of ED staff on antimicrobial prescribing for CAP in my 
institution.”  
a. Strongly Agree   
b. Agree 
c. Natural 
d. Disagree  
e. Strongly disagree  
 
7- What is/are the recommended tool/s to assess the severity of CAP in your 
department? 
a. PSI 
b. CURB65 
c. SMARTCOP 
d. CORB 
e. None 
f. Other (please specify…………………………)  
 
 
8- In general,  would you please briefly describe the role of the antimicrobial 
stewardship program in your hospital’s ED. (optional) 
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Thank You 
Thank you for taking time out to participate in this survey. We truly value the information that 
you have provided.   
 
Your survey has been submitted!  
 
Please note that any information entered on this page is not linked to your responses in the 
survey. 
 
If you wish to enter the prize draw to have the chance to win an iPad mini, please click on the 
“go to prize”. Once you press that button, you will be asked to provide your name and Email 
address. This is optional, you can press the “no, thanks” button if you don’t wish to enter into 
the prize draw. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name:……………………… 
Email:……………………… 
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Appendix F. RHH local CAP guidelines 
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Appendix G. CAP power point slides for educational sessions  
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Appendix I: CAP clinical pathway component of intervention, as 
provided to ED. 
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Appendix J. Samples of a detailed monthly feedback to the ED 
staff. 
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Appendix K. Ceftriaxone Usage at the RHH (Auditing tool). 
Patient’s study number: 
Gender: Male   Female 
Age: Wight:  
Allergic to Penicillin: Yes No 
Medical history, CXR or Lab results (if required in TG14 guidelines): 
 
 
Ceftriaxone-based therapy regimen:  
Information needed for patients admitted to the ED 
Ceftriaxone received at ED: 
Patient admitted: 
Ceftriaxone continued after 
admission: 
Yes No 
Yes No 
Yes No 
Ceftriaxone indication: 
Ceftriaxone use 
 
Details of microbiological testing 
 
 
 
 
 
empirical 
 
directed 
Organism……………………….. 
 
prophylaxis 
 
 
Dosage: 
 
Duration of ceftriaxone therapy: 
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Is the use of ceftriaxone indicated in 
the TG14? 
Yes 
 
No 
If yes, is the ceftriaxone-based 
therapy  
consistent with TG14? 
Yes 
 
 
No 
Prescribed by: 
 
 
 
 
 
 
Intern 
Resident 
Registrar 
Specialist/Consultant  
Outcome: 
Discharged (LOS) 
Died 
 
Comments: 
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Appendix L. Ethical approvals  
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